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ABSTRACT 
 
Measles is a leading cause of mortality in infants in countries with suboptimal 
vaccination coverage. This disease is caused by a negative-strand RNA virus, 
measles virus (MeV). Wild-type strains of the virus use two cellular receptors to 
invade cells and establish infection: the signalling lymphocyte activation molecule f1 
(SLAMF1), which is present on certain immune cells, and nectin-4, which is 
expressed in the lung epithelium. During infection, MeV can spread through the 
release of virions or by inducing cell-cell fusion. The aim of this thesis is to determine 
the molecular mechanism underlying viral entry and exit. Herein, I observed that, 
upon attachment to SLAMF1+ cells, MeV particles induce extensive but transient 
membrane blebbing and cytoskeleton contraction. MeV entry occurred 
simultaneously with fluid-uptake and was sensitive to inhibitors of macropinocytosis 
and cytoskeleton dynamics. In contrast, the cortical actin network restricted the early 
stages of MeV-induced cell-cell fusion, in RhoGTPases, ezrin and moesin dependent 
manner. By resolving the proteome of infected cells, conserved phosphorylated 
residues in the viral haemagglutinin were also shown to impact on dimerization and 
cell-cell fusion. These results suggest the manipulation of several cellular 
components and pathways during entry and exit of MeV.   
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GENERAL INTRODUCTION 
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Viruses are a leading cause of mortality and morbidity for humankind. Since the birth 
of the first civilisations, infectious diseases have had a significant impact on the 
public health, economy and development of nations. Together with smallpox, 
measles virus (MeV) is one of the first pathogens known to infect humans in record, 
being firstly described and distinguished from smallpox infection by the Persian 
physician Rhazes, in the 10th century AD. MeV’s origin is proposed to coincide with 
the domestication of cattle in Mesopotamia, in approximately 10,000 BC; MeV is 
thought to have jumped from an ancient common ancestor of the bovine pathogen, 
rinderpest virus (RPV) [1]. Spreading during the expansion of the Roman empire, 
MeV was probably endemic in Europe, North Africa and the Middle East in the 1st 
century BC [2]. Some speculate that the disease had reached China and Southeast 
Asia by the 7th century, transmitted by merchants via the Silk Road [3]. MeV did not 
spread to the New World until the 15th century, when Portuguese and Spanish 
explorers colonised the Americas. The introduction of this pathogen, in combination 
with smallpox, had a devastating impact on the naïve populations of the continent, 
with some estimates suggesting they reduced the indigenous populations by 90%. In 
1758, in Scotland, MeV was first identified as the causative agent of measles by 
Francis Home [4]. True global spread was finally achieved in the 1850s, when British 
sailors introduced the disease in Australia [5]. After centuries of causing morbidity 
and mortality in human populations, the first efficacious measles vaccine was 
developed in 1963 by John Enders and colleagues, a live attenuated vaccine derived 
from the original isolation of the virus (made from an 11-year-old boy, David 
Edmonston) [6].  The number of people affected by measles has progressively 
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reduced since the introduction and wide-distribution of this vaccine, a trend that is 
supported by ongoing international efforts to eradicate MeV.  
 
1.1 The Morbillivirus genus 
Taxonomically, MeV belongs to the genus Morbillivirus, and by extension to the 
Paramyxoviridae family, two groups that classify enveloped, non-segmented, 
negative-sense, single-stranded RNA viruses. Aside from MeV the genus 
Morbillivirus contains viruses that infect several species of mammals, including 
carnivores, ruminants, cetaceans and primates. RPV was the causal agent of a 
plague in cattle and other ungulates, and, while extant, had a profound impact on 
livestock throughout the centuries [7]. In infected cattle this virus caused a substantial 
mucosal degradation of the oral-nasal cavity and digestive tract together with 
prolonged leukopenia; symptoms that were coincident with severe dehydration and 
diarrhoea that commonly led to death [8]. After extensive vaccination campaigns, the 
Food and Agriculture Organisation (FAO) together with the World Organization for 
Animal Health (OIE) achieved the global elimination of RPV, becoming the second 
viral disease ever to be eradicated, after smallpox [9].  Other ruminants are infected 
by a closely related virus, Peste des petits ruminants virus (PPRV) which causes a 
similar disease in sheep and goats. This disease is endemic in several regions of 
Africa, Southeast Asia, India and Middle East where it is responsible for a vast 
economic burden [10]. Although PPRV is also able to infect cattle asymptomatically, 
propagation of the disease is limited by cross-reaction with RPV-induced antibodies 
[11]. Several control campaigns are already underway, and some authors consider 
PPRV the most likely next eradicable pathogen [12-14]. 
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1.1.1 Hosts and disease 
Members of the Morbillivirus genus can infect a wide range of animals, including 
humans, dogs, cats, whales, sheep and goats, cattle, dolphins, bears, etc., causing a 
transient immunosuppression and several respiratory and neurological illnesses. 
Morbilliviral infections are wide spread among carnivores, with major pathogens 
including canine distemper virus (CDV), phocine distemper virus (PDV) and the 
recently identified feline morbillivirus (FmoPV). CDV’s natural hosts include several 
families of the Carnivora order, including dogs, foxes, racoons, skunks, hyenas, and 
tigers [15, 16]. It causes similar symptoms to RDV and PPRV infections, as well as a 
profound, rapidly-progressing encephalitis [17]. Due to its prominent neurotropism, 
CDV is used as model to study multiple sclerosis [18].  In the last decade an 
expansion of the already broad spectrum of CDV hosts has been observed, 
suggesting a propensity for the virus to quickly adapt to new host species [19]. After 
an outbreak in a monkey population in China, studies showed that CDV can rapidly 
adapt in vitro to human receptors, raising concerns about the possible adaptation of 
this virus to humans in nature [20-22]. Although CDV has been shown to infect 
domestic cats [23], a distinctive feline-specific morbillivirus, FmoPV, was first 
identified in domestic cats in China and Japan associated with tubulointerstitial 
nephritis, and it is now assumed to have a global distribution [24-26]. PDV outbreaks 
have been reported in seal populations, especially in Northern and Western Europe, 
with recorded mortality rates up to 60% [27, 28]. This disease is symptomatically 
related to CDV in dogs, causing a severe demyelinating disease [29, 30].  
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Morbilliviruses have also been identified in other marine mammals. These are 
described as cetacean morbilliviruses (CeMV) and infect porpoises, dolphins and 
whales [31, 32]. Genetic comparison studies show that CeMV is more similar to RPV 
than to PDV and CDV, suggesting a different route for its evolution [33]. Mortality in 
CeMV infection is associated with severe pneumonia and lung failure, accompanied 
by general immunosuppression and multifocal encephalitis [34].  
Finally, several morbillivirus-like RNA sequences have been identified in tropical bats 
and rodents [35]. Despite the lack of infectious viruses isolated from these animals, 
these data suggest a much broader tropism for morbilliviruses than previously 
thought, and may also represent possible zoonotic transmissions to humans, which 
may collide with MeV eradication efforts. The global burden of morbillivirus infections 
in humans and livestock, combined with the potential for zoonotic transfer, highlight 
the importance of this genus of viruses. Improving our understanding of virus 
infection and transmission will generate better control mechanisms and therapeutic 
approaches for measles and other morbilliviruses.  
 
1.2 Measles virus: the causative agent of measles 
The morbillivirus that infects humans, MeV, causes a disease of the same name, 
known as measles. Humans are the natural host of MeV, but other primates can be 
experimentally infected [36]. Although public health actions, mainly vaccination, have 
decreased the number of cases reported worldwide, measles is still a leading cause 
of morbidity and mortality among young children in Africa and Asia [37]. Secondary 
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infections also contribute to the mortality rate, i.e. when opportunistic pathogens take 
advantage of the long-term immune suppression induced by MeV [38, 39].  
 
1.2.1 Measles, the disease 
1.2.1.1 Transmission 
Measles is an airborne disease and MeV is transmitted via aerosols through the 
respiratory route (Fig.1-1A). Once in its host, the virus first infects resident alveolar 
macrophages and dendritic cells of the airway tract. Infection later spreads to local 
lymph nodes before being finally transmitted to the epithelial cells of the lungs and 
trachea. After viremia, the virus infects the airway epithelium and releases infectious 
viral particles into the lumen which are expelled into the environment and transmitted 
to new hosts [36, 40]. In addition, mesenchymal and neuroendocrine cells are also 
important target cells for MeV, and are likely to be involved in the immune- and 
neuropathologies associated with infection [16].  
 
1.2.1.2 Symptoms 
Measles is commonly diagnosed through the characteristic rash it causes, but it is 
also associated with general cold-like symptoms and an increase in complications 
related to secondary infections, such as pneumonia. Measles has a latent period of 
10 to 14 days, and symptomatically initially presents with fever, conjunctivitis and a 
cough, as well as small white lesions on the mucosa 
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Fig.1-1. Measles virus is the causative agent of measles. (A) Droplets containing 
MeV particles inhaled by the host interact with resident dendritic cells and 
macrophages of the lung. Infection spreads to the local lymph nodes where it 
develops and causes viremia. After systemic distribution of the virus, circulating 
lymphocytes infected with MeV interact with the basal surface of the airway 
epithelium, which becomes infected. New viral particles are then released into the 
lumen of the lung and expelled. Adapted from [41]. (B) Koplik’s spots are one of the 
earliest signs of MeV infection and are characterised by small white spots on the 
internal epithelia of the cheek. Adapted from [42]. (C) The maculopapular rash of 
measles appears later on during infection, initially presenting on the neck and face 
before spreading through the rest of the body. Adapted from [42].  
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of the mouth known as Koplik’s spots (Fig.1-1B). This is followed by a maculopapular 
rash with concentrated distribution on the face and chest (Fig.1-1C) [1, 43]. The 
typical maculopapular rash caused by MeV results from an inflammatory reaction 
where deposits of viral proteins complexed with MeV-specific antigens. Accordingly, 
no infectious viral particles can be recovered from the rash. Histological analysis of 
the rash has shown that epithelial cells infected with MeV are closely associated with 
infiltrated T lymphocytes [44], while no rash is observed in patients lacking a strong 
immune response [45, 46]. Concurrent to the manifestation of the maculopapular 
rash is the development of an adaptive immune response. Immune reactions are 
usually sufficient to clear infection, and after this period infectious virus particles 
cannot be recovered from the blood [47-49]. Interestingly, viral RNA can still be 
detected in lymph nodes and lung epithelial cells for up to three months, suggesting a 
persistence of viral genetic material after the resolution of infection [50]. Although life-
long immunity is achieved, a prolonged immunosuppression, which lasts for several 
months, increases the susceptibility to secondary infections. In fact, bacterial and 
viral-associated pneumonia are responsible for the majority of fatal cases during 
measles infection [1, 51].  
 
1.2.1.2 Rare complications 
Other severe, yet rarer, complications of MeV infection are related to the central 
nervous system and present as a distinct range of sequelae and symptoms. Acute 
demyelinating encephalomyelitis, an autoimmune disease, can occur one month after 
the initial infection. Although associated with MeV infection, viral proteins and RNA 
cannot be detected in the brain [52]. In other cases, a persistent infection of MeV can 
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develop causing severe forms of encephalitis that only manifest several months, or 
even years, after the initial infection. Subacute sclerosing panencephalitis (SSPE) 
and measles inclusion body encephalitis (MIBE) are the most common complications 
in this context.  While MIBE only occurs in immunocompromised patients, within nine 
months after infection, SSPE manifests several years after acute infection. In both 
cases, neurological damage of the brain is a consequence of virus-derived 
pathogenesis (demyelination, astrogliosis, infiltration of lymphocytes, etc.) and leads 
to dementia, seizures, spasms and death [53, 54]. Treatment is limited for measles-
related encephalopathies, and there is no current cure.  
 
1.2.2 Epidemiology 
Despite an efficacious vaccine being available, measles still has a global incidence 
and causes thousands of deaths per year. The majority of cases in recent years have 
been documented in South East Asia, the West Pacific region and Africa [55]. 
Furthermore, measles is still a leading cause of death among children in Africa and 
some parts of Asia. In 2014, there were 266,701 cases of measles reported 
worldwide with over 145,000 estimated deaths in 2013 [56] and 114,900 in 2014 [55]. 
Measles is a disease characterized by both high mortality and morbidity [57]. 
However the number of reported cases of measles has been steadily decreasing 
since 1980, as a consequence of widespread immunization with most countries 
undertaking national vaccination programmes [56]. After the introduction of 
immunization, measles incidence dropped from 70.9 cases/100,000 individuals/year 
to 0.9 cases/100,000/year. Models have shown that a 1% increase in vaccine 
coverage equates to a 2% decrease in incidence [58]. Prior to routine vaccination, 
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measles caused an estimated 2.6 million deaths per year and it was estimated that 
90% of children had contracted the disease by the age of 10 [59]. According to WHO, 
over 95% of measles deaths occur in countries with low income and weak healthcare 
infrastructure.  
Measles is sustained through an unbroken chain of human-to-human transmission, 
and no animal or environmental reservoir is known to exist [60]. Although persistent 
infection occurs in the population, especially within cases of SSPE, as described 
above, these are not considered reservoirs for onward infection, since neurons and 
glial cells infected with measles produce defective virions. Interestingly, some 
serological studies have presented evidence of measles virus infection in wild 
populations of primates in India and Indonesia [61, 62]. These cases are assumed to 
be the result of transmission from human to primates [60].  
 
1.2.2.1 Transmission 
The transmission of measles occurs through contaminated respiratory aerosols, i.e. 
those produced by sneezing, coughing or alternatively through direct contact with the 
throat phlegm, nasal secretions or other contaminated body fluids of infected people, 
such as excretions from the eye and urine. Environmental transmission of MeV is 
also possible, e.g. in closed spaces, such as medical examination rooms and 
aeroplanes, because the virus remains contagious on fomites and in the air for up to 
2 hours [63, 64]. In fact, measles is one of the most communicable human diseases 
and can be transmitted as early as 4 days prior to the onset of the maculopapular 
rash, with the peak of transmission occurring a week later [1]. Most measles cases 
occur in late winter and spring in temperate regions, and after the rainy season in 
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tropical regions [56, 65]. The most likely cause of these observed seasonal peaks is 
overcrowding induced by the winter or rainy seasons.  
 
1.2.2.2 Molecular epidemiology 
Despite the existence of a single serotype, various circulating genotypes of MeV 
have been reported. Measles surveillance is mainly provided by a network of WHO 
laboratories. Additionally, the online database, Measles Nucleotide Surveillance, 
provides a repository as well as bioinformatics tools to analyse measles sequences 
(http://www.hpa-bioinformatics.org.uk/Measles/Public/Web_Front/main.php). 
Molecular epidemiological studies often examine the complete sequence of the 
nucleocapsid (N) or haemagglutinin (H) genes (see chapter 1 section 1.3) or, more 
frequently, the C-terminal 450 nucleotides of N, which is the most variable region of 
the MeV genome [66]. Currently, field isolates are classified into 8 clades (A to H) 
and 24 genotypes, indicated with numbers. To date, the identified MeV genotypes 
are A, B1, B2, B3, C1, C2, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, E, F, G1, 
G2, G3, H1 and H2 [67]. All genotypes belong to wild-type virus isolates that have 
caused epidemics apart, from genotype A, which comprises all the vaccine strains of 
MeV [68]. A study of global MeV genotype distribution identified three main regions 
where certain genotypes are predominant: in Africa genotype B3 is most common, 
apart from Namibia where genotype B2 prevails; in Southeast and Eastern Asia 
genotypes D9 and H1 are commonly detected, while in Europe and the Americas, D4 
and D5 genotypes are predominant [69].  
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1.2.3 Diagnosis 
There are several approaches to aid the diagnosis of measles, such as the unique 
clinical symptoms, virus neutralisation tests with patient’s sera or genotyping of the 
virus. Early clinical symptoms, such as Koplik’s spots, can be used to diagnose the 
disease. When incidence is low, diagnosis is more difficult, since other respiratory 
pathogens or inflammatory diseases may offer differential diagnoses (because of the 
fever and rash symptoms) [60]. In addition, clinical diagnosis might also be hindered 
since the maculopapular rash associated with measles does not always occur in 
individuals with weakened immune responses, i.e. those caused by underlying 
malnutrition or immunosuppressive diseases [70]. 
The detection of MeV-specific antibodies, present in blood sera or oral fluids, is the 
most common method applied for measles diagnosis. Levels of immunoglobulin M 
(IgM), during acute infection, or immunoglobulin G (IgG), in the convalescent phase, 
are used for serological detection of MeV infection [56, 71]. Since the production of 
IgM precedes IgG, MeV-specific antibodies might not be detected until 4 days after 
the onset of the maculopapular rash [52, 70]. As a result, false positives or false 
negative results can be potentiated by the low concentration of IgM and the under-
sensitivity of the assays used for serological tests [12]. 
Depending on the health infrastructure, cases of measles can also be confirmed by 
culturing MeV in permissive cell lines isolated from body fluids. Preferentially, 
Epstein-Barr virus-transformed B lymphocyte cell lines should be used for diagnosis, 
since it has enhanced sensitivity to wild-type strains of the virus. MeV has been 
detected in oral and nasopharyngeal swabs [72], blood [73], eye rheum [74] and 
urine [75].  
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Finally, to simultaneously evaluate the genotype of MeV and diagnose disease, 
detection, amplification and sequencing of MeV RNA through reverse-transcriptase-
polymerase chain reaction (RT-PCR) should be performed. This method is used to 
study the molecular epidemiology and phylogenetics of MeV and to classify isolates 
into respective genotypes.  
 
1.2.4 Vaccination 
The burden of measles disease worldwide has significantly decreased in the last 50 
years, after successive vaccination campaigns. The main measles vaccine is derived 
from the first isolation of the virus [76], the Edmonston strain. To generate this 
vaccine the virus underwent a total of 71 passages in a series of primary human cell 
lines and embryonated chicken eggs [77]; an inactivation process similar to that used 
during the development of the poliomyelitis vaccine. In Europe the measles vaccine 
is administered as a trivalent vaccine, MMR (measles, mumps and rubella). It is 
administered in two doses: the first one administered between 9 and 15 months of 
age and the second dose when the child is 4 to 6 years old [78]. The recent re-
emergence of measles in Europe has mainly been caused by suboptimal vaccination 
coverage, i.e. less than the minimum 95% coverage stipulated by the WHO, and 
importation of the virus from countries in which the disease is endemic. Accordingly, 
unvaccinated individuals represent the majority of measles cases in Europe [79]. 
Susceptible individuals comprise people who (1) were not previously affected by 
measles, (2) immunosuppressed people or pregnant women, (3) people that despite 
being vaccinated fail to produce an immune response and (4) people who are under 
the age to be vaccinated or older unvaccinated people [80]. In addition, several 
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people are not eligible for vaccination, namely if they have allergies to any of the 
vaccine’s components or have underlying severe illness or immunodeficiency, since 
measles-related fatalities have occurred in immunocompromised people [80, 81].  
 
1.2.5 Treatment 
There are no specifically approved antiviral treatments for measles although several 
antiviral compounds have been discovered [82]. Severe complications from measles 
can be avoided through good healthcare, ensuring adequate nutrition, fluid intake 
and the treatment of dehydration. Secondary infections associated with measles can 
be treated through the administration of antibiotics. The WHO also recommends 
vitamin A supplements to children diagnosed with measles. This treatment restores 
low vitamin A levels during measles that occur even in well-nourished children and 
can help prevent eye damage and blindness. Vitamin A supplements have been 
shown to reduce the number of deaths from measles by 50% [83]. 
 
1.3 Genome structure 
The genome of MeV shares similarities with other paramyxoviruses, which are non-
segmented, single-stranded, negative-sense RNA viruses. MeV genomes comprise 
an RNA molecule of 15,894 nucleotides with negative polarity  [84]. They are 
composed of six transcription units, in cis, sequentially encoding for the N, the 
phosphoprotein (P), the matrix (M) protein, the fusion (F) protein, H and the large (L) 
protein, the order of which was first deduced in 1985 (Fig.1-2) [85]. Two additional 
proteins are also produced by MeV genomes: the C protein, which is produced from  
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Fig.1-2 Organisation of the MeV genome. Genomes of MeV are a single molecule 
of RNA in the negative-sense and contain six transcription units in cis. From 3’ to 5’, 
the transcription units encode for the nucleocapsid protein (N), phosphoprotein (P), 
matrix protein (M), fusion (F) protein, haemagglutinin (H) and the large (L) protein. 
Additionally, MeV genomes can produce two additional protein, C and V, by leaky 
scanning of the optimal Kozak sequence or editing of the P mRNA transcript, 
respectively. A typical MeV genome contains 15,894 nucleotides (nt). Adapted from 
ViralZone, ExPASy Swiss Institute of Bioinformatics Bioinformatics Resources Portal   
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the P transcription unit as an alternative ORF [85], and the V protein, whose 
production results from editing of the viral mRNA transcript of P [86]. The P and L 
protein, together with the N protein and the genome form the ribonucleoprotein 
(RNP) complex. The L and the P proteins form the RNA-dependent RNA polymerase 
(RdRp) complex, responsible for viral replication and transcription, of which L is the 
main component and P is a co-factor. The RNP also protects the viral RNA from the 
activity of RNAses [87]. The M protein’s function is classically attributed to viral 
budding while the two envelope glycoproteins (GPs) F and H are responsible for viral 
attachment and fusion of the viral envelope with the cell [1]. A specific intergenic 
region consisting of three nucleotides separates each open reading frame (ORF); the 
sequence 3’-GAA-5’ (as the genome is negative sense) marks the intergenic regions 
between N, P, M, F and H, while the sequence 3’-GCA-5’ is found at the intergenic 
region between H and L. Of note, the untranslated region between M and F is much 
longer than the others and comprises around 1000nt [85, 88]. This region is unique to 
morbilliviruses and has a high GC content and variability. Furthermore, two 
promoters are located at the termini of the genome: the 3’end leader or genome 
promoter, which is comprised of 56nt, and the 5’ trailer or antigenome promoter, 
composed of 40nt [84]. 
 
1.3.1 Molecular evolution 
MeV genomes undergo very little variation both in vitro and in the field compared to 
other negative-sense RNA viruses [66, 69]. Two estimations of mutation rate for MeV 
in the field have been made: 5×10-4 and 4×10-4 substitutions per base per year [89, 
90]. Both estimations are much lower than the calculated error rates of other RNA 
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viruses, such as 8×10-4 for hepatitis C virus, 1.8 ×10-3for influenza A virus and 2.5 
×10-3 for the human immunodeficiency virus 1 (HIV-1) [90], a feature that is shared 
by other paramyxoviruses [91]. Interestingly, the mutation rate of MeV polymerase in 
vitro is similar to other RNA viruses [92, 93], suggesting significant biological or 
structural pressures that might be applied during the MeV life cycle in nature. A 
recent studied used random insertional mutagenesis to study how various sections of 
the MeV genome tolerated insertions in MeV genome [94]. They concluded that 
although N, P and M protein could tolerate small insertions, F, H and L were highly 
sensitive to mutagenesis. The L gene is the most conserved gene in the MeV 
genome followed by the F gene. Although MeV glycoproteins might be under intense 
antigenic pressure, MeV F and H sequences are very stable during in vivo passage 
[95]. The M gene is also well conserved among the morbilliviruses, and 
paramyxoviruses in general [96]. This might be due to the high number of 
interactions with other viral components and cellular proteins. In conclusion, MeV 
undergoes very little variation, in comparison to other RNA viruses, which suggests a 
high selective pressure environment upon infection. 
 
1.4 Virion structure 
Measles virions are large pleomorphic particles with sizes ranging from 120nm to 
1µm (Fig.1-3) [97, 98]. The envelope is heavily decorated with the two glycoproteins 
(forming spikes at the viral envelope of ~15nm from the membrane [97]) while the 
interior is composed of an RNP, complexed or wrapped in helices of the M protein 
[99]. Although densely packed viral envelopes have been observed for the majority, if 
not all, of paramyxoviruses, this RNP-associated structure formed by MeV M proteins  
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Fig.1-3 Structure of virions of measles. (A) Micrograph of MeV particles observed 
by transmission electron microscopy and negative stain. [100] (B) Representation of 
a MeV particle. Measles virions contain two viral glycoproteins in their envelope, F 
and H, while the interior contains the viral genome wrapped into a helix with N and 
subsequently with M. M can also interact with the inner leaflet of the lipid bilayer. 
Additionally, L and P protein are present in close association with the nucleocapsid. 
Adapted from [99]. (C) Diagram of the N, P and L interactions. Adapted from [101]. 
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has not been observed in other viruses. MeV is polyploid, i.e. it can incorporate more 
than one RNP per particle; if this is an artefact of in vitro infection or relevant to the 
biology of the virus while in vivo is not clear [102]. Some studies that investigated 
generating segmented viral genomes, show that MeV can incorporate several RNPs 
with different sizes, suggesting the packaging of RNPs into the particle might not be 
a highly selective process [103]. 
The RNP complex is a helical arrangement of the N protein bound to the RNA 
genome and is approximately 1µm in length, 19.5nm in diameter and has a central 
empty core of 5nm [104] (Fig.1-3C). When negative-stained and visualised under 
electron microscopy (EM), the RNP complex has a herringbone structure similar to 
other paramyxo- and pneumoviruses [105]. CryoEM studies on the RNP revealed 
that the structure has significant flexibility, and it has been suggested that the N- 
terminal domain of N is responsible for this conformational plasticity [106]. The 
polarity of the genome within the RNP structure has also been determined: with the 
“pointy end” of the herringbone representing the 5’-terminus [105]. The RNP complex 
was shown to be composed of 97% protein with a density of 1.30g/cm3 in CsCl 
gradients [107].  The exact stoichiometry of the MeV RNP has not been defined yet, 
but assuming some similarly to other paramyxoviruses, it is estimated that the RNP 
complex is composed of 2649 monomers of N [108], ~260 monomers of P and 
approximately 25 copies of L [109]. The precise number of N monomers required to 
encapsidate a genome is easily deduced because all paramyxo- obey the “rule of six” 
[108, 110]. This rule, which means the genome must be a multiple of six nucleotides 
in length is explained by the interaction of N with the RNA molecule: each monomer 
of N binds to six nucleotides at once. It is assumed that an excess or deficit of 
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nucleotides (in the genome) will interfere with the interaction of N at the genome 
termini and destabilise the RNP complex [111].  
 
1.4.1 Particle to plaque-forming unit ratio 
In vitro, the particle to plaque-forming-unit (PFU) infectivity ratio for MeV is relatively 
high and has been suggested to be greater than 10 (>10:1) [112]. Even though MeV 
is one the most infectious pathogens known, it is intriguing that the particle-to-PFU 
ratio is so high. Presumably, this number might be due to the formation of defective 
particles.  A common feature of in vitro MeV infections is the formation of defective 
RNPs that can lead to the formation of defective-interfering particles, which are 
known to be present in vaccine stocks [113]. These faulty RNPs contain large 
deletions of the original RNA sequence or positive-sense RNA molecules. A common 
topology for these defective RNAs is the 3’ copy-back structure, where 5’ to 3’ 
replication of the antigenome stops at a specific point, reverses the reading sense 
orientation and copies back the initial part of the genome again.  Interestingly, the 
budding process of MeV does not seem able to distinguish antigenomic, genomic or 
partial (defective) RNPs, since all these types can be found in virions [114].   
 
1.5 Transcription 
MeV gene expression is accomplished by the action of the RdRp complex, which 
synthesises viral mRNAs directly from the negative-sense RNA genome. The leader, 
or genome promoter, of MeV genomes located at the 3’ end of the RNA molecule 
acts as the transcriptional promoter sequence. The polymerase complex, composed 
27 
 
of L and its co-factor P, recognises this region and generates a nascent molecule of 
RNA. This nascent mRNA molecule is capped at the same time of transcription by 
the L protein. The polyadenylation of the 3’ end of viral mRNAs is thought to be the 
result of “stuttering” of the transcription complex on the sequence 5’-
RUUAUAAAACUU-3’ located at the 3’ end of the transcription unit, where R is a 
purine [115]. Polyadenosine tails are composed of 70 to 140 A residues, and 
although the exact mechanism by which L+P stop polyadenylating is not known, 
cellular mRNAs have similar length polyA tails.  
As mentioned previously, the transcript of the protein P can be edited to allow 
translation of the V protein. In the middle of the P ORF, a sequence similar to the 
gene end element (3'UAAUUUUUCCC-GUG-5’) instructs the viral transcription 
complex to introduce an extra G residue, that is not present in the template. Even 
though morbilliviruses only express one edited transcript, leading to the production of 
V, other paramyxoviruses can produce V and W proteins depending on the insertion 
of one or two G residues, respectively [116]. The lack of expression of W proteins in 
morbilliviruses could be a result of tight regulation of the editing process. 
 
1.5.1 Regulation of gene expression 
The main mechanism for regulation of morbillivirus gene expression is the 
transcriptional gradient, formed during viral mRNA synthesis, i.e. transcription 
initiation and viral mRNA production is proportional to the distance of the transcription 
unit from the 3’ promoter of the genome (Fig.1-4). This can be explained by the stop-
restart feature of the L+P complex during transcription, and governed by the  
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Fig.1-4 MeV transcription generates an mRNA gradient. (A) The L and P protein 
complex binds to the 3’ terminus of MeV genome and initiates transcription. After the 
first transcription unit is complete, the polymerase can either continue to the next 
ORF and start its transcription or abandon the RNA molecule and bind to the 3’ end 
of the same or other genome molecules. The same happens at the end of all 
transcription units. This feature of the RdRp, known as the stop-and-restart function, 
leads to the formation of a gradient of viral mRNA, in which the most abundant 
transcripts are 3’ terminal, i.e. N, followed by P, M, F, H and L. 
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probability of the complex to abandon the template RNA molecule and re-start from 
3’ terminus. At the end of each transcription unit the polymerase either ceases 
transcription altogether and disassociates from the genome, or continues to 
transcribe the next gene. Since the polymerase is thought to only begin transcription 
at the 3’ end of the genome the result is a gradient of transcription.  Several studies 
have attempted to determine the characteristics of this gradient. In particular, during 
an acute infection, all viral transcripts decay at a similar rate [117], which in general is 
very low [118]. Two studies showed a steep attenuation of gene expression from N to 
P by analysing mRNA abundance [119, 120] - a threefold reduction in mRNA copy 
numbers – but this degree of change is attenuated for the genes further downstream 
(approximately 0.8 times of the previous ORF). However, there is another transition 
where continued transcription dramatically attenuates in likelihood, the H-L interface, 
where the total number of L nascent transcripts is approximately 10 times less than 
H.  
Recent evidence has suggested a role for the C protein as a “quality control” factor in 
measles replication [121]. Recombinant MeVs that lack the expression of C generate 
increased levels of defective RNAs. Analysis of the “breakpoints” between correct 
and copy-back RNA showed accumulation of specific AG and UC mutations, 
while the sequences flanking these mutations match to the binding sites of adenosine 
deaminase actin on RNA-1 (ADAR-1), a protein that acts on double strand RNA and 
edits it. Since viral dsRNA accumulates during viral infections lacking C protein, along 
with phosphorylation of the dsRNA-dependent protein kinase [122], which leads to 
the activation of immune responses, it is possible that C mediates N-RNA 
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interactions during transcription to avoid the formation of defective RNPs and 
activation of innate immunity [123].  
 
1.6 Regulation of translation 
Little is known about the mechanisms that regulate translation during the MeV 
lifecycle. Frequently, untranslated regions located downstream or upstream of the 
ORF play a role in stabilisation of the mRNA molecule. The M and F genes are the 
only two genes that have significant untranslated regions (UTRs), located at the 3’ 
end of M and the 5’ terminus of F.  This long UTR is a unique feature of 
morbilliviruses and is highly variable and also has a high GpC dinucleotide content. 
Some have speculated that this region might fold into complex secondary structures. 
In studies with CDV genomes, viruses that carried deletions in this region had 
increased replication and reduced virulence [124].  The role of the MeV M-F UTR in 
the MeV lifecycle is not completely understood yet and is likely to affect several steps 
of the virus; nevertheless, it has been show that this region is not required for MeV 
growth in vitro and in vivo, but has been shown to alter translation rates of the F 
mRNA [125].  
Interestingly, in a random mutagenesis insertional study of the MeV genome, non-
coding regions were much more tolerant to insertions than ORFs [94]. In particular, 
the 5’ UTRs of each gene were less tolerant to insertions than the 3’UTRs, 
suggesting a putative regulatory role for the 5’ UTRs in the regulation of the MeV 
lifecycle. 
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1.6.1 Location of transcription and replication 
In other viral infections, such as positive-sense RNA viruses, viral transcription and 
replication occur in dedicated structures, such as membranous replication factories 
[126]. However, similar structures have not been observed for negative-strand 
viruses, including MeV. Transcription and replication of MeV is thought to occur in the 
cytoplasm, since MeV can replicate in anucleated cells [127]. Immunofluorescence 
staining of several components of the viral RNP shows a punctate pattern of N and P 
proteins near the nucleus of the cell, co-localising with viral mRNA [95, 128]. 
Similarly, the L protein, known to co-localise with N, P and M, also shows a 
perinuclear punctate pattern [129], suggesting the existence of specific replication 
sites within the cell. Even though MeV can replicate in the presence of cytochalasin 
B, a drug that inhibits polymerisation of actin filaments, suggesting replication does 
not require the cytoskeleton [130], several cytoskeletal components have been 
shown to interact with the RNP. In particular, MeV L proteins interact with tubulin, the 
major constituent of the microtubules, to increase viral RNA synthesis [131], while 
cofilin, a protein involved in the severing of actin filaments, was shown to interact with 
N and be required for assembly of the RNP [132]. Although a specific site for RNA 
synthesis has not been described for MeV, it is possible that interaction with 
cytoskeletal components might help to concentrate viral proteins.  
 
1.7 Replication  
Replication is the process of producing full-length negative-sense RNA copies of the 
genome, using a positive-sense RNA template (the antigenome) (Fig.1-5). Briefly,  
34 
 
 
 
 
 
 
 
 
 
 
Fig.1-5 Schematic diagram of MeV transcription and replication. To initiate 
transcription, the RdRp complex binds to the 3’ end of a negative-sense (genome) 
RNA copy of MeV and starts mRNA synthesis. To initiate genome replication, the 
RdRp complex must produce a positive-sense copy of the genome (antigenome) 
which is encapsidated by N monomers. After this molecule is produced, the RdRp 
then synthesises a full-length copy of the genome, using the antigenome as a 
template, which is also immediately encapsidated by N. 
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during this process the RdRp complex produces a positive-sense copy of the 
genome, which is immediately encapsidated by N monomers. Subsequently, the 
same protein complex binds to the 3’ terminus of the antigenome molecule (via the 
antigenome promoter) and starts synthesising a complementary RNA molecule (the 
nascent genome) that is also immediately encapsidated by N. The molecular 
mechanisms behind the switch between transcription and replication are not well 
characterised. Some hypothesise that certain conformational changes in L lead to the 
intergenic regions (that may direct the disengagement of L during transcription) being 
ignored by L, so a full-length transcript is made [133].  
Although both positive and negative RNPs are produced during the replication phase 
of the life cycle, genomes are produced at a greater proportion than antigenomes 
[120, 134]. This is due to an apparently stronger promoter at the 3’ of the 
antigenome, in comparison to the genome promoter on the negative sense RNP. In 
related viruses, such as Sendai virus, the ratio of genome to antigenome is governed 
by expression of C protein; in this model, early infection is dominated by the 
synthesis of antigenomes since the total amount of C is low, but later in infection, 
with accumulation of C, this protein binds to the leader of the genome blocking its 
replication [135].  
 
1.8 Translation 
MeV does not encode its own translation machinery and relies on host ribosomes to 
produce viral proteins. During acute infection, viral RNA accounts for 25% of the total 
RNA in the cell [133]. Concurrently, MeV induces the complete shut-off of host 
protein synthesis. MeV translation was found to be independent of several translation 
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initiation factors, including eIF4G, eIF4E and 4E-BP1 [136]. It has also been reported 
that host translation was blocked by binding of the N protein to eIF3-p40 [137]. 
Nevertheless, it is thought that MeV translation is dependent on the phosphorylation 
of eIF2α [136], an initiation factor. 
MeV 5’UTRs are composed of only short 20 to 60 stretches of nts and lack 
recognisable functional structures. However, a predictive study suggested the 
existence of a short hairpin in the 5’ UTR of the N ORF [138]. This region was found 
to bind to the La/SSB antigen, and depletion or over-expression of this protein 
impacted on the translation of N [138]. 
 
1.9 Immune Response 
During the initial stages of infection MeV primarily infects cells of the immune system. 
As a result immune responses to MeV can be affected by this tropism and long-
lasting effects occur that impact on immune function long after infection is cleared. 
Some studies have shown that vaccine strains of MeV have a reduced tropism for 
lymphocyte populations [139, 140], and this perhaps explains the success of the 
attenuated virus in inducing a long-term immunity without the manifestation of clinic 
symptoms – even though the vaccine strain of MeV has been detected in a patient 
suffering from MIBE [141].   After initial contact with immune resident cells in the 
upper respiratory tract, MeV infection is transported to the lymph nodes where it 
replicates very efficiently. Viruses then enter the bloodstream through the circulation 
of infected peripheral blood mononuclear cells [47, 142].  
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1.9.1 Innate Immunity 
The first response to viral infection, including infection with MeV, is an innate immune 
response. Infection of lung epithelial cells leads to the production of interleukin-8 
[143] and interferon-β [144]. The production of IL1 and IL8 was also shown to be 
increased in patients infected with MeV [145]. MeV-induced IFN-β production is 
dependent on viral replication [146] since viral RNA is thought to be recognised by 
the pattern recognition receptors RIG-I and MDA5 [147, 148]. As opposed to this, 
MeV infection of CD4+ T lymphocytes leads to inhibition of type I IFN production 
[144]. Other viral components were shown to induce immune responses, i.e. upon 
interaction with the Toll-like receptor 2 (TLR2) [149], MeV H induces the production 
of IL-6, while the N protein interacts with interferon regulation factor 3 (IRF3), 
activating it and leading to IFN-β production [150, 151]. Finally, defective interfering 
particles can also induce the production of IFN-β [152]. Interestingly, vaccine strains 
of MeV are more potent inducers of IFN-β production then wild-type viruses, and this 
could be another important mechanism that explains the attenuation of the virus 
[153].  
MeV accessory proteins C and V have been implicated in virulence and in distinctive 
differences in the immune response to wild-type and attenuated viral infections [154, 
155]. As discussed previously, the C protein might be implicated in RNA synthesis 
and production of defective interfering particles, and although C is not required for in 
vitro infection, it’s deletion in a recombinant virus decreased replication in vivo [156, 
157]. The V protein prevents type I IFN production by direct binding to IKKα, a 
regulator of the NF-κB signal transduction cascade [158] and interferes with IFN 
signalling by binding to MDA5 [159, 160] and the STAT1 and STAT2 proteins [161, 
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162]. V protein has also been shown to be associated with reduced cytopathic effect 
in vitro and fast replication [163].  
 
1.9.2 Adaptive Immunity 
The emergence of an adaptive immune response, comprising humoral antibodies 
specific for MeV proteins and committed T cells, occurs concurrently with the 
development of the maculopapular rash, ~10 days after infection [164]. In monkeys, 
the most important control mechanism for viral infection appears to be CD8+ T 
lymphocytes, since depletion of this population sustains viremia for longer periods of 
time and leads to higher viral titres in the blood [44]. While CD4+ cells remain in the 
blood for longer periods of time after infection is cleared, the CD8+ T cell population 
rapidly decreases [165-167].  Along with this shift in cellular immunity, humoral 
immunity also shifts after the resolution of infection. Along with the activation of CD8+ 
T cells and CD4+ Th1 cells, an increase in the production of IL-2 and IFN-γ is 
observed, but this rapidly decreases after the establishment of memory B cells [166, 
168]. During recovery, regulatory CD4+ T lymphocytes remain activated for a long 
period of time [169].  
After efficient clearance of infection, MeV causes a prolonged immunosuppression 
that can last up to nine months [1, 39]. Although no infectious particles can be 
recovered from convalescent individuals, viral RNA can still be detected in circulating 
blood cells for several months. Interestingly, only wildtype strains of MeV cause this 
dysregulation of the immune system after infection, even though a similar long-term 
immunity is achieved with vaccine strains of MeV. The mechanisms underpinning this 
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immunosuppression are still not known however, some suggest that a combination of 
temporary leukopenia, dysregulated functions of antigen presenting cells and 
permanent type 2 cytokine production contributes [164].  
 
1.10 Cellular targets of viral infection 
Several MeV proteins have been implicated in virulence and pathogenesis of MeV 
infections, most prominently the C and V proteins. In a yeast two hybrid screen [170]. 
MeV C protein was shown to interact with the immunity-related GTPase M (IRGM), a 
protein that is known to interact with pattern recognition receptors and the autophagy 
machinery to induce antimicrobial responses [171]. Interestingly, MeV infections 
increased the formation of autophagosomes in cells and targeting IRGM was shown 
to decrease the formation of viral particles [170]. Furthermore, MeV infection was 
shown to induce two waves of autophagy in the cell, the first one soon after 
attachment and the second occurring 12 to 24 hours post-infection [172]. MeV C is 
also involved in the later phases of autophagy. In this study, viral proteins escape 
autophagic protein degradation and the induction of autophagy was shown to 
increase the formation of viral particles. Even though vaccine strains of MeV can 
induce autophagy during entry, by activation of the CD46-GOPC pathway [173], 
virulent strains (that do not use the CD46) could also induce autophagy [172]. 
Although some have suggested that the induction of autophagy by MeV prevents cell 
death [172], other reports show MeV-induced apoptosis. MeV infection was 
demonstrated to induce apoptosis in HeLa cells [174] and MeV H protein (from the 
vaccine strain) alone could induce apoptosis via the TRAIL-mediated pathway and 
the mitochondrial-controlled pathway [175].  
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MeV infection has also been shown to induce the downregulation of housekeeping 
genes [144]. In particular, the protein phosphatase 5 (PP5) was inactivated during 
infection, leading to the suppression of the DNA-dependent protein kinase activity, 
the reduction of SP1 phosphorylation levels and c-Myc degradation, all of which are 
involved in the regulation of expression of several housekeeping genes [176]. 
Although the mechanism behind this downregulation is unknown, it is possible that 
the accumulation of N leads to the inactivation of PP5.  
Another study that looked at gene expression in persistently infected human 
glioblastoma cells observed a downregulation of the mitochondrial short chain enoyl-
CoA hydratase (ECHS) [177], which is involved in the β-oxidation of fatty acids. 
siRNA knockdown of this protein leads to reduced cytopathic effects and MeV 
replication. Similarly, in persistently infected neuronal cells, genes regulating 
cholesterol biosynthesis were dysregulated when compared to uninfected cells [178]. 
Furthermore, knock-down of cholesterol biosynthesis impaired MeV budding in acute 
infection. These reports suggest that MeV might exploit lipid biogenesis pathways to 
promote viral budding. Such pathways might be dysregulated in persistently infected 
cells where viral exit is impaired.  
 
1.11 Entry and exit 
 
MeV exploits several cellular molecules and pathways to spread within the host. 
Particularly, the two envelope proteins of the virus, F and H, are involved in 
attachment and invasion of permissive cells to MeV, interacting with several 
receptors and controlling the fusion of the viral envelope to the plasma membrane. 
43 
 
The present thesis is focused on the mechanisms underlying viral spread; following 
sections therefore summarise what is currently known of MeV entry and exit. 
 
1.11.1 Envelope proteins 
1.11.1.1 Haemagglutinin  
MeV encodes two envelope proteins, H and F, whose function is to direct viral entry 
and exit. MeV H is a type II transmembrane protein composed of an N-terminal 
cytoplasmic tail (37 residues), a single pass transmembrane domain, a long 
extracellular stalk domain and a C-terminal cube-shaped globular head (Fig.1-6A) 
[179, 180]. In contrast to the majority of paramyxovirus haemagglutinin proteins, MeV 
H lacks neuraminidase function and it does not bind to sialic acids [181]. In spite of 
this, the globular head of H still resembles the sialidase conformation of other 
viruses, characterised by a β-propeller structure composed of six β-sheets (Fig.1-
6B).  The globular head is thought to be the main region for attachment and 
interaction with cellular receptors, while the stalk domain interacts with F. The 
cytoplasmic tail of H was shown to modulate fusion activity and surface expression 
[182]. MeV H is thought to be present at the virus envelope as a dimer-of-dimers, 
although some studies have described both monomeric and dimeric forms of H [181, 
183]. Dimerization was demonstrated to occur via the formation of two disulphide 
bonds at two cysteine residues, C139 and C154 [184].  
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Fig.1-6 Structure of MeV haemagglutinin. (A) MeV H is a transmembrane protein 
composed of an intravirion tail, a transmembrane domain, a long stalk and a globular 
head. MeV H is present at the surface as a dimer-of-dimers. The globular head 
interacts with cellular receptors while the stalk domain is known to interact with F. (B) 
A crystal structure of the globular head of H (inset in A). The H ectodomain has six β-
propeller blades, named β1 to β6. The β1 blade interacts with the other monomer of 
H, while blades 4 to 6 interact with cellular receptors. H is N-glycosylated and two 
carbohydrate moieties have been resolved in this structure [181]. 
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1.11.1.2 Fusion protein 
The F protein of MeV, and by inference the fusion proteins of all morbilliviruses, is a 
type I transmembrane protein that contains several glycosylated residues in its 
ectodomain [185]. Although the structure of MeV F has not been resolved yet, 
comparisons with the crystal structure of the related paramyxovirus, human 
parainfluenza virus type 5, as well as mutagenic studies have allowed the 
identification of several structural domains [186, 187]. The structure of F is described 
as a large globular head supported by short stalk, a single-pass membrane spanning 
domain and a short cytoplasmic tail of 33 amino acids. (Fig.1-7). The ectodomain of 
F is composed of three heptad repeat regions (HR): HRA and HRC are well 
conversed domains and are located in domain III (D3) which is the top and 
furthermost region of F in relation to the viral envelope, and HRB, which comprises 
the stalk domain in the pre-fusion conformation. Domains I and II (DI and DII) 
comprise the base of the globular head, while DII contains the region that interacts 
with H. The N-terminal domain contains a highly hydrophobic, leucine zipper 
structure – known as the fusion peptide – which is thought to be the fusion element of 
F  [188]. The transmembrane domain was shown to impact on fusion activation [186] 
but this was not seen for the cytoplasmic tail [182]. This protein is translated in the 
endoplasmic reticulum and its location is encoded by an N-terminal signal peptide of 
28 amino acids [189]. Initially, F is synthesised as a single peptide of 60 kDa, known 
as F0, which is fusion incompetent. Further proteolytic processing in the trans-Golgi 
network, catalysed by the furin protease, leads to the formation of two peptides – F1 
of 40 kDa and F2 of 20 kDa - which are covalently linked by a disulphide bond [190, 
191]. This process is calcium-dependent and furin acts on a polybasic site of F. 
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Fig.1-7 Structure of MeV fusion protein. (A) MeV F is a transmembrane protein 
present on the virus envelope as a trimer. F is composed of an intravirion tail, a 
transmembrane domain, a short stalk and a small globular head. The globular head 
is further dived into four domains: the top of F is composed of the DIII domain, while 
the bottom part is comprised of DI and DII; the fusion peptide is located between the 
DII and DIII domains. (B) Although the crystal structure of MeV F has not been 
resolved, a model based on the structure of the paramyxovirus human parainfluenza 
virus type 5 was generated and the relevant domains identified. Adapted from [192]. 
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Proteolytic activation of F proteins of related viruses has been shown to be 
accomplished by several mechanisms. For example, Hendra virus F is cleaved by 
protease cathepsin L [193] and is dependent on an endocytosis motif present in its 
cytoplasmic tail [194], while RSV F is cleaved in the macropinosome upon viral entry 
[195].  
 
1.11.1.3 Assembly and protein processing 
As mentioned previously, F and H are glycosylated. In particular, two asparagine 
residues in F2 peptide were found to be N-glycosylated [196]. These modifications 
are important for subsequent protein cleavage and correct transport to the plasma 
membrane. Meanwhile, several residues of MeV H have also been shown to be 
glycosylated, including residues N200 and N215 [181].  In CDV, the N-glycans of H 
were shown to impact on virulence [197]. Glycosylation of paramyxoviral proteins is 
very common e.g. studies have shown that Hendra and Nipah virus glycoproteins 
contain several N-glycosylated residues, some of which impact on fusion activity and 
antibody neutralisation evasion [198], however there have also been O-glycosylated 
residues recorded as well [199].  
MeV F and H proteins are thought to interact with each other in the endoplasmic 
reticulum [189]. In particular, the stalk of MeV H is known to interact with F and play a 
fundamental part in the triggering of F [200]. MeV F is a trimer, similarly to other 
paramyxoviral F protein. An exception to this rule was recently described for Nipah 
virus F, which is present as a hexamer[201].  
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Similarly to other enveloped viruses, morbilliviruses can spread by particle formation 
and by cell-cell fusion - a phenomenon called syncytium formation. Both processes 
are thought to rely on the same fusion mechanism, accomplished through the 
interaction of the viral GPs with virus specific cellular receptors. Recent 
crystallography and site-directed mutagenesis studies of the H protein-receptor 
interaction have elucidated the fusion mechanism of morbilliviruses. The H-protein is 
presented in two different tetramers when interacting with the receptor; the 
ectodomain is composed by a membrane-proximal stalk formed by a four-helical 
bundle, with an upper straight part and a lower supercoiled region, and a membrane-
distal six-blade β-propeller structure [202].  
 
1.11.2 Cellular receptors 
 
Several viruses interact with proteins or carbohydrates present at the plasma 
membrane of the cell to promote its entry and access the cytoplasm. Interaction with 
specific protein molecules, known as viral receptors, is fundamental to the spread of 
virus infection and virulence. Consequently, the tissue tropism of MeV is greatly 
explained by the interactions between the two GPs present at the envelope of the 
virus and a set of proteinaceous receptors expressed in different cells of the host. At 
present, two receptors are known to be responsible for the permissivity of different 
cells to wild-type MeV: the signalling lymphocyte activation molecule f1 (SLAMF1) or 
CD150, which is expressed at the surface of activated T and B lymphocytes and 
other cells of the immune system [23, 203], and Nectin-4 (or poliovirus receptor-
related 4), found the basolateral surface of epithelial cells [204, 205]. For attenuated 
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strains, CD46 also functions as a receptor for MeV. SLAMF1 is considered the main 
cellular entry receptor for wild-type strains [206, 207].  
 
1.11.2.1 SLAMF1 
 
The discovery of SLAMF1 as a receptor for MeV was pivotal to the understanding of 
MeV tropism and pathogenesis but also brought insights into the MeV fusion 
process. SLAMF1, also known as SLAM or CD150, was first identified by Tatsuo et 
al. and it was the first recognised receptor to be used by both attenuated and wild-
type strains of MeV. Subsequently it has also shown to be a universal morbillivirus 
receptor used by the rest of the members of the genus [203, 208]. SLAMF1 was 
identified using a cDNA library transfected into HEK293T cells - ordinarily refractory 
to MeV infection - in conjugation with VSV-based pseudoparticles typed with wild-
type MeV H and F.  
SLAMF1 belongs to a superfamily of proteins whose members are important 
immunomodulators involved in lymphocyte maturation. This family is composed of 
nine members, classified as SLAMF1 to 9, that are present on the cell surface as 
dimers and function as cell ligands with signalling ability. Their tissue distribution is 
restricted to haematopoietic cells [209]. Recently, antimicrobial functions have been 
attributed to several members of this family, including SLAMF1 [210], SLAMF2[211] 
and SLAMF6 [209]. This molecule acts as a self-ligand and is involved in the 
stimulation and activation of T and B cells [212]. SLAMF1 is an integral membrane 
protein and its cytoplasmic tail contains three SRC homology 2 (SH2) binding 
domains (Fig.1-8). The membrane-proximal domain interacts with the SLAM- 
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Fig.1-8 Schematic representation of SLAMF1. SLAMF1 is a transmembrane 
protein that contains two immunoglobulin-(Ig)-like domains, a membrane distal 
variable (V) domain and membrane proximal constant C2 domain. This protein has a 
single membrane spanning domain and a long cytoplasmic tail. Its cytoplasmic tail 
contains three Src homology 2 (SH2)-binding motifs that are known to interact with 
several cellular proteins.  
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associated protein (SAP), recruiting FYN that phosphorylates the membrane-distal 
tyrosine initiating a signalling cascade that culminates in activation of NF-κB and 
cytokine production [213]. Similarly, the membrane-proximal domain can interact with 
Ewing’s sarcoma associated transcript 2 (EAT-2) protein, which is expressed in 
macrophages and dendritic cells, possibly leading to cytokine production in these 
cells without interaction with the membrane-distal tyrosines [214]. The cytoplasmic 
tails of these receptors contain several signalling motifs known to interact with a 
myriad of proteins. One interaction partner is the SLAM-associated protein (SAP) 
which is known to interact with at least six members of this family [209]. SAP 
interaction can be both dependent and independent on the phosphorylation of 
tyrosine-containing motifs, such as the SH2 domains in the cytoplasmic tail of 
SLAMF1. This primary interaction between SAP and the cytoplasmic tail of SLAMF1 
governs SAP-mediated signalling. SAP interaction with these SH2 domains can block 
the binding of SHP-1 and SHP-2, two tyrosine phosphatases, and recruit the Src 
kinase Fyn[215]. The congenital truncation of SAP is associated with the X-linked 
lymphoproliferative disease [216].  
SLAMF1’s antimicrobial functions are centred on the sensing of incoming bacteria, 
recruitment of the autophagy machinery and clearance of the microbe [210]. SLAMF1 
in macrophages recognises the outer membrane porins C and F present at the 
surface of Gram-negative bacteria. This interaction leads to the recruitment of Beclin-
1, a protein involved in the scaffolding of the autophagic complex, and later the 
formation of UVRAG, VPS34 and VPS35. This process was shown to be dependent 
on the production of phosphotidyinositol-2-phosphate (PI3P), which leads to the 
formation of the NAPDH oxidase complex and recruitment of EEA1, necessary for 
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phagocytosis and clearance of the microbe. The SLAMF6 protein was reported to 
recognise E. coli with potential roles in colitis [217]. Interestingly, macrophages that 
lack the expression of SLAMF1 have defective responses to LPS, while in dendritic 
cells SLAMF1 might also play a role in cytokine production.  
1.11.2.2 Nectin-4 
After the discovery of SLAMF1 receptor, a new paradigm emerged. Wild-type strains 
of MeV were known to infect several types of tissues, such as the lung epithelium, 
upper respiratory tract, mouth, nose, bladder, intestines and the liver, that lack 
expression of SLAMF1 [218-220]. This was clear evidence for the existence of at 
least another receptor that granted MeV tropism for these cell types. In 2011, Noyce 
et al. discovered that MeV infection was sensitive to the loss of tight junctions and 
later identified Nectin-4 (also known as poliovirus-receptor-like 4) as the epithelial 
receptor of MeV [221]. This molecule belongs to the family of nectin proteins which 
are components of adherens junctions and contribute to cell adhesion. This molecule 
has been identified in several cancer cell lines [222] and has recently been 
recognised as a lung and breast tumour cell marker [223, 224] . Nectin-4 contains a 
short cytoplasmic tail and a transmembrane domain, while its extracellular domain is 
composed of three immunoglobulin-like loops: two conserved C2 domains and a 
variable (V) region (Fig.1-9) [225]. Its cytoplasmic tail is known to interact with afadin 
and confer attachment to the cortical cytoskeleton. 
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Fig.1-9 Schematic diagram of nectin-4. Nectin-4 is present as dimer and is a 
transmembrane protein that contains three immunoglobulin (Ig)-like domains and a 
cytoplasmic tail. MeV interacts with the ectodomain of nectin-4 to gain access to 
epithelial cells and establish infection. Nectin-4 is a component of the adherens 
junctions, forming cis- and trans-dimers between neighbouring cells.  
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This protein can interact with other monomers of nectin-4 as well as several 
members of its wider family [225]. Although its predicted molecular weight is 55.5 
kDa, post-translation modifications, such as N-glycosylation of its ectodomain, are 
responsible for a shift in molecular weight. Despite the suggestive name, nectin 
family members do not function as poliovirus receptors [226]. Nevertheless, nectin-1 
and nectin-2 have been shown to function as receptors for several 
alphaherpesviruses [227, 228]. Although SLAMF1 and nectin-4 were initially 
identified as MeV receptors, they have also been shown to act  as viral receptors for 
the other established morbilliviruses [203, 205, 229-232]. It is therefore interesting to 
analyse the ability of different morbilliviruses to use non-host receptors. CDV, in 
particular, was found to readily use human Nectin-4 where adaptation to human 
SLAMF1 required only a single amino acid substitution in the H protein, D540G [22].  
 
1.11.2.3 CD46 
Despite its restricted use by only attenuated but not wild-type strains of MeV, cluster 
of differentiation 46 (CD46) was the first MeV receptor identified [233, 234]. CD46 is 
a regulatory protein of the complement system and is ubiquitously expressed except 
for on erythrocytes [235].  As part of the innate immune response, the complement 
system is a collection of humoral proteins present in the blood that catalyse 
inflammatory reactions and mediate the lysis of cellular pathogens or promote the 
opsonisation of microbes and their uptake by phagocytic cells [236]. CD46 is an 
important regulator of complement and is part of a larger family of complement 
regulatory membrane proteins. In particular CD46 plays a role in the inactivation of 
C3b and C4b opsonins [237, 238]. CD46 is a transmembrane protein composed of a 
63 
 
cytoplasmic domain (two known isoforms, CYT-1 or CYT-2), a transmembrane 
domain and two extracellular regions: (1) a membrane-proximal region that contains 
two glycosylated, serine-, threonine- and proline-rich domains known as the B and C 
domains, and (2) a membrane-distal region that contains four complement control 
(CCP) domains, also known as short consensus repeat 1 to 4 (Fig.1-10) [237].  
Mutations in, or deficiency of, CD46 are associated with over-activation of 
complement due to a reduced capacity for inactivating C3b and C4b. Additionally, the 
accumulation of C3b onto the surface of endothelial cells can lead to the formation of 
thrombi, causing macroangiopathic anaemia and renal failure [239, 240]. This protein 
has also been shown to be involved in certain reproductive processes. In particular, 
the expression of CD46 on the surface of spermatozoa is associated with the fusion 
process between the oocyte and the sperm [241, 242]. Consequently, a deficiency in 
CD46 expression in males is linked to infertility [243, 244].    
Similarly to several SLAM and nectin family members, CD46 has also been shown to 
interact with several other pathogens. In particular CD46 is a cellular receptor for 
human herpes virus 6 [245], group B adenoviruses [246] and for the bovine viral 
diarrhoea virus [247]. The Gram-negative bacteria Neisseria gonorrhoeae [248] and 
Neisseria meningitis [249] as well as the Gram-positive bacterium Streptococcus 
pyogenes [250] also establish interactions through CD46. In the context of bacterial 
infection via CD46, it has been suggested that CD46-mediated signalling leads to 
rearrangements of the cytoskeleton that permit the invasion of these pathogens 
[251]. Particularly, Neisseria infection leads to the phosphorylation of the cytoplasmic 
tail of CD46 by the Src-tyrosin kinase c-Yes; these phosphorylated residues then 
interact with ezrin – a protein involved in the crosslinking of plasma membrane to  
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Fig.1-10 Schematic diagram of CD46. The molecule CD46 is a membrane protein 
comprised of a cytoplasmic tail, a transmembrane domain and an ectodomain. There 
are two isoforms of CD46 with different cytoplasmic tails, known as CYT-1 and CYT-
2. In the ectodomain, the membrane-proximal B and C domain are rich in serine, 
threonine and proline (STP). The membrane-distal region contains four short 
consensus repeat (SCR) domains named 1 to 4. Domains SCR1 and 2 are known to 
interact with MeV [252]. 
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actin filaments – and the accumulation of cytoskeletal components facilitate pathogen 
entry [253, 254]. Phosphorylated residues in the cytoplasmic tail of CD46 have also 
been implicated in the cortical actin network and the modulation of cell polarity and 
integrity of the epithelial barrier [255, 256]. In recent years, with the elucidation of 
autophagy mechanisms, the activity of the cytoplasmic tail of CD46 has been linked 
with the formation of autophagosomes through the recruitment of Golgi-associated 
PDZ and coiled-coil motif-containing (GOPC) protein [173, 257].  
 
1.11.2.4 Other receptors and entry co-factors 
1.11.2.4.1 Moesin 
Several other molecules have been linked to the entry step of the MeV life cycle, 
even though they do not function as viral receptors. One such protein is the 
membrane organising extension spike protein (moesin), a protein that bridges actin 
filaments of the cell cortex to plasma membrane proteins [258]. Although this protein 
was initially thought to be a receptor for MeV [259], this was subsequently disproved 
by other groups and its role in MeV remains unclear. In the study performed by 
Dunter et al., the authors used an antibody that specifically inhibited MeV infection in 
certain cell lines [259, 260]. Further incubation of this antibody with surface-labelled 
cells and subsequent immunoprecipitation pulled down a 75kDa protein, with 
sequence similarity to moesin. The same research group later described that moesin 
and CD46 may act as a complex during MeV entry [261]. Studies by other groups 
showed that cells lacking moesin are still permissive to MeV [262] and the antibody 
used previously has cross-reactivity to CD46 [263]. The commonly attributed 
localisation of moesin is to the inner leaflet of the plasma membrane in association 
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with the cytoskeleton of cell cortex; and it is therefore hard to imagine how it could 
act as a primary viral receptor.  Nevertheless, two reports on the localisation of 
moesin suggest its presence at the cell surface [264, 265]. More recently, a report 
highlights the important of this protein in the transmission of MeV infection between 
dendritic cells and lymphocytes [266]. Although moesin is not seen as a MeV 
receptor, it is possible that it plays a yet undetermined role in MeV entry. 
1.11.2.4.2 NK-1 
Another example of a protein that might be involved in the entry of MeV is the 
substance P receptor neurokinin-1 receptor (NK-1). Substance P is a small peptide 
(11 amino acids) that functions as a neurotransmitter and is associated with pain and 
inflammatory responses [267]. NK-1 is the receptor for substance P and is expressed 
at the synaptic neuronal endings of neurons in the brain and spinal cord [268]. The 
initial work of Harrowe et al. showed that MeV F protein shares sequence similarity to 
substance P and incubation with substance P reduced MeV-induced cell-cell fusion 
[269]. This is particularly relevant to MeV transmission to the nervous system. It has 
been documented that cell-to-cell fusion induced by MeV infection in neurons, that 
occurs primarily at synapses, does not require the activity of H protein or expression 
of known receptors [270-272]. Further studies demonstrated that interfering with the 
expression or activity of NK-1 reduced MeV infection in susceptible mice [273]. It is 
possible that MeV spread to neurons might be regulated by NK-1, where F might be 
triggered by this interaction. Nevertheless, the search for a neuronal receptor is a 
topic of current investigation [274].  
69 
 
1.11.2.4.3 TLR2 
As part of cellular innate immunity, pattern recognition receptors, such as RIG-I-like 
receptors or Toll-like receptor (TLRs), play a crucial role in recognizing pathogens 
and subsequently activating immune responses [275]. One such receptor is TLR2, 
which is a cell surface receptor present on several immune cells, such as 
macrophages, dendritic cells, T and B lymphocytes, as well as epithelial and 
microglial cells. This receptor is known to recognise pathogen-derived molecules 
including lipoproteins, lipotechoic acid and peptidoglycans [276]. Although its 
mechanism of action is dependent on the cell in which it is expressed, TLR2 
activation leads to several inflammatory responses: increased production of reactive 
oxygen species [277], NF-κB activation [278], stress responses [279], etc. 
Interestingly, wild-type strains of MeV H were reported to interact with TLR2 on 
dendritic cells, leading to the production of IL-6 and upregulation of SLAMF1 [149]. 
This interaction between H and SLAMF1 was specific to virulent strains and sensitive 
to one single amino acid substitution (N481Y), which is also involved in CD46-
mediated entry of attenuated strains. TLR2 activation during MeV infection is 
associated with virus-induced immune suppression and viral tropism.  
1.11.2.4.4 DC-SIGN 
Similarly, the dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) molecule has been shown to interact with MeV H and F during 
the initial stages of immune cell infection [280]. DC-SIGN is C-type lectin pattern 
recognition receptor, expressed on dendritic cells (DCs) and macrophages, that 
recognises endogenous glycoproteins, such as intercellular adhesion molecule 2 
(ICAM2) and 3 (ICAM3) which impact on cell migration and cell-cell communications 
[281, 282], but also interacts with pathogens, mediating phagocytosis and immune 
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responses [283, 284]. In studies performed by de Witte et al. in 2006 and 2008, DC-
SIGN activity was shown to be necessary for infection even though its expression in 
non-permissive cells does not permit MeV entry. Furthermore, they showed that this 
molecule mediates the spread of MeV from DCs to T lymphocytes. In particular DC-
SIGN appears to be involved in trans-infection of MeV into T cells in a process that is 
independent of both SLAMF1 expression and DC infection [280, 285]. Consequently, 
in the macaque model, lung-resident DCs expressing DC-SIGN were shown to be 
initial targets of MeV and pivotal to subsequent spread of the infection [286]. DC-
SIGN is now seen as an important attachment factor and pivotal molecule in the 
establishment of MeV infection. Interestingly, this molecule has been implicated in 
the attachment and entry of numerous viruses, including RSV [287], Ebola virus 
[288], Influenza A virus [289], herpes simplex virus 1 [290], HIV-1 [291], etc. This 
association of DC-SIGN with a broad collection of viral envelope proteins is likely to 
be related to the ability of this receptor to recognise glycosylated proteins – as viral 
envelope proteins usually are – and the role it plays in antigen presentation.  
These examples of interactions between MeV envelope proteins and cellular 
receptors are likely to impact, at some level, on the steps of viral attachment and 
entry. Reports have shown that atypical interaction of intravirion proteins with cell 
surface proteins might aid the establishment of infection. Despite a growing list of 
interaction partners for MeV proteins and their putative functions as cellular 
receptors, researchers have predicted the existence of at least two other receptors. 
As mentioned previously, MeV can also infect the nervous system, particularly 
neurons and astrocytes [141, 272, 292]. Although F interaction with NK-1 may 
contribute to infection of these cells, it is possible that a specific H-interacting 
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receptor exists on these cells. In addition, endothelial cells can also become infected 
with MeV [174, 219]. Since endothelial cells lack the expression of any of the 
identified receptors for virulent strains of MeV (SLAMF1 and nectin-4) it is possible 
that another cellular protein grants permissivity to these cells.  
 
1.11.3 Virus Entry 
The initial stages of MeV infection are likely to involve the interaction of several 
proteins and the exact stoichiometry of this process is not known. Nevertheless, 
mutagenic studies of viral proteins, crystallographic approaches and the biochemical 
characterisation of receptors and viral H and F proteins have unravelled some of the 
details of virus entry. The measles virion is decorated with H tetramers and F trimers; 
each tetramer of H ad trimer of F form a complex called the “fusion complex” and it is 
considered the minimum requirement for MeV entry. When a virion is adsorbed onto 
the plasma membrane of a permissive cell, H interacts with SLAMF1 leading to a 
series of conformational changes in this protein and, subsequently, in the F protein. A 
dramatic refolding of F exposes a highly hydrophobic peptide that penetrates the 
plasma membrane of the cell. The reconfiguration of the structure of F brings the two 
membranes together, leading to the coalescence of the outer lipid leaflets of both 
membranes, a step known as hemifusion, and later the formation of a fusion pore by 
the complete fusion of both viral envelope and the plasma membrane. Through this 
fusion pore, MeV genome is released into the cytoplasm where replication occurs. 
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1.11.3.1 Attachment 
As mentioned previously, the globular domain of H contains binding sites for its 
several receptors [293-296]. Vaccine strains of MeV that use CD46 as a receptor 
diverge from wild-type MeV H by accumulating several mutations in the globular 
head – most importantly the N481Y substitution, which was shown to be important for 
attachment and triggering of fusion in CD46-positive cells [297, 298].  When 
interacting with SLAMF1, MeV H binds to the V domain with three residues in 
SLAMF1 being particularly important for binding, I60, H61 and V63 [299, 300]. 
Complementarily, several residues in H have been identified to mediate binding to 
SLAMF1 [301] and fusion [293, 294].  
Both mutagenic and crystallographic studies have been applied to elucidate the 
binding mechanism of MeV H to its receptors. A total of five crystal structures of MeV 
H have been resolved, most them in association with SLAMF1, CD46 or nectin-4. 
Initially, MeV H-CD46 complexes were resolved (Fig.1-11) [302, 303]. This structure 
showed that H is present as a dimer and interacts with two molecules of CD46 
containing the SCR1 and SCR2 domains (Fig.1-11A). The main interaction site is on 
β-propeller 4, which contains an indentation that interacts with the SCR1 and SCR2 
domains. A total of three contact sites between H and CD46 were identified: (1) 
region 1 is composed of a double proline motif (I37-P38-P39-L40), located at the N- 
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Fig.1-11 Structure of the MeV H receptor binding domains. A representation of 
the amino acids involved in binding to (A, in red) CD46, (B, in green) nectin 4 and (C, 
in blue) SLAMF1. The lower panel (D) reflects a superimposition of these three 
binding sites on the MeV H structure [192].   
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terminus of CD46 and the SCR1 domain, that inserts into a hydrophobic pocket in H 
located between the 4th and 5th β-propellers; (2) the second interaction site involves a 
hydrogen bond formed by Y481, a pivotal amino acid involved in CD46-tropism [297, 
298], that interacts with C65 of CD46 that is located between the SCR1 and SCR2 
domains; finally, (3) the third contact region is composed of Y67 and Y85 of CD46 
that interacts with V451 and Y481 of H.  
Similar studies have been performed for the SLAMF1-H interaction [180, 181]. MeV 
H interacts with the V domain of SLAMF1 via its 4th, 5th and 6th β-propellers (Fig.1-
11C). Four binding sites are thought to govern SLAMF1-H interactions: (1) in site 1 
two aspartic acid residues of H (505 and 507) interact with K77 and R90, 
respectively, of SLAMF1, (2) in site 2, two salt bridges established between the E123 
of SLAMF1 and D530 and R533 of MeV H (which are known to contribute to the 
stabilisation of the interaction), (3) site 3 is composed of a planar interaction between 
five amino acids in the 6th β-propeller of H (P191-R195) and five other amino acids in 
the V domain of SLAMF1 (S127-F131); (4) lastly, at site 4, a patch of aromatic 
residues in H (Y541, Y524, Y543 and F552) interacts with F119, R130 and D75 of 
the SLAMF1.  
Finally, the interaction of the MeV attachment protein with nectin-4 has also been 
described, again primarily with mutagenesis-based and crystallography approaches 
[296, 304]. The V domain of nectin-4 was shown to interact with an indentation 
formed between the 4th and 5th β-propeller blades, similar to the interaction of 
Edmonston strain MeV H with CD46 (Fig.1-11B). The Nectin-4-H interaction involves 
three binding sites: (1) in the first contact region, the H residues Y524, L526, Y541 
and Y543 on the 5th β-propeller blade, which have previously been shown by 
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mutagenesis to be important for virus entry [295, 304], interact with seven amino 
acids in nectin-4 (S99-F106) while a stretch of amino acids in the β4 blade (P458, 
M459, L462-G465, L482 and F483) binds to F101-G104 in nectin-4; (2) the second 
site of interaction consists of a loop of amino acids in the interface between the 4th 
and 5th β-propeller blades (T498, Y499 and D505) that interacts with Q30, G32 and 
Q33 of nectin-4; while (3) the 3rd site of interaction is composed of the amino acids 
H52-Y55 in the nectin-4 V domain that interact with the loop located between the 4th 
and 5th β-blades (Y499 and L500) of H and amino acids in the β3 blade (K387-K389).  
Biochemical studies that allowed the determination of the dissociation constant (Kd) 
for MeV H and its receptors identified the following, described here in ascending 
order: 𝐾𝑑 𝑛𝑒𝑐𝑡𝑖𝑛−4 = 20 𝑛𝑀 < 𝐾𝑑 𝐶𝐷46 = 75 − 100 𝑛𝑀 < 𝐾𝑆𝐿𝐴𝑀𝑓1 = 80 − 500 𝑛𝑀 [204, 
301, 305]. This suggests that MeV H binds with higher affinity to nectin-4, with some 
studies suggesting that ligand-receptor disengagement is mediated by other domains 
of nectin-4 not primarily involved in binding [306].  
 
1.11.3.2 Fusion mechanism 
The fusion mechanism of the H and F oligomeric complexes with their cellular 
receptors has been a topic of intense investigation with diverse studies, from 
mutagenesis to crystallography, allowing the development of a good understanding 
of how the process unfolds. Nevertheless, the exact transitional conformations and 
the overall process of membrane fusion still remain unknown. The F protein of MeV is 
a class I fusion protein, i.e. the conformational changes that F undergoes to mediate 
membrane fusion are irreversible [307]. A schematic representation of the fusion 
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process is depicted in Fig.1-12. The minimum unit for viral fusion is composed of a 
tetramer of H which interacts with a trimer of F, a macromolecular complex known as 
the fusion complex. The fusion complex is present at the surface of measles virions 
and the plasma membrane of MeV-infected cells (Fig.1-12A).  After binding of H to 
its receptors (Fig.1-12B) – even when only one dimer of Hs is interacting with the 
receptor – H triggers a sequence of conformational changes in F (Fig.1-12C). This 
signal which induces the activation of F can be transferred across the interface of the 
two dimers, as the overall tetramer organisation of H is maintained during fusion 
[308]. Although MeV H is necessary to trigger F in the presence of the receptor, F 
can also be activated by exposure to high temperature in the absence of receptor or 
H [309]. This suggests that H might reduce the energy barrier required to trigger F. 
The important step during this process is understanding how the signal is transferred 
onto F upon coupling of H with the cellular receptor. The fourth and fifth blades of the 
β-propeller are involved in the interaction with the receptor while the stalk domain is 
involved in the triggering of the F protein [180]. Before triggering F, the H tetramer 
assumes a planar “heads-down” configuration; the interaction with the receptor 
possibly induces conformational changes in the tetramer, leading to the segregation 
of the stalks of the two dimers [180, 308].  Mutagenesis of the stalk of H interferes 
with its ability to trigger fusion, and it is believed that the detachment of H and F is 
required to induce fusion [310]. Two domains located to the upper central and lower 
central stalk sections are involved in triggering and modulating fusion: the lower 
domain is responsible for activating F and initiating fusion while the upper domain is 
required to promote fusion beyond the initial activation step [309, 311-313]. Activated 
F protein exposes the fusion peptide and inserts it into the membrane of the target  
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Fig.1-12 Schematic representation of the fusion mechanism of MeV. In its 
resting state, a tetramer of H assumes the “heads down” configuration, in which F 
strongly interacts with the stalk domain of H (A). Upon binding to SLAMF1, the 
tetramer of H undergoes a conformational change described as the “heads up” 
configuration (B). This will release F and trigger it, leading to the initiation of the 
fusion process (C). At this point, F unfolds exposing the fusion peptide that 
penetrates the target membrane (D). Further conformational modifications in the F, 
bring the two lipid bilayers to close proximity (E), where hydrophobic interactions 
between phospholipids lead to an intermediate stage called hemifusion (F). Finally,  
two membranes fuse completely leading to the release of the viral genome into the 
cytosol (G). Adapted from [308] and [317]. 
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cell (Fig.1-12D). Predictably the distance of the binding domain of the receptor from 
the surface influences fusion efficiency of the virus, suggesting a limited reach for the 
fusion peptide with respects to the plasma membrane [314]. Further refolding of the F 
protein consists of the formation of a transient structure called “hairpin”, in which N-
terminus of the F1 fragment, inserted into the plasma membrane of the host, moves 
closer to the C-terminus of the protein, located in the viral envelope - bringing the 
viral and host membranes to close proximity (Fig.1-12E). The outer leaflets of the 
plasma membrane and the viral envelope coalesce – this step is known as 
hemifusion (Fig.1-12F). When hemifusion is reached, the inner layers of 
phospholipids mix, culminating in the formation of the fusion pore where the contents 
of the virion are released into the cytosol (Fig.1-12G) [315, 316].  
 
1.11.3.3 Endocytosis 
The entry of paramyxo- and pneumoviruses has long been regarded as independent 
of endocytosis mechanisms as infection occurs by direct fusion of the viral envelope 
to the plasma membrane of the cell [318, 319]. This conclusion was drawn in 
recognition of two of the main phenotypes of infection: (1) the pH-independent 
activation of paramyxoviral fusion proteins and (2) the ability of several viruses to 
induce cell-cell fusion, suggesting that fusion is essentially mediated by receptor 
binding. Since the seminal work of Helenius and colleagues on the entry mechanism 
of Semiliki virus [320], clathrin- and caveolin-mediated endocytosis have been 
regarded as entry pathways that viruses hijack to establish infection – studies that 
were possible due to the use of lysosomotropic agents and electron microscopy. 
Unfortunately, the lack of suitable techniques to investigate other endocytosis 
83 
 
pathways, such as macropinocytosis, phagocytosis, flotillin-dependent endocytosis, 
etc., hindered research into the entry mechanisms of viruses that did not use clathrin- 
and caveolin-dependent endocytosis [321]. Recent advances in immunofluorescent 
tracking of viral particles, siRNA screens and a wide collection of pharmacological 
inhibitors have, however, allowed the dissection of several endocytosis pathways that 
remained previously uncharacterised. As a consequence, several paramyxoviruses 
and pneumoviruses have been shown to internalise by distinct pathways, such as 
RSV [195, 322], Sendai virus [323], Nipah virus [324, 325], Newcastle disease virus 
[326] and human metapneumovirus [327]. However, these entry pathways have not 
been assessed during morbillivirus infection. Nevertheless, a study using lentivirus 
pseudotyped with MeV glycoproteins showed endocytosis into lymphocytes [328] 
while soluble MeV H is internalised in CD46-positive cells via clathrin-mediated 
endocytosis or macropinocytosis [329]. These studies suggest that MeV might be 
endocytosed during the initial stages of infection. 
 
1.11.3.4 Membrane interactions 
In recent years, MeV has been shown to manipulate the cellular membrane 
impacting on viral spread. Particularly, work performed by the Schneider-Schaulies 
research group has convincingly shown the modulation of sphingomyelinases during 
viral entry. Sphingolipids are a group of lipids that contain a sphingosine side chain 
and are components of cellular membranes that play important roles in cell signalling 
[330]. Sphingomyelin, a type of sphingolipid that contains ceramide, is hydrolysed by 
sphingomyelinases generating important secondary messengers during molecular 
signalling and signal transduction after extracellular stimulus [331]. In 2011, Avota et 
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al. showed that upon binding of MeV to DC-SIGN, ceramides accumulate on the 
outer leaflet of the plasma membrane due to the activity of sphingomyelinases [332]. 
This concentration of ceramide at the entry site was demonstrated to be necessary 
for the recruitment of SLAMF1 and internalisation of MeV. Subsequent studies 
showed that MeV modulates the activation of T cells by controlling the activity of the 
neutral sphingomyelinase, impacting on the formation of the immunological synapse 
and suppression [333]. Other studies showed that altering the shingosine-1-
phosphate levels – a component of the signalling pathway of sphingomyelin – 
impacted on MeV replication, highlighting the importance of sphingolipids in the virus 
lifecycle [334]. The accumulation of ceramide at the plasma membrane leads to the 
coalescence of lipid rafts into larger microdomains; such domains are known to 
entrap and concentrate several membrane proteins, including cellular receptors, 
where the virus can enter [335, 336]. Such ceramide-enriched domains have been 
implicated in the fusogenicity of cellular membranes but also in internalisation 
pathways such as phagocytosis [337, 338]. Together these data are evidence of a 
highly organised mechanism of entry for MeV that perhaps requires clustering of 
cellular receptors and intracellular signalling, in contrast with the current paradigm of 
viral envelope fusion at the plasma membrane. 
 
1.11.4 Virus exit 
The molecular details of MeV budding are not described yet, but limited evidence has 
suggested a mechanism similar to other paramyxovirus (see Fig.1-13 for a schematic 
representation of MeV egress.  Briefly, MeV glycoproteins interact in the endoplasmic 
reticulum where they form an inactive fusion complex. Hijacking the vesicular  
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Fig.1-13. Schematic diagram of MeV egress. (A) MeV F and H proteins interact in 
the endoplasmic reticulum (ER) after being synthesised, forming the fusion complex. 
This complex is transported to the surface in a ESCRT-independent manner. The M 
protein interacts with recently formed RNP complexes and mediates transport to the 
plasma membrane using Rab11-positive endosomes. At the cell surface, MeV M 
bridges the fusion complex with the RNP by interacting the cytoplasmic tail of MeV 
glycoproteins. This interaction leads to the formation of virions and subsequent 
release into the extracellular environment. Adapted from [353].   
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trafficking system, both glycoproteins are transported to the plasma membrane. The 
M protein may interact with the RNP which are co-transported to the cell surface by 
unknown mechanisms. It is commonly believed that M functions as a crosslinker 
between the cytoplasmic tails of MeV F and H and the RNP, initiating particle 
formation culminating in the release of the virion into the extracellular environment. 
Additionally, it has been suggested that cell fusion might be required for virus spread 
in vivo [339, 340]. Several studies have indicated that M modulates virus assembly 
and, interestingly, mutations in this protein change the balance of viral spread from 
particle to syncytia formation [341]. MeV enveloped proteins are expressed in the 
basolateral surface of polarised epithelial cells; however, when co-expressed with the 
M protein, they are re-directed to the apical surface, where the virus is naturally 
released [339, 342]. The underlying mechanism for this process is, only now, starting 
to be dissected. Firstly (1) M protein coats the RNP complex [99]; then (2) this 
complex associates with Rab11a positive recycling endosomes (Rab11a regulates 
exocytosis of recycling vesicles at the plasma membrane [343]) and is transported 
along the microtubules in the direction of the apical surface [344]. Lastly, (3) at the 
plasma membrane site, M protein interacts with the cytoplasmic tails of H and F 
proteins, combining the RNP with the envelope proteins and stabilizing the complex. 
This interaction is crucial for generating virus particles. Accordingly, mutations in 
either the M protein or glycoprotein cytoplasmic tails are thought to favour cell fusion 
over particle formation [345, 346]. One cellular protein that has been implicated in 
playing a role in modulating virus exit is actin, a component of the cytoskeleton which 
is known to contribute to the budding of other viruses [347]. Actin filaments have 
been identified in MeV particles and it has been shown that actin located to the 
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cortex of cells is required for the later stages of virus infection [348]. Other studies 
showed that actin competes with the cytoplasmic tails of viral GPs for interaction with 
M protein, promoting cell fusion [349]. Some paramyxoviruses  take advantage of the 
endosomal sorting complex required for transport (ESCRT) proteins, a group of 
proteins that finish vesicle formation by inducing scission of the plasma membrane to 
complete budding [350]. However, MeV particle formation does not require proteins 
of the ESCRT pathway and its true budding mechanism is yet to be determined 
[346]. Nevertheless, viral budding in MeV infections is associated with cholesterol-
rich microdomains (lipid rafts) [351] and CDV requires cholesterol in the viral 
envelope, but not in target cells, to allow infection [352], which suggests a substantial 
role for this molecule in virus maturation. In fact, MeV infection modifies the 
expression levels of two enzymes involved in the synthesis of cholesterol in cells 
(hydroxy-3methylglutaryl-conenzyme A reductase and squalene monooxygenase) 
[178]. 
  
1.12 General Aims 
 
During infection, MeV infects a variety of cells that differ not only in their composition 
and nature, but also in the three-dimensional tissue architectures in which they 
reside. MeV has to overpass biological barriers, such as the extracellular matrix and 
mucus of the respiratory epithelium, to successfully infect target cells. When at last, 
MeV interacts with its cellular receptors, its genome must be transported into the 
cytoplasm so replication can start. As highlighted in this introduction, the 
mechanisms of MeV cellular spread are poorly characterised. Recent advances in 
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immunofluorescence microscopy, high-throughput screens and the expansion of 
well-characterised pharmacological inhibitors have been fundamental for unravelling 
these mechanisms for other viruses. Herein, I intend to explore two main questions 
related to viral spread: 
1 – What are the molecular mechanisms governing the entry of MeV particles into 
the SLAMF1+ cells? 
2 – What cellular components control MeV exit via cell-cell fusion and/or viral 
budding?  
Specifically, I intend to use pseudotyped MeV particles and purified MeV particles in 
combination with pharmacological inhibitors, dominant negative mutants and 
microscopy to determine the entry route of MeV. A quantitative cell-cell fusion assay 
will also be used to study cellular requirements during early stages of MeV-induced 
cell fusion. Finally, to examine the later steps of MeV infection, particularly in relation 
to viral budding, I will take advantage of quantitative proteomic techniques to 
evaluate the membrane proteome of MeV infected cells. 
 
 
 
 
 
2. Chapter 2 - Materials and Methods 
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Chapter 2 
MATERIALS AND METHODS 
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2.1 Cell lines 
All cell lines were maintained at 37°C with 5% CO2. Human Embryonic Kidney 293T 
(HEK293T, kindly provided by Dr Maelle Lorvellec, University of Birmingham (UoB) 
[354]) cells, human lung adenocarcinoma epithelial cell line A549 (provided by 
Professor Jane McKeating, UoB [355]), human cervical cancer (HeLa) cells (kindly 
provided by Dr Magdalena Krzyzaniak, University of Basel [195]) and human 
osteosarcoma (U-2 OS, provided by Dr Jo Morris, UoB [356]) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, USA) supplemented with 
10% foetal bovine serum (FBS, Sigma-Aldrich, USA) and 1% ampicillin/streptomycin 
(Sigma-Aldrich, USA). African green monkey kidney (Vero) cells engineered to over-
express human SLAM (Vero-SLAM, provided by Dr Kevin Brown, Public Health 
England/Health Protection Agency) were cultured in DMEM and 10% FBS under 
geneticin (G418) selection (0,4mg/mL, Sigma-Aldrich, USA). Epstein-Barr virus-
immortalized peripheral B lymphocytes (LCLs, a kind gift from Dr Claire Shannon-
Lowe, UoB [357]) were cultivated in RPMI-1640 (Sigma-Aldrich, USA) supplemented 
with 10% FBS and 1% penicillin/streptomycin.  
HEK293T and A549 cell lines, engineered to over-express human SLAMf1 (from now 
on referred to as HEK293T-SLAM and A549-SLAM, respectively), were previously 
generated in our lab, as described previously [229].  These cells were maintained in 
DMEM with 10% FBS, supplemented with 1µg/mL puromycin (Sigma-Aldrich) as a 
selection marker.  Briefly, the wild-type human SLAMF1 ORF was integrated via 
transduction into HEK293T or A549 cells, using a HIV backbone containing the Ψ 
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packaging signal, the long terminal repeat (LTR) 1 and 2 and the HIV-1 gag-pol 
protein.  
 
2.2 Viruses  
2.2.1 Recombinant viruses 
Recombinant MeV strain IC323 carrying the enhanced green fluorescent protein 
(EGFP) ORF (p(+)MV323EGFP, a kind gift from Professor Yanagi, University of 
Tokyo, Japan) was generated as described previously [20]. Briefly, a plasmid 
containing the full genome of MeV strain IC323 with a 5’ insertion of the EGFP gene, 
as a separate transcription unit, was transfected into HEK293T cells, previously 
infected with recombinant fowlpox virus encoding the T7 RNA polymerase, along with 
three plasmids encoding for MeV proteins N (pMeV-N-IC323), P (pMeV-P-IC323) and 
L (pMeV-L-IC323). After initial recovery, MeV was produced in Vero-SLAM cells. 
When infection was fully developed, cells were freeze-thawed once and centrifuged 
at 1000×𝑔 for 10min at 4°C. Supernatant was then collected and stored in aliquots at 
-80°C. Virus tissue culture infectious dose 50 (TCID-50) was calculated using the 
Reed-Müench method [358].  
 
2.2.2 Virus Purification 
Vero-SLAM cells, grown in eight T175 flasks to a confluence of approximately 40%, 
were infected with MeV (MOI~0.1) in 8mL of serum-free DMEM with 1% P/S for 1h at 
37°C. This inoculum was then removed and replaced with 10mL of complete 
medium. Three to four days later, flasks were vigorously shaken and supernatants 
were collected and clarified as before. Supernatants were layered onto a 20% 
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sucrose cushion (weight/volume in Hank’s balanced salt solution (HBSS)), 25mM 
HEPES NaOH, pH=7.4) and centrifuged at 125,000xg for 3h at 4°C in a SW32 Ti 
rotor (Beckman Coulter). The resultant pellets were resuspended in 1mL of HBSS-
HEPES, pooled, layered onto a 30-45-60% stepped sucrose gradient and centrifuged 
at 154417xg for 3h at 4°C in a SW40 rotor (Beckman Coulter). Two opalescent 
bands were visualised under polarized light: one at the 60-45% interface (lower 
band) and the other below the 30-45% interface (upper band) (Fig2-1A). The lower 
band was extracted using a needle and dialysed separately overnight using 10 kDa 
molecular weight cut-off membrane tubing, against 1L of HBSS-HEPES. Purified 
virus was then aliquoted, stored at -80°C and titrated. Only the lower band was used 
in experiments since it had a higher virus titre. To analyse quality, purified MeV 
particles were resolved in an SDS-PAGE gel and protein bands were silver stained 
(Fig2-1B and C). 
 
2.2.3 Spinoculation 
LCLs (2×105 cells) were concentrated to a final volume of 300µL. Cells were then 
infected with MeV (as indicated) at 4ºC for 1h at 300×g. Cells were washed and 
resuspended in culture medium and incubated at 37ºC.  
 
2.2.4 Virus growth curve 
Vero-SLAM and LCLs were infected with MeV-EGFP IC323 strain at indicated MOIs. 
Vero-SLAM cells were incubated with a low volume of virus-containing solution at 
37°C, for 1h, while LCLs were infected by spinoculation, as described above. After 
inoculation, the media was replaced and at 0, 12, 24, 48, 72, 96 and 120h post- 
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Fig.2-1 Purification of MeV particles. (A) Harvested supernatants of infected cells 
were pelleted and concentrated through a step-gradient sucrose cushion from 20 to 
60% sucrose in HBSS. Virus was visualised under polarised light where two bands 
were identified. (B/C) Purified particles were resolved in SDS-PAGE gel and 
analysed by western blot (B) and silver stain (C).  
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infection, samples were frozen to -80°C. The TCID50 was then calculated in Vero-
SLAM cells.  At the same time points, whole cell lysates were generated using RIPA 
buffer (Life Technologies, Inc.) according to the manufacturer’s guidelines and 
reduced in Reducing Sample Buffer (Thermo Fisher Scientific, USA) at 37°C for 
30min. 
 
2.3 Molecular Cloning 
2.3.1 Plasmids 
All the constructs mentioned and/or used in this project are listed in Table 2-1.   
 
2.3.2 Polymerase Chain Reaction 
All PCRs were performed using KOD polymerase (Toyobo Co, Ltd) according to the 
manufacturer’s guidelines. KOD polymerase has strong proof-reading activity and 
was initially isolated from the hyperthermophilic archaea Thermococcus 
kodakaraensis. A typical PCR reaction contained 0.2mM of each dNTP, 1mM of 
MgCl2, 0.15µM of each primer, 50ng of template DNA, 1U of KOD and water to a 
final volume of 50µL. A representative PCR reaction cycle is as follows: 
95°𝐶, 2′ 
25 𝑐𝑦𝑐𝑙𝑒𝑠 [
𝑇𝐷 = 95°𝐶, 10′′ 
𝑇𝐴 = 40°𝐶, 30′′
𝑇𝐸 = 68°𝐶, 1′
] 
 
Where TD is denaturing temperature, TA is the annealing temperature and TE is 
extension temperature. TA was modified accordingly to match the denaturation  
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Table 2-1. List of plasmids used in this project. All plasmids used and described 
in this thesis were either sourced from indicated labs, generated in our lab or bought 
from the biotechnology repository company Addgene. 
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Name Description (expressed protein) Origin 
pDublin-H MeV Dublin wildtype strain H 
Our lab 
 
pDublin-F MeV Dublin wildtype strain F 
pDublin-HΔ24 
MeV Dublin wildtype strain H with a 
truncated 24aa cytoplasmic tail 
pDublin-FΔ30 
MeV Dublin wildtype strain F with a 
truncated 30aa cytoplasmic tail 
pIC323-H MeV IC323 wildtype strain H 
pIC323-F MeV IC323 wildtype strain F 
pIC323-HΔ24 
MeV IC323 wildtype strain H with a 
truncated 24aa cytoplasmic tail 
pIC323-FΔ30 
MeV IC323 wildtype strain F with a 
truncated 30aa cytoplasmic tail 
pPAK-1-WT wild type p21-activated kinase 1 
pPAK-1-CA 
Constitutively active p21-activated 
kinase 1 (T423E mutation) 
 
pVSV-G 
Glycoprotein (G) of vesicular stomatitis 
virus (VSV) 
Prof Jane McKeating 
[359] 
pNL-4.3 
Replication-defective, envelope-
defective HIV-1 provirus expressing 
Firefly luciferase gene 
p8.91 HIV-1 gag-pro-pol Dr Edward Wright 
[360] pCSFLW Replication-defective, envelope-
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defective HIV-1 provirus carrying 
Firefly luciferase 
 
pEPS15-DN-RFP 
Dominant negative Epidermal growth 
factor receptor pathway substrate 15 
ΔEH2/EH3 fused with RFP 
Dr Joshua Rappoport 
[361] pCav-1-DN-GFP 
Dominant negative Caveolin-1 (P132L 
mutation) fused with EGFP 
pDyn2-DN-RFP 
Dominant negative Dynamin-2 (K44A 
mutation) fused to RFP 
pRhoA DN 
Dominant negative RhoA -2 (T19N 
mutation) fused to GFP 
Dr Patrick Caswell 
[362] 
pRhoA CA 
Constitutively active RhoA -2 (Q63L 
mutation) fused to GFP 
pRac1 DN 
Dominant negative Rac1 -2 (T17N 
mutation) fused to GFP 
pRac1 CA 
Constitutively active Rac1 (Q61L 
mutation) fused to GFP 
Cdc42 DN 
Dominant negative Cdc42 (T17N 
mutation) fused to GFP 
Cdc42 CA 
Constitutively active Cdc42 (Q61L 
mutation) fused to GFP 
pRLuc1-7 
Split Renilla luciferase and EGFP 
reporter (lighter fragment) 
Prof Zene Matsuda 
[363] 
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pRLuc18-11 
Split Renilla luciferase and EGFP 
reporter (heavier fragment) 
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temperatures of each set of primers. The length of TE was modified to the size of 
each plasmid at a rate of approximately 1 min per 1kb. 
The constructs pDublin-H, pDublin-F expressing the ORF of MeV strain H and F, 
respectively, and pDublin-HΔ24 and pDublin-FΔ30 expressing 24 and 30 amino 
acids deletion, respectively, of the cytoplasmic tail of the parental protein were 
generated as follows (See Fig.2-2 for an overall representation of the cloning 
procedure). HΔ18 and HΔ24 were amplified from MeV Dublin strain H ORF using the 
forward primers 5’-AATTGGATCC ACCATGAACAGAGAACATCTTATGATT-3’ and 
5’-AATTGGATCCACCATGGGAAGTAGGATAGTTATACAGA-3’, for Δ24 and Δ18 
truncations, respectively, both containing a BamHI restriction site (underlined), and 
the reverse primer 5’-AATT-GATATC CTACTATCTGCGRTTGGTTCCAT-3’ 
containing the EcoRV restriction site. Both inserts were digested with BamHI-HF and 
EcoRV-HF restriction enzymes (New England Bio Labs, Inc., USA) and ligated into 
the BamHI/EcoRV restriction sites of pcDNA3.1.  Similarly, the construct Dublin FΔ30 
encodes a truncated version of the MeV Dublin strain F protein lacking 30 amino 
acids at the C-terminus. This was amplified from pDublin-F, using the forward primer 
5’-AATT-GCTAGCACCATGGGTCTCAAGGCGAG-3’ and the reverse primer 5’-
AATT-GATATCCTACTACGCCCCCTGCAGCAACATATT-3’, containing the NheI and 
EcoRV restriction sites (underlined), respectively. The resultant PCR product was 
digested with NheI-HF and EcoRV-HF (New England Bio Labs, Inc., USA) and 
ligated into the NheI/EcoRV restriction sites of pcDNA3.1. The constructs IC323 H-
WT, HΔ24 and HΔ18 encode the wild-type, N-terminal 24 and 18 amino acids 
truncations of the MeV IC323 strain H ORF, respectively. They were amplified from 
the p(+)MV323EGFP construct using the forward primers  
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Fig.2-2. Schematic representation of the cloning procedure. (A) Target genes 
were amplified by PCR using primers containing adequate restriction sites, as 
indicated. After amplification, amplicons were purified from the enzymatic reaction 
mix and digested using restriction enzymes at 37ºC for 1h. Digested DNA was further 
purified and incubated with digested and dephosphorylated plasmidic vector 
pcDNA3.1, in the presence of T4 ligase at 16ºC overnight. Successfully ligated 
plasmids were then transformed into competent cells. 
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5’-AATTGGATCCACCATGTCACCRCAACGAGACCR-3’, 5’-AATT-
GGATCCACCATGaacagagaacatcttatgatt-3’ and 5’-AATTGGATCCACC 
ATGGGAAGTAGGATAGTTATyaacaga-3’, all of them containing the BamHI 
restriction site, and the reverse primer 5’-AATTGATATCCTACTA-
TCTGCGRTTGGTTCCAT-3’ containing the EcoRV restriction site (underlined). 
Finally, the constructs IC323 F-WT and FΔ30 encode the wild-type and C-terminal 30 
amino acid truncation, respectively of MeV IC323 strain F protein. Both were 
amplified from p(+)MV323EGFP using the forward primer 5’-
AATTGCTAGCACCAGGGCCAAGGAACATACACAC-3’, containing the NheI 
restriction site, and the reverse primers 5’-AATT-
GATATCCTATCAGAGTGACCTTACATATGA-3’ and 5’- AATT-GATATC 
CTACTACGCCCCCTGCAGCAACATATT-3’, both containing the EcoRV restriction 
site. Inserts were digested with NheI-HF and EcoRV-HF and ligated into the 
NheI/EcoRV restriction site of pcDNA3.1.  
 
To generate the two constructs encoding PAK-1, mRNA was extracted from 
HEK293T cells using the GenEluteTM Mammalian Total RNA Miniprep Kit (Sigma) 
according to the manufacturer’s guidelines. A cDNA library was generated from the 
extracted mRNA using the Moloney Murine Leukaemia Virus Reverse Transcriptase 
(M-MLV RT, Promega) and a sequence of 15 thymine bases as a primer (OlidT). 
DNA encoding PAK-1 was amplified by PCR using the forward primer 5’-
AATTGGATCCACCATGTCAAATAACGGCCTAGACA-3’ containing the BamHI 
restriction site (underlined) and the reverse primer 5’-
AATTGCGGCCGCCTATTAGCTGCAGCAATCAGTG-3’ containing the NotI 
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restriction site. Digested cDNA was ligated into pcDNA3.1 and the point mutation 
T423E was introduced by site-directed mutagenesis using the primer 5’-
AGCAAACGGAGCGAGATGGTAGGAACC-3’ and its respective reverse 
complement.  
The correct sequence of all plasmids was confirmed prior to use in experimentation.   
 
2.3.3 Site-directed mutagenesis 
Several constructs were generated by site-directed mutagenesis (SDM), as indicated. 
In summary, 300ng of template DNA was used in a 50µL PCR reaction, as before, 
containing 200nM of forward and reverse primers containing substituted codons for 
each desired mutation (See appendix section A.1 for a complete list of primers 
used). The basic PCR reaction was set as follows: 
95°𝐶, 2 𝑚𝑖𝑛 
18 𝑐𝑦𝑐𝑙𝑒𝑠 [
𝑇𝐷 = 95°𝐶, 10′′ 
𝑇𝐴 = 40°𝐶, 30′′
𝑇𝐸 = 68°𝐶, 3𝑚𝑖𝑛 30′′
] 
 
TA was modified accordingly to each set of primers. The length of TE was modified to 
the size of each plasmid at a rate of approximately 1’ per 1kb. Amplified DNA was 
then incubated with DpnI (New England Bio Labs), according to manufacturer’s 
guidelines), for at least 2h at 37ºC to remove remaining template DNA. The resulting 
DNA was then transformed into competent cells, as described below.  
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2.3.4 Transformations 
Ligations or plasmid stocks for transformation were mixed with 50µL of competent 
cells (Alpha-Select Bronze Efficiency, E. coli chemical competent cells, Bioline) on 
ice for 30 min before being heat-shocked for 45sec at 42°C. Heat-shocked bacteria 
were subsequently incubated on ice for a further 2min. Cells were then incubated 
with 200µL of super optimal broth with catabolite repression (SOC) medium (Sigma) 
at 37°C for 1h, with constant shaking, prior to streaking on LB agar (Sigma-Aldrich) 
plates containing relevant antibiotics. Of note, working concentrations of 100 µg/mL 
of carbenicillin (Sigma-Alrich) and 50µg/mL of kanamycin (Sigma-Alrich) were used. 
After overnight incubation at 37°C, a single colony of each transformation was picked 
from the plate and amplified by further incubation in Luria’s Broth containing relevant 
antibiotics.  
 
2.3.5 DNA extraction and purification 
Depending on the experiment, plasmid DNA was purified using either GeneJET 
Plasmid Miniprep Kit (Thermo Scientific), GenEluteTM HP Plasmid Midiprep Kit 
(Sigma-Aldrich) or EndoFree® Maxiprep Kit (QIAGEN) according to the respective 
manufacturer’s guidelines. Purification of DNA from enzymatic solutions, or agarose 
gels, was accomplished using illustra® GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare Life Sciences).  
 
2.3.6 Gel electrophoresis of DNA 
Gel electrophoresis of DNA was performed using 0.7%, 1% or 1.5% agarose gels in 
TBE (Trizma Base, boric acid and EDTA) buffer. DNA was mixed with Gel Loading 
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Dye (New England Biologicals) and run at 100-120V for 30 to 45 minutes. DNA 
bands were visualized using either intense blue light (if they were going to be used 
for downstream cloning) or ultraviolet (UV) light (in all other cases). 
 
2.4 Transfections 
2.4.1 DNA Transfections 
All DNA transfections were performed by incubating purified DNA in GibcoTM Opti-
MEMTM (200µL for 6-well plates, 50µL for 24-well plates) with either TransIT-X2TM 
Dynamic Delivery System (Mirus Bio LLC) – for fusion assays (see chapter 2 
section 2.5.6) – or polyethylenimine (1mg/mL, Sigma-Aldrich) – for all other 
transfections. Mixtures were left for 20 min before being added dropwise to cells.  
 
2.4.2 siRNA Transfections 
A549-SLAM cells (7×105 cells 6-well plate) were transfected with 25nM of a pool of 
three target-specific short interfering RNA (siRNA), between 19 and 25 nucleotides 
long, targeting p21-activated kinase (PAK) proteins (including PAK-1, αPAK siRNA 
(m): sc-29701, Santa Cruz Biotechnology) using DharmaFECTTM 1 Transfection 
Reagent (DharmaconTM, GE Health Life Sciences) as per the manufacturer’s 
instructions. As a control, scramble siRNAs purchased from Santa Cruz 
Biotechnology were transfected in a similar manner. The efficient knock-down of 
PAK-1 protein expression was confirmed 48 and 72h post-transfection by western 
blot. 
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2.5 Cell Biology 
2.5.1 Pharmacological inhibitors 
All of the pharmacological inhibitors used in this project are described in Table 2-2. 
These drugs were all tested in relevant cell lines for cytotoxicity using the reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in living cells (see 
chapter 2 section 2.5.2). Drug concentrations that lowered viability beyond 87% of 
that seen in solvent-treated cells were not used.   
 
2.5.2 MTT assay 
To assess the level of cytotoxicity induced by the pharmacological inhibitors 
described previously, I used a cell viability assay based on the redox reaction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) [364]. To begin MTT powder 
was dissolved in PBS to a final concentration of 5mg/mL. 15µL of this MTT solution 
was added to cells after treatment with pharmacological inhibitors at specific 
concentrations/times. This mixture was then incubated for 2h at 37ºC, the media 
removed and resultant formazan crystals dissolved using 50µL of isopropanol. 
Absorbance was then read at 600nm using a spectrophotometer. 
 
2.5.3 Pseudotyped virus particles entry assay 
Lentivirus-based viruses pseudotyped with MeV or VSV glycoproteins were used in 
this project. With the purpose of developing an efficient pseudotype assay for MeV, 
we used three distinct lentivirus-based backbones: (1) NL4.3-Fluc-Env-Rev- ([359], a 
first generation replication- and envelope-defective construct based on HIV-1, 
containing an extra ORF encoding the Firefly luciferase; (2) a combination of p8.91  
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Table 2-2. List of pharmacological inhibitors used in this project. All drugs used and 
described in this thesis were either sourced from indicated labs or purchased from 
indicated biotechnology companies.  
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Name Origin 
Chloroquine 
Sigma-Aldrich 
 
(-)-Blebbistatin 
Phorbol 12-myristate 13-acetate (PMA) 
Bafilomycin A1 
5-(N-Ethyl-N-isopropyl)amiloride (EIPA) 
IPA-3 
Chlorpromazine 
Cytochalasin D 
Calbiochem® Merck 
Millipore 
Jasplakinolide 
Taxol 
Wiskostatin Enzo Life Sciences 
ML141 
Tocris 
CK-666 
Glycyl-H1152 Cayman Chemical 
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(encoding for HIV-1 gag-pol) and CSFLW (HIV-1 provirus, lacking env and gag-pol 
genes and encoding for Firefly luciferase) ([360]; (3) and a combination of pCMVi 
(encoding Moloney Murine Leukaemia Virus gag-pol) and MLV-FLuc (MMLV 
provirus, lacking env and gag-pol genes, and containing an extra ORF encoding for 
Firefly luciferase) [360].  
To generate PPs, 7×105 HEK293T cells were transfected with: (1) 3.5µg each of 
pDublin-FΔ30 and pDublin-H Δ24 (encoding cytoplasmic tail truncations of MeV 
protein F and H) or 1 µg of pVSV-G and (2) 1.5 µg of p8.91 and 1 µg of CSFLW or 
1.5 µg of pCMVi and 1 µg of MLV-FLuc or 1.6 µg of NL4.3-Fluc. Supernatants 
containing viral pseudotyped particles (PPs) were collected 48 and 72h later, pooled 
and clarified by centrifugation 1000×𝑔 at 4°C for 30min. Prior to transduction 
(infection) A549-SLAM or HEK293T-SLAM cells were seeded in a 96-well dish at 
5×104 cells per well. After 24h these cells were pre-treated with pharmacological 
inhibitors, at the indicated concentrations, in FBS-free DMEM for 30 min at 37°C 
followed by the addition of 100μL of solution containing PPs. This mixture was then 
incubated for 5h. Alternatively, A549-SLAM or HEK293T-SLAM cells were 
transfected with 1µg of indicated constructs in 6-well dishes and 48h later these cells 
were transferred to 96-well plates. Cells were then incubated with 100µL of PPs for 
5h. In all instances the media in PP infections was replaced after the 5h incubation. 
Following 72h of further incubation, lentiviral transduction efficiency was assessed by 
lysing the cells and measuring luciferase activity using the Luciferase Assay System 
(Promega), according to the manufacturer’s instructions, on a Centro LB960 
Microplate Luminometer (Berthold Technologies). 
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2.5.4 Virus entry assay 
A549-SLAM cells were pre-treated or post-treated, in relation to virus infection, with 
pharmacological inhibitors. Pre-treated cells were incubated with the drug for 30 min 
prior to addition of virus (MOI~1) and incubated for an additional 1h at 37°C in the 
presence of a drug, while post-treated cells were inoculated for 1h, washed and 
incubated with a drug for 37°C for 90 min after infection. In both cases, cells were 
then trypsinised to remove non-internalized virus, replated and incubated for another 
24h. Syncytia were counted under UV-light (to visualise GFP expressed by the virus) 
and whole cell lysates were generated using Laemmli buffer and analysed by 
western blotting. To assess glycoprotein sensitivity to trypsin, A549-SLAM were 
incubated with MeV (MOI=30) at 4°C for 1h. Inoculum was then removed and cells 
were washed in cold PBS and incubated at 37°C for 0, 15 or 30min. At these 
timepoints, cells were either trypsinised or detached with 2mM EDTA in PBS 
(untreated) for 7min at 37°C, pelleted and analysed by western blot. As a control, 
uninfected cells were treated in a similar way. To assess fusion upon entry mediated 
by the virus, we used a dual split reporter containing the Renilla luciferase gene[363]. 
HEK293T-SLAM cells were transfected with one part of the reporter, synchronously 
infected with purified MeV (MOI~30), washed and incubated at 37°C for 0, 15, 30 or 
60 prior to co-culturing with HEK293T-SLAM expressing the complementary part of 
the reporter. When testing the effect of chlorpromazine (CPZ), cells were incubated 
for 30 min with 5µg/mL, prior to the adsorption of virus. The drug treatment was 
maintained throughout the short time-course of the experiment. At each timepoint, 
cells were incubated for 2h before luciferase activity was measured in a luminometer 
through the addition of 2μg/mL of cell-permeable coelenterazine 400A (Biotium). 
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2.5.5 Virus entry assay with pharmacological inhibitors 
A549-SLAM cells were pre-incubated with 50μL of DMEM supplemented with 
inhibitors at the indicated concentrations for 30 min at 37°C. Virus was then added 
(MOI=1) and incubated at 37°C for 1h. Inoculum was removed and cells were 
trypsinised to remove non-internalized virus. Alternatively, cells were infected in the 
absence of drugs for 1h at 37°C, inoculum was then removed and drugs were added 
and incubated for 90min. Cells were trypsinised, replated and incubated for 24h. Foci 
of infection were counted under UV-light and whole cell lysates were generated using 
Laemmli buffer (Thermo Fisher Scientific, USA) and samples were analysed by 
Western blot. 
 
2.5.6 Fusion assay 
The quantitative fusion assay was adapted from Brindley et al [308]. Briefly, 
HEK293T cells were transfected with one part of a dual split reporter Renilla 
reniformis Luciferase-GFP together with 1µg of pDublin-H and pDublin-F (effector 
cells). Separately, HEK293T-SLAM cells were transfected with the complementary 
part of the split reporter (target cells). 48h post transfection, cells were detached from 
the plate and co-cultured at a 1:1 ratio to a final cell density of 1x105 cells per well (in 
a white-bottomed 96 well dish). When indicated, pharmacological inhibitors at 
indicated concentration were added to the co-culture mix. Cultures were then 
incubated for a specific amount of time, as indicated in the relevant results section, at 
37°C, before the medium was removed and 60μL of 2μg/mL of coelenterazine 400A 
(Biotium, USA) was added to each well. Luciferase activity was measured in a 
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luminometer, after 2min of incubation with coelenterazine; luminescence was 
recorded and integrated for a total of 10’’. In addition, to see if the addition of the drug 
had an effect on the activity of the split reporter, cells were transfected with both 
parts of the dual split reporter and incubated in the presence of the drug. Luciferase 
activity was measured as described above. In subsequent experiments, other 
plasmids were added to either effector or target cells, as indicated. Total transfected 
DNA was always balanced with pcDNA3.1 and all cells were transfected with the 
same amount of plasmid DNA.  
 
2.5.7 Fluid-phase uptake 
A549 or A549-SLAM cells were plated onto poly-L-lysine treated glass coverslips and 
serum-starved for 16h. Prior to infection, cells were pre-chilled on ice and infected 
with MeV (MOI=10) or mock-infected (DMEM with 20% FBS) for 1h at 4°C with 
gentle agitation. Cells were then washed in cold PBS and incubated at 37°C in FBS-
free medium containing 0.25µg/mL of Dextran-Alexa Fluor®488 10,000 MW 
(Molecular Probes Life TechnologiesTM, UK) for 20min. Phorbol 12-myristate 13-
acetate was used at a concentration of 200nM as a control. Cells were then moved to 
ice to stop internalisation and membrane-bound dextran was removed by incubation 
with cold bleach buffer (10mM sodium acetate, 50mM NaCl, pH 5.5) for 10 min 
followed by washing with PBS. Cells were then fixed with 4% PFA and prepared for 
Confocal Laser Scanning Microscopy (CSLM). To visualise the cells we used a Leiss 
LSM 510 Meta Confocal Microscope equipped with a Lasos 30mW (405-30) 405nm, 
a Lasos 30mM multiline Argon/2 458-514nm and a Lasos 2mW HeNe, 594nm 
confocal laser. Images were recorded using the LSM 510 Software. 
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2.6 Immunofluorescence Assays 
Cells were plated onto glass coverslips and synchronously infected with MeV (at 
indicated MOIs) at 4°C for 1h with gentle rocking. As an uninfected control, cells were 
incubated with media containing 20% FBS. Cells were then washed and incubated in 
PBS at 37°C for the indicated lengths of time or, in the fluid uptake assay, incubated 
in PBS containing 0.25µg/mL of Dextran-Alexa Fluor®488 10,000 MW (Molecular 
Probes® 627 Life Technologies). Surface-bound dextran was removed by incubation 
with cold bleach buffer (10mM sodium acetate, 50mM NaCl, pH 5.5) for 10 min 
before being washed with PBS. In all cases, cells were fixed in 4% PFA for 10 min at 
room temperature, permeabilised with 0.1% TRITON® X-100 in PBS for 10 min and 
then blocked with 1% BSA in PBS for 30 min at room temperature. Cells were 
incubated with primary antibodies (Table 2-3) in 1% BSA at 4°C overnight, washed in 
PBS and incubated with secondary antibodies conjugated with AlexaFluor Dyes 
(Invitrogen) for 1h at room temperature. Slides were mounted using Hoechst 33342 
in Mowiol 632 ® mounting medium (Merck Millipore). Cells were visualised by CLSM 
(see chapter 2 section 2.9.3).  
 
2.6.1 Actin staining 
A549-SLAM cells were plated onto a glass cover slip and serum-starved for 16h. 
Cells were then pre-chilled on ice for 5 min and infected with MeV-GFP (MOI=15) for 
1h at 4°C with gentle agitation. Inoculum was removed and cells were washed with 
PBS. Cells were incubated at 37°C for 0, 10, 20 or 60 min prior to fixation with 4% 
PFA for 10 min at room temperature. Cells were then permeabilised with 0.01% 
121 
 
TRITON® X- 100 in PBS for 10min, washed and blocked with 1% BSA in PBS for 
30min. A solution of 0.5µg/mL of the phalloidin conjugate tetramethylrhodamine B 
isocyanate (Phalloidin-TRITC, Sigma-Aldrich, USA) in PBS was added to the cells 
and incubated at room temperature for 30min. Cells were finally washed several 
times with PBS and analysed by CLSM as described in chapter 2 section 2.9.6. 
 
2.7 Flow Cytometry of MeV-EGFP-infected cells 
A549-SLAM cells were either pre- or post-treated with 25 or 50µM of EIPA for 30 min 
and infected for 1h at 37°C with recombinant MeV (MOI=1) that also expressed 
EGFP. After this period, cells were trypsinised, re-plated onto 6-well dishes and 
incubated at 37°C for 6.5h. Cells were then detached using a 2mM EDTA solution in 
PBS for 20min, washed and fixed in 4% PFA. Cells were resuspended in PBS and 
analysed for EGFP fluorescence by flow cytometry (CyAn 642 TM ADP analyser, 
Beckman Coulter). 
 
2.8 Biochemistry 
2.8.1 Protein quantification 
To quantify total protein in solution, I used two methods: a bicinchoninic acid (BCA) 
assay [365], using Pierce BCA Protein Assay Kit (Thermo Scientific), and the 
Bradford assay [366], using Bradford Protein Assay Reagent (Bio-Rad), both 
according to the manufacturer’s guidelines. When constituents of protein solvent 
interfere with the readout of the colorimetric assay, protein samples were diluted out 
in BCA/Bradford reagents until no background was observed and extrapolated to 
calculate actual concentrations.  
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2.8.2 Silver stain of protein gels 
After SDS-PAGE, resolved protein gels were stained using the SilverQuestTM Silver 
Staining Kit (Thermo Scientific), according to the manufacturer’s guidelines. Stained 
gels were then photographed or scanned to calculate band densities. In case protein 
bands were extracted, as required for analysis by mass spectrometry, gel fragments 
were destained using the destaining reagents provided in the kit. 
 
2.8.3 Antibodies 
All antibodies used are listed in Table 2-3.  
 
2.8.4 SDS-PAGE and Western Blotting 
All protein samples were generated using radioimmunoprecipitation assay (RIPA) 
buffer (Cell Signalling Technology, USA), in the presence of Pierce Lane Marker 
Reducing Sample Buffer (Thermo Fisher Scientific, USA), or Laemmli buffer (120mM 
Tris-Base, 4% SDS, 20% glycerol, 0.02% bromophenol blue) as indicated, and 
reduced at 95°C or 37°C for 5 or 30min, respectively, as indicated. Samples were 
loaded into 7.5, 10 or 15% polyacrylamide gel, as indicated, and run by SDS-PAGE 
at a constant current of 40mA. Protein samples were then transferred to a methanol-
activated polyvinylidene difluoride (PVDF) membrane by semi-dry transfer (at a 
constant voltage of 15V). Protein-transferred membranes were then blocked with a 
5% skimmed milk solution in tris-buffered saline (TBS) containing 0.01% Tween20 
(Bio-Rad Laboratories, Inc., USA). Primary antibodies, for blotting, were diluted at 
indicated concentrations in 5% skimmed milk in TBS with 0.01% Tween20. The  
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Table 2-3. List of antibodies used in this project. All antibodies used and described in 
this thesis were either sourced from indicated labs or purchased from indicated 
biotechnology companies. 
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Description Species Origin 
Anti-cytoplasmic tail of Measles virus 
haemagglutinin  
Rabbit 
Prof. Roberto Cattaneo’s 
lab 
Anti-measles virus nucleocapsid 505 Rabbit 
Anti-glyceraldehyde 3-phosphate 
dehydrogenase (mAb 2118) 
Rabbit 
Cell Signalling 
Technology 
Anti-phospho-Ezrin 
(Thr567)/Radixin(Thr564)/Moesin (Thr558) 
(41A3, mAb 5175) 
Rabbit 
Anti-ezrin/radixin/moesin (mAb 3142) Rabbit 
Anti-phospho-cofilin (Ser3, mAb 3313) Rabbit 
Anti-cofilin (D3F9, mAb 5175) Rabbit 
Anti-alpha-p21-acivated kinase (mAb 2602) Rabbit 
Anti-Rabbit IgG1 coupled with horseradish 
peroxidase  
Mouse 
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following antibodies were purchased from Cell Signalling Technology, USA: Anti-
GAPDH (1:1000), Anti-Ezrin/Radixin/Moesin (3142), Anti-Phospho-Ezrin 
(Thr567)/Radixin (Thr564)/Moesin (Thr558) (41A3, mAb 3149), Anti-Phospho-Cofilin 
(Ser3, mAb 3313), Anti-Cofilin (D3F9, mAb 5175). These antibodies are all of rabbit 
origin while Anti-Rabbit IgG1 coupled with horseradish peroxidase (HRPO) is of 
mouse origin. All primary antibodies were incubated with the membrane overnight at 
4°C. Secondary antibodies were incubated for 90 min at room temperature. 
Membranes were exposed to Clarity Western ECL substrate (Bio-Rad Laboratories, 
USA) according to manufacturer’s guidelines and exposed to autoradiographic film.  
 
2.8.5 In vitro dephosphorylation of MeV H 
HEK293T were transfected with MeV H-HA and MeV F as described previously. After 
48h, cells were lysed in TNE buffer containing Protease Inhibitor Cocktail Mix (Pierce 
Thermo Scientific), scraped into suspension and subsequently resuspended again on 
ice using a gauge syringe. Lysates were pelleted and 20µL of supernatants were 
incubated with 200 units of λ Protein Phosphatase (λPP, New England Bio Labs) in 
the presence of MnCl2 for 30 min at 30°C. As a control, 25mM of the λPP inhibitor 
Na3VO4 was added to final mix prior to incubation. The enzymatic reaction was 
stopped through addition of Laemmli buffer.  
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2.9 Microscopy 
2.9.1 Morphological changes upon virus entry using phase-contrast 
microscopy 
Serum starved A549-SLAM cells were pre-chilled on ice and MeV (MOI~45) bound to 
the cells at 4°C for 1h. Mock-infected cells were treated with DMEM with 20% FBS. 
After 1h the inoculum was removed and cells were washed in ice-cold PBS before 
being moved to 37°C for 10min.  Cells were then fixed with a solution of 4% 
paraformaldehyde (PFA) in PBS and visualized by phase-contrast microscopy using 
an inverted UV microscope (Nikon Eclipse TE2000-5 microscope coupled with a 
Nikon HB-10101AF Super High Pressure Mercury Lamp) equipped with a camera 
(Hamamatsu Digital Camera C472-95). Ten micrographs of each condition were 
recorded and cells presenting membranous blebs were counted in relation to total 
cell count.  
 
2.9.2 Scanning electron microscopy 
Similarly to the phase-contrast studies, serum-starved A549-SLAM cells were pre-
chilled on ice before MeV (MOI~45) was bound to the cells at 4°C for 1h (as a 
uninfected control, I have incubated cells DMEM with 20% FBS). The inoculum was 
then removed and the cells were washed in ice-cold PBS before being incubated at 
37°C for 10min. Infected cells were then fixed with a solution of 4% PFA and 2.5% 
Glutaraldehyde overnight at 4°C. Fixed cells were washed in PBS, post-fixed in 2% 
Osmium tetroxide, dehydrated in acetone and critical-point dried for 2h. Finally, cells 
were coated with a 3nm layer of platinum and visualized by scanning electron 
microscopy (JSM-7000F (JEOL) SEM - Oxford Instruments INCA EDS system).  
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2.9.3 Confocal laser scanning microscopy 
Immunofluorescence microscopy was performed using a Leiss LSM 510 Meta 
Confocal Microscope equipped with a Lasos 30mW (405-30) 405nm, a Lasos 30mM 
multiline Argon/2 458-514nm and a Lasos 2mW HeNe, 594nm confocal laser. 
Images were recorded using the LSM Software. 
 
2.10 Proteomics 
2.10.1 SILAC 
LCLs were cultured in RPMI-1640 medium suitable for SILAC triple labelling, i.e. 
supplemented with either: (1) unlabelled arginine and lysine (Light R0K0, RMPI-19 
Dundee Cell Products), (2) 13C labelled arginine and 2D labelled lysine (Medium 
R6K4, RPMI-22 Dundee Cell Products), or (3) 13C and 15N labelled arginine and 13C 
and 15N labelled lysine (Heavy R10K8, RPMI-21 Dundee Cell Products).  All SILAC 
culture media was supplemented with penicillin/streptomycin, 10 kDa dialysed FBS 
(Dundee Cell Products) and MEM non-essential amino acids (Gibco®, Thermo 
Fisher). Cells were passaged in labelling media for 15 passages prior to subsequent 
experiments. Complete incorporation of labelled amino acids was confirmed by mass 
spectrometry.  
LCLs labelled with heavy and light amino acids were infected with MeV (MOI~0.01), 
see chapter 2 section 2.2.3, and incubated for 64 or 96h. These infected cells were 
then pelleted and used for downstream protein and RNA extraction. As a control, 
medium-labelled LCLs were mock-infected and incubated for 96h prior to collection 
and subsequent protein and RNA extraction.  
129 
 
 
2.10.2 Enrichment of Membrane Proteins 
Labelled LCLs (3×107 cells per label) were pelleted, washed in PBS and pelleted 
again. Membrane proteins were extracted using the ProteoExtract® Native 
Membrane Protein Extraction Kit (#444810, Merk Milipore) according to the 
manufacturer’s guidelines. The total protein was then quantified (using both BCA and 
Bradford methods, see chapter 2 section 2.8.1) and the three samples (Light, 
Medium and Heavy) were mixed at equimolar ratio and subsequently analysed by 
mass spectrometry.  
 
2.10.3 LC-MS/MS analysis 
Protein samples containing three the differently labelled protein populations were 
resolved in a 10% SDS-PAGE gel. The running lane was fragmented into 10 slices 
and individual slices were tryptically digested using DigestPro (Intavis Ltd.). Peptides 
were then fractionated using 1% formic acid, injected onto an Ultimate 3000 
nanoHPLC system equipped with an Acclaim PepMap C18 nano-trap column 
(Thermo Scientific), washed in 0.5% acetonitrile and 0.1% formic acid, and resolved 
in a reverse phase analytical column over a 150 min organic gradient using the 
following segments: 1-6% solvent V over 1 min; 6-15% B over 58 min; 32-40% B 
over 5min; 40-90% over 1 min; held at 90% B for 6 min and then reduced to 1% B 
over 1 min. Solvent A: 0.1% formic acid. Solvent B: aqueous 80% acetonitrile in 0.1% 
formic acid. Peptides ionised by nano-ectrospray at 2.0 kV using a stainless-steel 
emitter with a capillarity temperature of 275ºC. Mass spectra were acquired using an 
Orbitrap Fusion Tribid mass spectrometer controlled by Xcalibur 2.0 software 
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(Thermo Scientific). FTMS1 spectra were collected at a resolution of 120000 over a 
scan range (mass-to-charge) of 350-1550, gain control target of 300000 and a 
maximal time of injection of 100 milliseconds. Charge state was set to include charge 
states 2 to 6 and precursors were filtered with monoisotopic selection. Formerly 
interrogated precursors were excluded. Isolation of the MS2 precursors were 
accomplished using a quadrupole mass filter set to 1.4m/z. ITMS2 spectra were 
generated with an AGC target of 20 000, maximum injection time of 40 ms and 35% 
of collision induced dissociation (CID) collision energy. The generated raw files were 
analysed, processed and quantified using Proteome Discoverer software v1.4 
(Thermo Scientific) and mined against a human protein database (UniProt Human 
database, 126385 entries) plus the MeV sequences Ichinose strain using the 
SEQUEST algorithm.  Mass tolerance limit of peptide precursors was set at 10 parts 
per million (ppm) and MS/MS tolerance at 0.6 Da.  The search criteria comprised of  
carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation of 
methionine (+15.9949) and respective SILAC labels as variable modifications.  
Peptide mining was performed in an in silico tryptic digested peptide database, 
allowing a maximum of 1 missed cleavage.  Additionally, reverse database search 
was performed and peptide data was filtered to verify a false discovery rate (FDR) of 
5%.   
 
2.11 Data Analysis 
2.11.1 Image analysis using ImageJ 
To evaluate the relative intensity of Western blot bands, films were scanned at 
maximum resolution (300dpi) and converted into unsaturated 8-bit images using 
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ImageJ (National Institute of Health, USA). Each lane was highlighted with a 
rectangular shape of equivalent size and pixel saturation was plotted onto a 
histogram. Peaks corresponding to each lane were selected in relation to basal levels 
of saturation and the area underneath the curve was measured using the same 
software. Densitometry values were then normalized to mock values. To calculate 
total cell fluorescence in the fluid-phase uptake experiment, micrographs recorded at 
488nm were converted to 8-bit images. A total of 16 cells per sample were 
individually selected and the area and mean fluorescence intensity was calculated 
using ImageJ. To each cell, four different regions of the surrounding area were 
selected and the correspondent background mean fluorescence was subtracted from 
the cell intensity. The corrected total cell fluorescence was then averaged and 
plotted. Finally, to measure the average area of cells stained with the actin-specific 
phalloidin conjugate, the background of individual micrographs was brought to a level 
of threshold (overflow) that enabled clear distinction of the cell’s edges from its 
surroundings. Each cell, or group of cells, was then individually selected and the area 
was calculated, summed and divided by the number of nuclei observed in the 
correspondent Hoechst stain micrograph. A total of 266 cells for mock, 222 cells for 
virus at 0 min post infection, 198 cell for virus 10min, 255 cells for virus 20 min and 
175 cells for virus 60 min were used to calculate the mean cell area. The average cell 
area was then plotted in pixel units.  
 
2.11.2 Matrix protein structure prediction and modulation 
To generate a model of the 3D structure of the Matrix protein, we used the software 
SWISS-MODEL, developed and available through the ExPASy server of the Swiss 
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Institute of Bioinformatics, University of Basel. The MeV matrix protein sequence 
(UniProt entry #P06942) was compared against the Newcastle disease virus matrix 
protein structure (RSCB PDB entry #4G1L) with which it shares 21.45% identity at 
the amino acid level.  The resultant model was calculated using ProMod Version 3.70 
to have a Global Model Quality Estimate (GMQE) of 0.53 and a QMEAN4 of -6.34 
[26]. Rendering of the 3D structure was achieved using the UCSF Chimera software. 
 
2.11.3 Bioinformatics Analysis of LC-MS/MS Data 
LC-MS/MS peptide data was analysed as described in Emmott et al., 2014 [367]. 
Analysis was performed using Proteome Discovered v1.4 MS analysis software 
(Thermo Scientific) against an in silico protein database comprised of Uniprot Human 
database with 8 additional sequences corresponding to the protein sequences of the 
MeV Ichinose strain (N, P, C, V, M, F, H and L; see appendix section A.2). Low 
confidence peptides, i.e. peptides which FDR higher than 5%, were removed and 
SILAC ratios, i.e. light versus heavy, light versus medium and medium versus heavy, 
were calculated. These SILAC ratios (0.01 to 100) were then converted to log 2 
values using Excel. Using graph pad, log2 SILAC ratios were plotted onto a 
histogram sorted by frequency distribution. After a Gaussian distribution curve was 
fitted onto the frequency distribution, mean and standard deviation of the Gaussian 
distribution were calculated and used to select a 95% confidence threshold using the 
formula: 
𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 = 1.96×𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 + 𝑚𝑒𝑎𝑛 
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2.11.4 Post-translation modifications discovery 
Post-translation modifications discovery was performed using the raw data files 
obtained and described in section 2.10.3 using the Proteome Discoverer v1.4, and 
against an in silico tryptically digested protein database consisting of the human 
protein database (UniProt Human database, 126385 entries) and the MeV 
sequences Ichinose strain. Search settings comprised the following peptide 
modifications: N-glycosylation of asparagines; ubiquitination of lysines; 
phosphorylation of tyrosines, serines and threonines; methylation of lysines; 
SUMOylation of lysines and α-acetylation of N-terminal amino acids. A FDR of 5% 
was set as threshold.  
 
2.12 Statistical Analysis and Graphs 
Statistical analysis was performed using GraphPad Prism 6 software where groups of 
two were analysed using the unpaired Student’s t test. I have considered a p-value 
lower or equal to 0.05 (*) as a minimum threshold for significance. **, p<0.01, ***, 
p<0.001. n.s., non-significant  
All graphs presented in this thesis were generated using either GraphPad Prism 7 or 
R programing console.  
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3 Chapter 3 – Development of three quantitative assays to 
study morbillivirus entry and exit 
  
135 
 
Measles virus spreads in vivo and in vitro via two main routes: cell-free and cell-to-
cell virus transmission. In the first, a virion attaches to the cell’s membrane where the 
viral protein H interacts with its receptor, e.g. SLAM. Subsequent triggering of the 
viral F protein allows release of the viral genome into the cytoplasm. Later on in 
infection, viral proteins concentrate at specific sites in the plasma membrane to form 
nascent virions which egress from the cell by budding; in particular, the matrix protein 
interacts with envelope glycoproteins and the RNP complex. Alternatively, MeV 
glycoproteins at the cell surface can interact, independently from virion genesis, with 
cognate receptors on a neighbouring cell, activating F and inducing the fusion of 
these two cells, defined as cell-cell fusion. In this instance, the cytosolic contents of 
the infected or viral glycoprotein expressing cell are mixed with the target cell and 
infection spreads. In this chapter, I describe the development of biochemical assays 
to quantify MeV cell-free and cell-cell transmission of the virus: (1) a pseudotyped 
virus entry assay based on a lentiviral backbone of HIV-1 genome that encodes a 
luciferase gene reporter and incorporates MeV encoded GPs; (2) a cell-cell fusion 
assay based on the expression of MeV glycoproteins, cellular receptors and a dual 
split reporter protein; and finally (3) a budding assay based on the egress of a viral 
matrix protein fused to luciferase. These assays are subsequently applied, in my 
other thesis chapters, to study measles virus transmission. 
 
3.1 Development of a MeV GP-based cell-cell fusion assay 
To study MeV-induced cell-cell fusion, I developed a MeV fusion assay based on a 
dual split reporter of EGFP and Renilla reniformis luciferase (RLuc) [308]. This split 
reporter is expressed from two constructs each encoding part of an EGFP and RLuc 
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fusion protein. These reporters are inactive when expressed individually, but become 
functional if the complementary parts interact [363]. A schematic illustrating the set-
up a typical MeV fusion assay is represented in Fig.3.1. Of note, a cell line was 
chosen that is normally refractory to infection (e.g. HEK293T) as this was considered 
to express a low level of endogenous SLAM or Nectin-4 expression. These cells 
were transfected with MeV F and H and one part of the split reporter (becoming 
‘effector’ cells) while a separate population, engineered to overexpress a cellular 
receptor, e.g. SLAM, was transfected with the complementary part of the split 
reporter (becoming ‘target’ cells). After 48h of incubation, cells were then detached 
from their plates, co-cultured at specific concentrations and incubated for a certain 
period of time. When these cells fused, their cytosolic contents mixed and the 
complementary parts of EGFP and RLuc interacted to form a functional dual reporter.  
The expression of the MeV H protein in the cell membrane of HEK293T cells was first 
confirmed by fractionation and isolation of membrane, cytosolic and nuclear fractions 
of the cell, followed by western blot (Fig.3.2). Antibodies against human 
Na+/K+ATPase, an enzyme that exports Na+ ions and imports K+ ions to the cell and 
localizes at the plasma membrane, and the mitogen-activated protein kinase kinases 
1 and 2 (MEK1/2), which is a cytosolic protein involved in certain signalling cascades, 
were used to evaluate the efficiency of fractionation and recovery of membrane and 
cytosolic proteins. MeV H co-fractionated with Na+/K+ATPase as shown by SDS-
PAGE/western blot, suggesting that MeV H is present and in the membrane fraction 
of the cell.  
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Fig.3-1. Diagram of the quantitative cell-cell fusion assay. HEK293T cells were 
transfected with plasmids encoding MeV F, MeV H and half of a dual split reporter 
EGFP and Renilla luciferase (RLuc1), while HEK293T-SLAM cells were transfected 
with the complementary part of the dual split-reporter (RLuc2). When target cells, 
expressing SLAMF1, are co-cultured with effector cells, expressing MeV F and H, cell 
contact mediates attachment of H, culminating in the triggering and activation of F 
followed by the fusion of effector and target cells. After cytosolic mixing, the two 
complementary parts of the dual reporter assemble and become functional, allowing 
a fluorescence and luminescence read-out. 
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Fig.3-2. Development of MeV-glycoproteins-based cell-cell fusion assay. (A) 
HEK293T were transfected with MeV H. Forty-eight hours later, cells were lysed and 
membranes were fractionated as described in chapter 2 section 2.10.2. Cytosolic 
(soluble fraction) and membrane fractions were resolved on a 15% SDS-PAGE gel 
and MeV H, MEK1/2 and Na+/K+ ATPase were identified by western blot. (B/C/D) 
Effector and target cells were co-cultured at different ratios to a total concentration of 
1x105 cells per well, as indicated, before being observed by fluorescence microscopy 
(B). Luciferase activity was measured as described in chapter 2 section 2.5.6 (C/D). 
(n=2 with 4 technical replicates). (C) Background levels of cell-fusion in 
HEK293Tlacking the expression of SLAMF1. (E/F) HEK293T transfected with part of 
the dual reporter were co-transfected with vesicular stomatitis glycoprotein (VSV-G) 
and co-cultured with target cells containing the complementary part of the dual-split 
reporter. After 24h, luciferase activity was measured before exposing the co-cultured 
cells to PBS solutions with adjusted pH as indicated. Cells were incubated for 4min 
prior to being observed by fluorescence microscopy (F) and the luminescence 
quantified as described previously (E) (n=1 with 4 technical replicates). Luciferase 
activity was plotted in relation to mock (RLUmock=964,787±113,846). Statistical 
analysis was performing using Student’s t test. *, p<0.05; **, p<0.01; ***, p<0.001; 
****,p<0.0001, n.s., non-significant. 
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To determine the optimum ratio for co-culturing effector and target cells, HEK293T 
cells were transfected with their respective plasmids, incubated for 24h, washed, 
resuspended and plated again for another 24h. This intermediate washing step was 
included in the protocol to remove extracellular plasmid DNA and avoid cross-
contamination between the two cell populations. Cells were then resuspended and 
co-cultured overnight at different ratios (of note, cell densities were also optimised to 
maximise cell-cell contacts, data not shown). An example of EGFP-positive fused 
cells observed during this assay is presented in Fig.3.2B (black arrows). RLuc 
activity was measured by removing the media and adding 60μL of 2μg/mL of a cell-
permeable luciferase substrate coelenterazine (Fig.3.2C/D). As a control, 
background levels obtained with co-culture with target cells lacking expression of 
SLAMF1 was performed (Fig.3.2C). The highest luciferase activity, proportional to 
the number of fused cells, was obtained at an equal ratio of target and effector cells 
(1:1). When comparing the different ratios of cell populations, co-cultures where 
effector cells were in greater abundance than target cells (e.g. ratios of 2:1 and 3:1) 
showed higher luciferase activity than the directly inverse ratio (1:2 and 1:3). A 
reduced number of GFP-positive cells and small syncytia were also observed in co-
cultures containing HEK293T target cells that had not been transfected with the 
SLAM receptor, perhaps due to very low expression of human Nectin-4 on this cell 
line [221]. 
An issue that arises from the co-culture system is the putative cross-transfection of 
DNA encoding for the complementary parts of the luciferase, i.e. when effector and 
targets cells are detached from the well (in which they were transfected) and 
subsequently co-cultured, residual plasmid DNA may be also uptaken by the 
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complementary cells leading to a false positive reading of the luciferase activity that 
did not arise from the fusion of cells. To test if cross-DNA-contamination was an 
issue in this system, I have used the fusion protein of vesicular stomatitis virus (VSV), 
glycoprotein (G), which is activated by exposure to low pH [368]. VSV-G was 
transfected into effector cells, instead of MeV F and H, and co-cultured overnight. 
Co-cultures were then exposed to several PBS solutions containing differently 
buffered pH, namely 7.5, in which cell fusion induced by VSV should not occur, and 
two acidic pH 6.5 and 5.5, that should activate VSV-G and cell-cell fusion, for 3 min 
at 37°C before being washed and the reporter activity measured (Fig.3.2E). As a 
control, effector cells lacking any viral glycoproteins were incubated with target cells 
under similar conditions (mock). Indeed, co-cultures treated with pH 7.5 buffer had 
similar luciferase activity compared to mock, suggesting that cell fusion did not occur 
and this is the background levels observed. However, when co-cultures were treated 
with 6.5 or 5.5 buffers, luciferase activity was 300 and 200% of mock, suggesting the 
vast majority of luciferase activity. Of note, the slightly lower level of luciferase activity 
recorded in cells exposed to pH 5.5 may be due to detachment of cells from the 
surface of the well. Upon examination by UV-enabled microscopy large syncytia were 
observed in VSV-G expressing cells at the same pH ranges (Fig.3.2F). These 
observations are in accordance with the low pH dependency of VSV-G to induce 
fusion and demonstrate the activity of the dual reported is cell-intrinsic and specific 
for the fusion of neighbouring cells, and the luciferase readings observed are not due 
to cross-transfection with DNA upon co-culture. In summary, I demonstrated that this 
assay was capable of directly correlating MeV-induced cell-cell fusion to recorded 
luminescence and fluorescence from a quantitative, dual-reporter based readout and 
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could be used to study the molecular determinants of MeV cell-associated 
transmission. 
 
3.2 Development of pseudoparticles using MeV GPs 
The initial step of any viral infection is attachment to the cell, commonly via cellular 
receptor(s) such as proteins or sugar moieties. Entry to the cytosol and/or nucleus, 
sometimes also involves hijacking cellular endocytosis pathways such as clathrin-
mediated endocytosis or macropinocytosis. It has been suggested that all 
paramyxovirus and pneumovirus entry, including MeV, occurs by direct fusion of the 
virus envelope with the plasma membrane. However, recent studies on various 
members of these families have shown that endocytic pathways are frequently 
involved in virus entry [195, 325]. To study the entry mechanism of MeV, I developed 
a quantitative entry assay based on pseudotyped virus particles (PPs) carrying MeV-
GPs. In this system, illustrated in Fig.3.3, a defective self-limiting pro-lentivirus, 
based on HIV-1, containing the Ψ packing signal, the long terminal repeats (LTRs) 
and the firefly luciferase reporter gene, is transfected into HEK293Ts together with 
constructs encoding for the MeV-GPs. Components of the lentivirus particle 
assemble at the plasma membrane and MeV glycoproteins are incorporated into that 
particle, forming a replication incompetent chimera known as a PP. Recovered PPs 
can be used to transduce target cells, e.g. those expressing the MeV receptor SLAM. 
In this instance the luciferase activity in transduced cells serves as a direct correlate 
for MeV PP entry.  
Previously, the intravirion tails of MeV GPs have been implicated in the correct 
assembly of MeV-PPs [369]. The mechanisms by which GPs are incorporated into  
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Fig.3-3. Schematic representation of the MeV pseudotype particle entry assay. 
To produce pseudotyped MeV particles, a plasmid encoding the HIV-1 gag-pol and 
another containing the pro-virus HIV-1 genome encoding the firefly luciferase (FLuc) 
were transfected into cells, alongside plasmids encoding MeV F and H lacking the 30 
or 24 amino acids, respectively, at the cytoplasmic tails. Supernatants of cells 
transfected with these constructs were collected at 48 and 72h, clarified by 
centrifugation and used to transduce SLAMF1-positive cells. Luciferase activity was 
measured 72h post-transduction.  
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PPs is not fully understood; however, the intravirion tails of MeV GPs might be 
interfering with the assembly machinery of the lentivirus, or perhaps differing 
localization between MeV GPs and lentivirus assembly sites may be responsible for 
hampering PP formation [370]. I hypothesised that variation in the efficiency of GP 
incorporation into PPs might be strain specific, therefore I examined the generation of 
PPs using the wild-type (WT) MeV F and H proteins from two different genotypes of 
MeV; Dublin (genotype D4) and IC323 (Ichinose-B95a, genotype D3), both of which 
are virulent strains, with 99.7% amino acid identity homology between the F proteins 
and 97.7% between the H proteins. To produce MeV-PP, HEK293T cells were 
transfected with plasmids encoding MeV F, MeV H and the pro-lentivirus construct 
pNL4.3-Luc-E-R- [359]. Extracellular secreted PPs were collected and clarified (for 
methods see Chapter 2 Section 2.5.3). As a negative control, parental plasmid 
(lacking any specific ORF for expression) was transfected along with the lentivirus 
backbone with the resultant pseudoparticles termed non-envelope (NE). As a positive 
control, VSV-G was transfected to generate VSV-PPs. VSV has a broad cellular 
tropism with several potential receptors for this virus [371], including the low density 
lipoprotein receptor family [372] and heparin sulphate [373].  
I first examined the effect of co-expressing components of the pseudotype system. 
Expression of the MeV H protein at the cell surface did not appear to differ between 
strains under co-expression of the lentivirus vector, as suggested by western blot of 
the plasma membrane fraction of MeV H- and lentivirus-transfected cells (Fig.3.4A). 
Similarly, luciferase activity in PP-producing cells was not affected by co-expression 
of MeV GPs in comparison to VSV-G transfected cells (Fig.3.4B). When target cells 
(HEK293T-SLAM) were transduced with PPs, pseudotyped with Dublin or IC323  
149 
 
 
 
 
 
 
 
Fig.3-4. Generation of PPs using WT MeV glycoproteins. (A) HEK293T cells were 
transfected with plasmids encoding MeV H of Dublin or IC323 strains. At 48h post-
transfections, cells were lysed and membrane proteins were extracted as described 
in chapter 2 section 2.5.3.  Cytosolic and membrane fractions were resolved onto a 
15% SDS-PAGE and MeV H, MEK1/2 and Na+/K+ ATPase were identified by 
western blot. (B/C) MeV-PP and VSV-PP were generated as previously described, 
using VSV-G or MeV H and F from MeV Dublin or IC323 strains. Cell lysates from 
producer cells were generated and luciferase activity was measured (B) (n=1 with 4 
technical replicates). Produced PPs were then used to transduce HEK293T and 
HEK293T-SLAM cells. Seventy-two hours later, cell lysates were generated and 
luciferase activity was measured (C) (n=6 with 4 technical replicates).  
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strains MeV proteins, no significant activity could be detected, compared to NE-PPs 
(Fig.3.4C), while PPs carrying the VSV-G entered target cells with high efficiency. 
These data, in combination with the proven ability of MeV GPs to generate syncytia 
in SLAM-expressing cells (as shown previously), suggested that although GPs of 
several MeV strains can be expressed at the cell membrane, they do not incorporate 
into HIV-1 based PPs.  
 
3.3 Truncation of MeV GP cytoplasmic tails facilitates pseudotyping 
Several truncations of the intravirion tails of MeV GPs have been reported to be 
required for their efficient incorporation into PPs. In particular, deletion of 18, 19 and 
24 amino acids in the H protein and 30 amino acids in the F protein have previously 
been shown to allow the generation of high titres of MeV-PPs, using both wild-type 
strains of MeV and the attenuated Edmonston strain, that uses CD46 as an 
additional receptor [369]. Therefore, I generated MeV H proteins lacking 24 or 18 
amino acids from the N-terminal intravirion tail, and separately a MeV F protein with a 
30 amino acid truncation from the C-terminal intravirion tail (Fig.3.5A). We first 
investigated whether these truncations affected the fusogenic potential of the MeV 
GPs in our cell-cell fusion assay, as described above (Fig.3.5B). HEK293T cells 
transfected with MeV GPs of the Dublin strain appeared to be more fusogenic than 
cells transfected with GPs belonging to the IC323 strain. With regards to their 
truncated variants, WT and HΔ24/FΔ30 truncated proteins exhibited demonstrably 
similar levels of fusion, whilst the HΔ18/FΔ30 proteins were significantly more 
fusogenic (Fig.3.5B). Nevertheless, since the antibody I had available to evaluate the  
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Fig.3-5. Truncation of MeV Glycoproteins’ intravirion tails enables entry. (A) 
Cytoplasmic tail deletions of MeV H, lacking 24 or 18 amino acids, and MeV F lacking 
30 amino acids. (B) A fusion assay was performed where effector cells were 
transfected with full-length (FL) MeV F and H, or mutants lacking 24, 18 or 30 amino 
acids of the cytoplasmic tails of MeV H and F, respectively (for both Dublin and IC323 
strains). Readings of co-cultures with target cells lacking SLAMF1 (background) were 
subtracted to the respective effector+HEK293T-SLAM co-cultures. At 48h post-
transfection, target and effector cells were co-cultured; luciferase activity was 
measured 24h later. (C) MeV-PP were generated using FL F and H, or mutants 
lacking 24, 18 or 30 amino acids of the cytoplasmic tails of MeV H and F, respectively 
(Dublin and IC323 strains). In addition PPs were generated with a combination of 
MeV H of Dublin or IC323 strains with Edmonston strain F protein. The generated 
PPs were then used to transfect HEK293T and HEK293T-SLAM cells. NE-PP entry 
values were subtracted to all MeV-PP RLUs. Statistical analysis was performed using 
Student's t tests, **p<0.01. 
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expression of MeV H was raised against the intravirion tail of this protein, fluctuation 
in MeV H mutant expression may also impact on cell-cell fusion. 
We then assessed the pseudotyping potential of these truncation mutants. Using 
combinations of Dublin and IC323 HΔ24, HΔ18 and FΔ30, as well as Edmonston 
vaccine strain FΔ30, PPs were generated and used to infect HEK293T and 
HEK293T-SLAM cells (Fig.3.5C). PPs pseudotyped with H and F GPs with 
truncations had higher luciferase activity in SLAM-expressing cells compared to 
HEK293Ts, suggesting both successful pseudotyping and receptor specificity for 
these mutants. For both the Dublin and IC323 strains, PPs containing HΔ24 showed 
higher luciferase activity than PPs with HΔ18. Moreover, PPs generated with MeV 
Dublin strain GPs showed higher reporter values than their IC323 counterparts. 
Accordingly, PPs carrying Dublin HΔ24 and Edmonston FΔ30 had higher values than 
PPs carrying IC323 HΔ24 and Edmonston FΔ30. As mentioned before, due to the 
limitations in analysing the effect of such intravirion tail truncation in the expression of 
glycoprotein by western blot/flow cytometry, the mechanism behind the eventual 
pseudotyping of MeV-PP is not clear. Overall, PPs carrying the HΔ24/FΔ30 GP 
combination, and Dublin strain in particular, showed the highest signals in this assay 
suggesting the highest MeV-PP entry was achieved under these conditions. This 
combination was therefore used in all subsequent experiments, unless indicated 
otherwise. 
3.4 The lentivirus system p8.91/pCSFLW generates high titres of MeV-
PPs 
Interestingly, using similar MeV GP truncations different titres of MeV-PPs are 
obtained, depending on the lentivirus system being applied and the research lab in 
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which they were produced [328, 369, 374]. To investigate whether different lentivirus 
systems could improve the titre of recovered MeV-PPs, I generated VSV-G and MeV 
PPs using (1) pNL4.3-Luc-E-R-, a first-generation provirus plasmid derived from HIV-
1 encoding, in cis, the gag-pol ORF, Ψ signal peptide, HIV-1 LTRs and firefly 
luciferase reporter gene; (2) p8.91 and pCSFLW, a second-generation lentiviral 
system providing the gag-pol in trans (p.8.91), and HIV LTRs with the reporter gene, 
respectively; or (3) pCMVi and pMLV-Fluc, an equivalent second-generation 
lentivirus-system encoding the Moloney Murine Leukaemia Virus (MLV) gag-pol and 
LTRs with reporter gene, respectively. PPs were generated as described in Chapter 
2 Section 2.5.3 and luciferase activity values were plotted after subtracting NE-PP 
(background) values (Fig.3.6B). Particles pseudotyped with VSV-G demonstrated the 
highest luciferase signals with the p8.91+pCSFLW system, followed by the pNL4.3-
Luc-E-R- (Fig.3.6A). Similarly, PPs bearing the MeV GPs generated with the 
p8.91+pCSFLW system yielded the highest luciferase activity. For both cases, PPs 
generated with the MLV-based system generated lower luciferase signals when 
compared to the HIV-based systems. Nevertheless, since the use of different 
lentiviral systems may impact on the number of particles produced, it is unknown if 
certain lentiviral constructs lead to the production of more particles or are more 
efficient in incorporating MeV GPs. As a result of these optimisation experiments 
further applications of MeV-PP in this project used the p8.91 and pCSFLW 
constructs. 
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Fig.3-6. PPs production using different lentivirus systems. (A) HEK293T were 
transfected with VSV-G or MeV F∆30 and H∆30 along with one of the following 
lentivirus-based constructs: NL4.3-Luc-E-R-, or p8.91 and pCSFLW, or pCMVi and 
MLV-FLuc. After 72h, supernatants were collected and clarified. HEK293T-SLAM 
cells were then incubated with PPs for 24h. Transduced cells were lysed at 72h post-
transduction and luciferase activity was measured. (B) Transduction of NE-PP 
produced by three different lentiviral systems. Statistical analysis was performed 
using Student’s t test. ***, p<0.001  
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3.5 Development of a MeV matrix-based budding assay 
The matrix protein of a wide range of enveloped viruses frequently functions as the 
driving force for viral budding and egress from the cell [375-377]. In MeV infection, 
the matrix (M) protein wraps the RNP complex [99] and interacts with Rab-11-positive 
endosomes to transport it to the plasma membrane [344]. At the plasma membrane, 
M is thought to oligomerise in lipid rafts to promote viral budding [351, 378]. Although 
the ESCRT system is a common exocytosis route hijacked by many viruses to 
escape the cell, MeV appears to use a different system to bud from cells [346]. To 
examine MeV egress in more detail, I developed a quantitative budding assay based 
on the activity of the M protein, i.e. its ability to generate virus-like particles (VLPs). 
To this effect, I generated a fusion protein comprising the MeV M protein fused to the 
firefly luciferase reporter, via a flexible linker (Fig.3.7). With the intention of assessing 
domains of the matrix protein that would better tolerate the insertion of the luciferase, 
I have generated a 3D model of the MeV M protein structure based on the related 
Newcastle disease virus Matrix protein structure. Details of protein modelling can be 
found in section A.3 of the appendix. According to the model, the N-terminus of M 
was located at the dimer interface while the C-terminal end was presented on the 
outside (Fig.3.7A). As dimer formation has been shown to impact on viral budding 
[379], I have fused the luciferase to the C-terminus of M, separated with a flexible 
linker (Fig.3.7B). This construct was transfected into HEK293T cells and incubated 
for 48h. Supernatants from these cells were collected, clarified by low speed 
centrifugation and overlaid onto a 20% sucrose cushion prior to high speed 
centrifugation. Resultant pellets were then lysed and the firefly luciferase activity 
measured using a luminometer (Fig.3.7C). Even though the evidence for the  
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Fig.3-7. Schematic representation of matrix-based quantitative budding assay. 
(A) 3D model of MeV M based on the crystal structure of the related Newcastle 
disease virus. The N-terminal end of a dimer of MeV (red and blue) is located at the 
dimer interface while the C-terminus is located on the side face of MeV M. (B) A 
fusion protein was generated carrying the N-terminal FLAG epitope, MeV Matrix, a 
flexible glycine-rich linker and the firefly luciferase gene. (C) After transfection into 
HEK293T, fusion proteins generate putative virus-like particles (VLPs). VLPs are 
then collected, purified and luciferase activity is measured. 
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formation of VLPs by expression of M herein is limited, a study using similar 
constructs and methodology demonstrated the isolation of M-derived VLPs by 
ultracentrifugation through a 20% sucrose cushion [346].    
To assess the sensitivity of this VLP-assay HEK293T cells were transfected with 
various amounts of the M-FLuc plasmid. Luciferase activity in the supernatants and 
cell lysates from these cells was then measured (Fig.3.8A). Luminescence levels in 
both cell lysates and supernatants increased in relation to the total amount of 
transfected DNA.  The minimum mass of transfected DNA required to detect 
luminescence signals, significantly different to background, was 73ng for cell lysates 
and 125ng for supernatants. The proportion between luciferase signals in cell lysates 
and supernatants was approximately 100-fold, suggesting that the majority of M 
remains inside the cell and does not form mature VLPs. Using an alternative 
approach, I subsequently compared the VLP formation efficiency of this fusion 
protein to wild-type MeV M. When transfecting cells with increasing amounts of M-
FLuc or wild-type MeV M and harvesting supernatants as described before, I 
observed that only wild-type M could be efficiently detected by western blot 
(Fig.3.8B), even though both constructs contained the FLAG-epitope on their 
respective N-termini. Wild-type M was mainly detected around 35 kDa and detection 
limit by western blot in cell lysates and supernatants was in cells transfected with 
250ng and 500ng, respectively. These results suggest that, even though the FLAG 
epitope could not be detected by western blot, the expression of this construct led to 
the efficient production of VLPs containing M-FLuc. 
The generation of fusion proteins, especially with large additions such as the 
luciferase reporter, can disturb the function of the target protein. MeV M budding  
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Fig.3-8. M-FLuc produces VLPs containing luciferase. The matrix-luciferase (M-
FLuc) fusion construct was transfected into HEK293T at the indicated concentrations 
and 48h later supernatants were collected, clarified and VLPs were pelleted through 
centrifugation. Luciferase activity was measured in whole cell lysates from producer 
cells or from pelleted VLP-containing supernatants  (A) or resolved onto a 12.5% 
SDS-PAGE gel and M-FLuc (95 kDa) and M-FLAG (35 kDa) were visualised by 
western blot (B/C) (n=3 with 3 technical replicates). Short and long exposures of the 
same western blot probed with anti-FLAG. 
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activity is dependent on oligomerization and interaction with several cellular and viral 
components. I hypothesised that M fusion with luciferase might impact on the general 
function of M, despite putative VLPs containing M-FLuc being detected. To minimise 
the impact of this fusion protein on VLP generation and M function, I supplemented 
M-FLuc transfection with wild-type M at different ratios to determine the optimal ratio 
and concentration for VLP generation (Fig.3.9). Co-transfection of wild-type MeV M 
had little impact on the activity of M-FLuc in cell lysates, implying a degree of 
saturation. However, in collected supernatants, a transfected DNA ratio of 1:3 (wild-
type:M-Fluc) correlated with significantly higher luciferase activity, when compared to 
the expression of M-Fluc alone. This provides evidence that the expression of wild-
type M at specific ratios improves luciferase-expressing VLP generation. This 
experimental set-up was therefore used in subsequent experiments.  
 
3.6 Discussion 
MeV spread requires the interaction of several viral proteins, most importantly H, F 
and M, with cellular components and it is likely that such interactions are highly 
complex and dependent on the context in which they are located. To overcome the 
complexity of a natural infection, I have isolated the functional units of viral spread, 
i.e. viral proteins involved in entry and exit, and incorporated them into quantitative 
assays, allowing the independent study of specific stages in the MeV lifecycle.   
I have developed two assays that rely on the activity of MeV H and F proteins – the 
cell-cell fusion and MeV-PP entry assays. These are assayed in different contexts 
and can be used to distinguish the molecular requirements during MeV entry and 
fusion at the plasma membrane. It is frequently assumed that the entry of  
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Fig.3-9. Co-expression of wild-type M and M-FLuc increases viral release. To 
evaluate the effect of co-transfection of M-FLAG in M-FLuc release, HEK293T were 
transfected with a total 2ug of plasmid DNA encoding M-FLAG and M-Fluc at ratios 
1:3, 1:1 and 3:1 or in isolation. After 48h, whole cell lysates were generated (A) and 
supernatants were collected, pelleted and lysed (B) prior to assessing luciferase 
activity (n=2 with 3 technical replicates). Student's t test, *p<0.05.  
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paramyxoviruses and pneumoviruses occurs at the plasma membrane, therefore 
forgoing the requirement to hijack endocytosis pathways. However, there is now 
growing evidence that several of these viruses are internalised [195, 325, 326, 374, 
380]. Pseudotyped viruses have been instrumental tools for studying virus entry [359, 
381, 382]. These systems take advantage of the genome packaging machinery of 
enveloped viruses, such as lentiviruses, to generate chimeric particles covered with 
unrelated viral envelope proteins. Previous studies have suggested that the 
intravirion tails of MeV GPs interfere with their correct incorporation into the lentiviral 
PP [369]. The data I have presented here supports this hypothesis. In addition, we 
have shown that the incorporation of GPs is not strain-specific; however, different 
strains can generate different PP titres. Since the expression of the H protein at the 
cell surface does not appear to vary extensively between strains by western blot 
analysis and Dublin strain GPs are more fusogenic than the IC323 strain, it is 
plausible that the higher entry levels observed with MeV Dublin PPs is due to a 
stronger interaction with MeV cellular receptors. Although predicted SLAM- and 
Nectin4-binding sites in the H proteins of MeV Dublin and IC323 are identical, 
substitutions in neighbouring areas may contribute to binding efficiency. Interestingly, 
the two strains also show different glycosylation patterns: the H protein of the Dublin 
strain has five potential N-glycosylation sites (N-X-S/T), while the IC323 strain has 
six; whilst the F protein of both strains have three and four, respectively. It has been 
reported that the N-glycosylation pattern of paramyxovirus GPs is involved in correct 
protein folding, virus replication and transport of the GPs to the cell surface [198, 
383].  For instance, for MeV and CDV, it was demonstrated that glycosylation sites in 
the F protein are not only critical for protein folding but also modulate fusion [384]. 
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This variance in these MeV GPs could explain their different properties in vitro.  Other 
studies have shown that envelope protein glycosylation patterns in recent field 
isolates of MeV play a role in the evasion of pre-existing antibodies [385, 386].  
These field isolates possess an addition N-glycosylation site that covers certain 
epitopes in the H protein. MeV H-specific antibodies circulating in the majority of 
human populations failed to inactivate MeV PPs when this glycosylation pattern was 
recreated, suggesting that certain post-translational modifications of H can cover 
epitopes involved in adaptive immune recognition. Since MeV PPs have many 
applications in gene therapy [328, 374], understanding how MeV glycoproteins affect 
evasion, entry and fusion can enable the development of better tools in this area.  
The availability of cell receptors in tissue culture allied with the ability of F to be 
triggered in the absence of low pH has led to the belief that cell-cell fusion and fusion 
upon virion entry share the same mechanism. However, taking into consideration that 
the expression of MeV F and H at the plasma membrane precedes the translocation 
of the RNP complex to the plasma membrane [292, 344, 349, 387], that MeV M is 
dependent on dimerization to interact with lipid rafts [388] and that competitive 
interaction of F-actin filaments with the cytoplasmic tails of MeV F and H [349], it is 
likely that these two fusion mechanisms are different. Measles virions are densely 
covered by MeV glycoproteins [387, 389] while MeV F and H oligomers expressed at 
the cell surface (when cell fusion is possible) are very scattered (Roberto Cattaneo’s 
lab scientific communication W45-10, Workshop 45, American Society for Virology 
Annual Conference, Blacksburg, VA 2016). The interactions with cellular receptors, 
and their availability, are also plausible mechanisms that may affect cell-cell fusion 
and viral entry. The fusion of lipid bilayers is regarded as a highly energetic process 
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and viral proteins, such as MeV F, might help to reduce the energy requirements 
[390]. Therefore, a cellular environment where either MeV GPs might not be 
expressed at great density (cell-cell fusion) or where the availability of receptors 
might be low (virus entry) is likely to impact on the progression of membrane fusion. 
Our separate assays can therefore help to clarify the mechanisms involved in each 
process.  
 
MeV is thought to be the main driving force for viral budding. It is likely that the 
interaction of M with the viral GP cytoplasmic tails and lipid-rafts promotes the 
curvature of the plasma membrane culminating in the formation of the virion. 
Although several viruses hijack cellular exocytosis mechanisms to bud, MeV budding 
appears independent of this pathway [346]. Nevertheless, limited evidence suggests 
the involvement of the cytoskeleton in the budding process and formation of viral 
particles [348, 391]. A quantitative budding assay will be useful for screening the 
molecular requirements for virus budding and to understand any active dependence 
on the cytoskeleton. The matrix-luciferase fusion construct I have generated is the 
main component of this assay and is based on the concept that the independent 
expression of MeV M leads to the formation of VLPs [346]. To minimise the impact of 
the luciferase fusion protein I included a glycine-rich flexible linker between the two 
proteins. The expression of this construct in HEK293T yielded the formation of 
putative VLPs containing luciferase, i.e. VLPs containing the M-FLuc fusion protein 
that were able to cross a 20% sucrose cushion at 17000×𝑔, while isolated proteins 
were likely retained on top of the cushion. The M protein of the related paramyxovirus 
NDV forms a lattice underneath the plasma membrane [392]. Although similar 
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phenotypes are hypothesised for MeV, MeV M has recently been shown to wrap the 
RNP complex in a helical configuration [99]. These supramolecular interactions of M 
monomers are possibly sensitive to the addition of extra domains such as a 
luciferase reporter. It is therefore unsurprising that the formation of VLPs is improved 
by the co-expression of wild-type M, as the co-ordinated interaction of several tagged 
M monomers might be alleviated by the expression of wild-type protein.  
Although these assays are powerful and quantitative I understand their limitations, 
especially with regards to comparisons to natural infections. The abundance of these 
proteins, their localisation in the cell and the complexity and temporal nature of 
multiple interactions during infection impacts on the overall function of these proteins. 
Therefore any significant findings obtained with these assays were subsequently 
examined and validated in full MeV infections. In summary, these three assays are, 
in isolation, quantitative techniques to study the function of MeV F, H and M proteins 
and several stages of the MeV lifecycle. Throughout this thesis, these three assays 
are used to study MeV entry and exit.  
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MeV is transmitted via aerosols and is thought to initially infect interstitial 
macrophages and dendritic cells of the lung [36]. Infection subsequently spreads to 
local draining lymph nodes and, after a viremia is established, the virus infects the 
airway epithelium releasing infectious viral particles into the lumen of the lung that 
are then expelled to the environment and transmitted to other hosts [36, 40]. 
Circulating field-isolates of MeV use two known proteinaceous receptors to invade 
different cell-types: SLAMF1 [203], is the immuno-tropic receptor for activated B and 
T cells, monocytes, dendritic cells and macrophages, while nectin-4 [204], a 
component of the adherens junctions found on the basolateral plane of polarised 
epithelium, is the epithelia-tropic receptor. These receptors are not thought to be 
expressed on the same cells, thus conferring a dual tropism to MeV that can explain 
both its immunosuppressive nature and the characteristic epithelial pathogenesis 
seen later in infection, especially in the lung. Functionally, SLAMF1 belongs to the 
immunoglobulin superfamily and acts as a self-ligand involved in the stimulation and 
activation of T and B cells [212].  
MeV encodes six structural and two non-structural proteins. Two of these – the H and 
F proteins - are highly glycosylated proteins present on the virus envelope that direct 
virus attachment to the cell surface and formation of the fusion pore between viral 
and cellular membranes. During this process MeV H interacts with SLAM or Nectin-4 
resulting in conformational changes that activate F [180, 296]. This induces the 
insertion of a highly hydrophobic peptide of F into the cell membrane, culminating in 
complete membrane fusion [202, 308]. Although this mechanism is integral to particle 
entry, it has also been observed, in vitro and in vivo, that MeV-infected cells can also 
induce cell-cell fusion of neighbouring cells resulting in multinucleated cells known as 
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syncytia [393].  This aspect of MeV dissemination is supported by the ability of MeV F 
and H glycoproteins to function at neutral pH.  
It is commonly believed that the MeV genome enters cells after direct fusion of the 
viral envelope with the plasma membrane without endocytosis of the particle [380]. 
However, previously published research indicating that soluble measles H protein 
[329] and, more recently, pseudotyped MeV particles may be endocytosed [374] 
suggested a more complicated mechanism of entry divergent from simple fusion at 
the plasma membrane and immediate entry of the genome. Indeed other 
paramyxoviruses, such as respiratory syncytial virus (RSV), Newcastle disease virus 
(NDV), Nipah virus and Sendai virus, have also been reported to use endocytosis 
pathways to invade cells challenging the concept that these enveloped viruses 
deliver their genome simply by fusing at the plasma membrane [195, 325, 394]. 
Another important aspect to consider is distinguishing between molecular level 
interactions of MeV glycoproteins with cellular receptors and larger scale bio-physical 
interactions between the large incoming particle of MeV and the cellular membrane. 
These larger-scale interactions between virions and the cellular membrane have 
been shown to be critically important in the entry of Ebola virus particles [395]. In this 
study I have revisited the mechanism of entry of MeV into cells, particularly those 
expressing the immune-cell receptor SLAMF1, since these are considered the initial 
target during infection.  
 
4.1 Internalisation of MeV particles 
To evaluate if MeV particles are internalised I first examined the sensitivity of the viral 
H protein to trypsin during the initial stages of infection. I hypothesised that if MeV 
virions fuse directly at the plasma membrane its glycoproteins (F and H) would 
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remain at the cell surface and be sensitive to tryptic digestion. In contrast, if MeV 
particles were internalised, then extracellular trypsin could not cleave the viral 
glycoproteins and F and H would remain intact (Fig.4-1A). After confirming the 
sensitivity of H (found on MeV particles) to trypsin (Fig.4-1B), purified MeV particles 
were attached to A549-SLAM cells (MOI=30) at 4°C for 1h, washed in PBS before 
raising the temperature to 37°C for 0, 15 or 30 minutes (min, synchronous infection). 
At these time-points cells were either immediately trypsinised for 7 min, or detached 
with a solution of EDTA (2 mM in PBS) and whole cell protein lysates generated. 
These lysates were then analysed by western blotting using an antibody raised 
against the intra-virion tail of MeV H (Fig.4-1C). Full-length MeV H was detected in 
non-trypsinised cells around the 75 kDa mark (black arrow); however, when cells 
were trypsinised for 7 min after incubation at 37°C for 0 or 15 min post-infection (mpi) 
H was only detected at 24 and 20 kDa (blue and white arrows, respectively), 
indicating trypsin digestion. In contrast when cells were incubated for longer (30 min), 
H was detected both at its undigested size (75 kDa) as well as at 24 and 20 kDa, 
suggesting protection from trypsin. To assess the sensitivity of MeV to trypsin post 
attachment, I repeated the experiment, instead allowing infection to continue for 48h 
after the trypsin or EDTA treatment. At this time-point, yields of produced virus were 
calculated as an indicator of productive infection (Fig.4-1D). As expected virus yields 
were reduced after trypsin treatment, both at 0 and 10 mpi, relative to untreated 
controls. This reduction was, however, markedly less following incubation for 20 mpi 
at 37°C, again implying protection from trypsin.  
In supporting experiments I addressed the same question using an adapted 
quantitative cell-to-cell fusion assay [308] in which target cells are transfected with  
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Fig. 4-1. Measles virions are resistant to tryptic digestion 30min post infection. 
(A) Diagram of experimental setup: purified MeV was attached to A549-SLAM cells 
(MOI=30) for 60min at 4°C, washed with PBS to remove unattached virus and 
incubated for 0, 15 or 30min at 37°C prior to trypsin treatment. (B) Sensitivity of MeV 
H to trypsin was confirmed by incubation of virions with trypsin for 7min at 37C, prior 
to SDS-PAGE/western blot analysis. (C) Total cells lysates were generated and 
resolved on a 15% SDS-PAGE gel prior to western blotting using a polyclonal 
antibody raised against the cytoplasmic tail of MeV H. Three H-specific bands were 
detected with the approximate size of 75 kDa (black arrow; full-length), 24 kDa (blue 
arrow) and 20 kDa (white arrow); the latter two only being detected after trypsin 
treatment. The results shown are representative of four individual experiments. (D) 
Similarly, cells were synchronously infected with MeV, incubated at indicated time-
points (minutes post-infection, mpi) and trypsinised for 7min at 37°C. Cells were 
pelleted, resuspended in complete media, incubated for 48 h and the total virus was 
then titrated. Student's t test, n.s., non-significant. 
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one half of a dual split-reporter, while effector cells are transfected with the 
complementary half. The dual reporter is only functional when target and effector 
cells fuse and cytosolic mixing takes place. I hypothesised that if MeV fuses at the 
plasma membrane, F and H would remain at the cell surface and induce cell-to-cell 
fusion when target cells are overlaid on top of MeV-infected cells. In contrast, if MeV 
particles are internalised, F and H would be removed from the cell surface and 
therefore be unable to interact with neighbouring cells to induce cell fusion (Fig.4-
2A). To examine this, purified MeV particles were attached to effector cells (MOI=30) 
as stated previously. These cells were then washed and incubated at 37°C for 0, 15, 
30 or 60 min prior to the addition of target cells for 90 min in the presence or absence 
of chlorpromazine (CPZ) (which blocks the formation of clathrin-coated pits), followed 
finally by the measurement of the luciferase activity in fused cells (Fig.4-2B). Cell-to-
cell fusion decreased following extended incubation periods at 37°C even in the 
presence of the inhibitor of clathrin-mediated endocytosis, a common endocytosis 
pathway for sequestration of proteins at the plasma membrane [396]. These data  
suggest that the viral glycoproteins do not remain at the cell surface following viral 
attachment in a mechanism independent of receptor recycling pathways. Together, 
these results suggest a proportion of viral particles are internalised upon entry. 
4.2 MeV entry is independent of low endosomal pH, dynamin, clathrin- and 
caveolin-mediated endocytosis.  
To assess if the observed internalisation of viral particles was dependent on common 
endocytosis pathways, I used a combination of lentivirus-based pseudotyped MeV 
particles (MeV-PPs) or recombinant MeV engineered to express EGFP, together with 
pharmacological inhibitors of these pathways. Entry of MeV-PP into A549-SLAM cells  
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Fig. 4-2. MeV glycoproteins are removed from the surface soon after 
attachment. (A/B) Diagram of experimental setup: HEK293T-SLAM cells carrying a 
split form of Renilla luciferase were synchronously infected with purified MeV 
(MOI=30) for 60min at 4°C, washed with PBS and incubated for 0, 15, 30 or 60min at 
37°C (in the presence or absence of 5µg/mL of chlorpromazine, CPZ) prior to the 
addition of HEK293T-SLAM cells carrying the complementary part of the luciferase. 
Cells were co-cultured for 90min before the addition of the luciferase substrate 
coelenterazine with produced light being measured using in a luminometer. Of note, 
values were normalised by subtracting the values from a negative control, i.e. cells to 
which virus was not attached and plotted as relative light units (n=3 with 4 technical 
replicates). Student's t test, **p<0.01 , ***p<0.001. 
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was unaffected by treatment with chloroquine (CQ) and bafilomycin A1 (BAF), two 
lysosomotropic agents that block endosomal acidification and caveolin-dependent 
endocytosis, however VSV-PP entry was significantly decreased (Fig.4-3A). 
Similarly, the dynamin-2 inhibitor dynasore (DYN) failed to block MeV-PP infection. 
When A459-SLAM cells were pre-treated with these drugs and infected with a 
recombinant MeV engineered to express EGFP (MOI=1), no difference was observed 
in the number of infected cells using UV-microscopy (Fig.4-3B and 3C). To evaluate 
if cellular factors involved in clathrin-mediated endocytosis (such as the epidermal 
growth factor receptor substrate 15, EPS15), caveolin-mediated endocytosis (Cav-1) 
or dynamin-dependent endocytosis (Dyn2) were required for infection, cells were 
transfected with constructs encoding dominant negative (DN) mutants of these 
proteins and infected with MeV-PPs or VSV-PPs (Fig.4-3D). Unsurprisingly, none of 
these mutants had an appreciable effect on MeV-PP entry confirming dynamin-, 
clathrin- and caveolin-mediated endocytosis are not required for MeV entry via the 
SLAM receptor. To assess if internalised particles co-localize with clathrin-, caveolin- 
or dynamin2-positive vesicles, A549-SLAM cells were transfected with plasmids 
encoding GFP-fused clathrin heavy chain (CHC-GFP), caveolin-1 (Cav1-GFP) or 
synchronously infected with MeV and incubated for 30 min at 37ºC. Cells were then 
fixed, stained with anti-nucleocapsid (MeV N) antibody and prepared for confocal 
laser scanning microscopy (CLSM) (Fig.4-4A). Only a limited number of MeV N-
positive puncta co-localized with CHC- and Cav1-positive vesicles while slightly more 
co-localized with dyn2-GFP-positive vesicles (Fig.4-4B). Despite the unexplained 
partial co-localisation of MeV particles with Dyn2- GFP, these data suggests that  
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Fig.4-3. MeV entry is insensitive to inhibitors and dominant negative mutants of 
clathrin- and dynamin-2-dependent endocytosis. (A) A549-SLAM cells were pre-
treated with chloroquine (CQ, 50µg/mL), bafilomycin A1 (BAF, 50µg/mL), dynasore 
(DYN, 100µM) or solvent for 30min at 37°C. MeV- or VSV-PP encoding the firefly 
luciferase reporter were added to the cells and incubated for 3h. Media was then 
replaced and cells were incubated for 72h before lysis, addition of the luciferase 
substrate luciferin and measurement of produced light (n=5 with 4 technical 
replicates). (B/C) Equivalently, cells were pre-treated with indicated drugs at the 
same concentrations for 30min and infected with MeV (MOI=1) for 1h. Cells were 
trypsinised, pelleted and resuspended in complete media and after 24h of incubation 
at 37°C, visualized under UV light (B) and the number of GFP-positive infected cells 
counted (C) (n=2 with 1 technical replicate). (B) Representative images of the typical 
fields of view used for quantification are shown. (D) HEK293T-SLAM cells were 
transfected with plasmids expressing dominant negative (DN) mutants of EPS15, 
cav-1 and dyn2 and 48h post-transfection transduced with MeV- or VSV-PPs. As a 
control, cells were transfected with an empty plasmid (Vector). After 72h cells were 
lysed and the luciferase activity was measured (5 replicates per condition, error bars 
represent standard deviation). Student's t test, *p<0.05 , **p<0.01, n.s. non-
significant. 
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MeV entry into SLAM-positive cells is independent of clathrin-, caveolin- and 
dynamin-2-mediated endocytosis.  
4.3 MeV induces extensive membrane blebbing and is sensitive to blebbistatin.  
Other mechanisms of entry into the cell, such as phagocytosis and macropinocytosis, 
involve a substantial rearrangement of the plasma membrane [397]. To examine if 
MeV was inducing similar rearrangements during entry, I synchronously infected cells 
with MeV (MOI~45) and, following fixation, observed their morphology by phase-
contrast microscopy (Fig.4-5A). MeV-infected cells presented significantly more 
membrane blebs (arrows, Fig.4-5A) than uninfected cells (Fig.4-5B). To further 
investigate these membrane modifications I performed scanning electron microscopy 
(SEM) on cells synchronously infected with MeV (MOI=30) and incubated for 10, 30 
or 60 min at 37°C prior to fixation and preparation for SEM (Fig.4-5C). Although 
uninfected cells showed a flat and well distributed morphology, MeV-infected cells at 
10 and 30 mpi were visibly more contracted, also appearing partially detached from 
the coverslip (upper panel). Closer observation of the plasma membrane (Fig.4-5C – 
see insets) showed that while uninfected cells presented occasional small filopodia-
like structures and an otherwise smooth plasma membrane (orange arrow, bottom 
left), the surfaces of MeV-infected cells at 10 and 30 mpi were almost exclusively 
covered with similar structures  (orange arrow, bottom middle). In addition, only 
infected cells at 10 or 30 mpi presented membrane blebs, these being located 
predominantly at the cell’s periphery dynamin2 (Dyn2-GFP) and 48h later (white 
arrows). Interestingly, infected cells incubated at 37°C for 60 min post viral 
attachment presented with a similar morphology to uninfected cells indicating that 
these morphological changes were transient (bottom right). 
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Fig.4-4. Internalised Measles virions do not colocalise with CHC, Cav-1 and 
only partially with Dyn-2. (A) A549-SLAM cells were transfected with plasmids 
encoding GFP (Green), Clathrin heavy chain 1 (CHC)-GFP, caveolin-1 (Cav1)-GFP 
or dynamin-2 (Dyn2)-GFP. Cells were then synchronously infected with MeV, 
incubated for 30min at 37ºC and prepared for and analysed by CSLM. 
Representative micrographs were taken (MeV nucleocapsid (N) is pseudocoloured in 
red) and (B) co-localisation of green- and red-channels was quantified. Scale bar 
represents 15µm. 
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Fig.4-5. MeV induces extensive membrane blebbing. (A) A549-SLAMs were 
serum-starved overnight at 37°C and subsequently pre-chilled on ice for 5min. MeV 
(MOI=45) was then attached to cells for 1h at 4°C. As a control (uninfected) cells 
were exposed to media containing 20% FBS under the same conditions. Cells were 
washed with cold PBS and incubated for 30min at 37°C before fixation with 4% PFA 
and visualisation by phase-contrast microscopy. (B) The percentage of cells that 
presented membrane blebs (white arrows in A) per field of view was calculated for 
both samples. (C) Similarly, serum-starved A549-SLAM were synchronously infected 
with MeV (MOI=30) and incubated for 0, 10, 30 or 60min at 37°C before fixation and 
preparation for SEM. Both uninfected and infected cells presented small filopodia-like 
structures at the surface (orange arrows) but only infected cells presented membrane 
blebs (white arrows). Student's t test, **p<0.01 
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The formation of membrane blebs is largely governed by the activity of myosin-II, a 
protein involved in the rapid contractility of the cortical actin cytoskeleton [398]. To 
evaluate the role of membrane blebbing in MeV entry I therefore pre-treated cells 
with blebbistatin, an inhibitor of myosin-II, and infected these cells with MeV-PPs, 
VSV-PPs (Fig.4-6A) or MeV (Fig.4-6B). Efficiency of blebbistatin in blocking fluid-
uptake was assessed prior to MeV infections (see appendix section A-4). Infection 
with both MeV-PP and MeV was reduced by this drug as was nascent MeV viral 
production in blebbistatin-treated cells (Fig.4-6C). In contrast blebbistatin had no 
effect on VSV-PP entry (Fig.4-6A). To assess the specificity of blebbistatin for MeV 
entry cells were infected with MeV and either, pre- or post-treated with a range of 
concentrations of this drug (Fig.4-6D). At all concentrations, the level of detected 
MeV H, after 24h of infection, was lower when cells were pre- rather than post-
treated with the drug. These results highlight the essential importance of membrane 
blebbing during MeV entry and are indicative of early events in the macropinocytosis 
pathway.  
4.4 MeV induces fluid-phase uptake and is sensitive to EIPA.  
 
Underlying the definition of macropinocytosis is the uptake of fluid from extracellular 
medium [399]. I hypothesised that if MeV promotes macropinocytosis upon entry, it 
should also induce the internalization of extracellular fluid and the formation of 
macropinosomes. Using a cell-impermeable, soluble and fluorescent 10 kDa dextran 
(0.25 mg/mL in PBS), cells were synchronously infected with MeV (MOI=10) and 
then incubated at 37°C for 20 min. For controls, cells were pre-incubated with DMEM 
with 20% FBS (uninfected) or 200nM of the macropinocytosis-inducer phorbol 12-
myristate 13-acetate (PMA) [400]. 
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Fig.4-6. MeV infection is sensitive to treatment with blebbistatin. (A) A549-SLAM 
cells were pre-treated with blebbistatin (BLEB) or solvent for 30min before the 
addition of MeV- or VSV-PP. Cells were then incubated with PPs for 3h, washed with 
PBS and incubated for 72h in complete media prior to measurement of luciferase 
activity. (B/C) In a similar experiment, cells were pre-treated with 100µM of 
blebbistatin for 30min and infected with MeV (MOI=1) for 1h. Cells were then 
trypsinised and incubated for 24h before assessment of no. of GFP-positive cells and 
the total yield of virus. (D) To address if blebbistatin had a dose-dependent effect on 
MeV entry, A549-SLAM were either pre- or post-treated with the drug, in relation to 
the point of infection, at the indicated concentrations, trypsinised and subsequently 
incubated at 37°C for 24h. Total cells lysates were generated and resolved on a 15% 
SDS-PAGE gel prior to western blotting using a polyclonal antibody raised against 
the cytoplasmic tail of MeV H. Student's t test, *p<0.05, **p<0.01, n.s., non-significant 
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After this period, surface bound dextran was removed by incubation with bleach 
buffer and cells were fixed and prepared for CLSM. MeV-infected cells were 
analysed by CSLM after fixation (Fig.4-7A and B) and showed a SLAM-specific 
increased uptake of the fluorescent dextran when compared to uninfected and PMA-
treated cells (Fig.4-7C and D). In addition, the dextran’s intracellular distribution was 
clearly more punctate, indicative of macropinosome formation (Fig.4-7B; white 
arrows). To assess the specific sub-cellular localization of internalised measles virus 
particles within dextran-positive vesicles, cells were synchronously infected with MeV 
(MOI=10), washed and incubated with dextran-containing medium at 37ºC for 15, 30, 
45 and 60 min, prior to preparation for CLSM (Fig.4-8A). Internalized MeV N was 
shown to be associated with dextran-containing vesicles at 30 and 45 min, followed 
by a reduction in co-localisation at 60 mpi (Fig.4-8B). Furthermore, to specifically 
address the role of SLAM in inducing fluid-phase uptake during MeV infection, I 
synchronously infected parental A549 cells (lacking the MeV receptor SLAM) or 
A549-SLAM cells (engineered to overexpress SLAM) with MeV particles and 
incubated with dextran-containing medium for 45 min at 37ºC (Fig.4-9). Dextran-
uptake was significantly higher in infected A549-SLAM cells confirming the SLAM-
specificity of our observations (Fig.4-9A and B).  
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Fig.4-7. MeV induces fluid-phase uptake upon entry. (A) A549-SLAM cells were 
synchronously infected with MeV (MOI=10) for 1h at 4ºC, washed in cold PBS and 
incubated at 37°C for 20min with DMEM containing 0.25mg/mL of Dextran Alexa 
Fluor-488 conjugate. Cells were then moved to ice, washed, bleached and fixed in 
4% PFA. Samples were prepared for and analysed by CLSM. Representative 
micrographs of uninfected cells treated with 20% FBS-containing DMEM and MeV-
infected cells and cells treated were recorded. (B) Quantification of internalised 
Dextran (pseudo-coloured green) was performed by calculating corrected total cell 
fluorescence based on mean fluorescence intensity (MFI). Scale bars are 
representative of 20um. Statistical analysis was performed using Student’s t-test, 
*p<0.05. 
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Fig.4-8. Internalised MeV N colocalises with dextran-containing 
macropinosome-like structures. (A) In order to observed internalised MeV 
particles, A549-SLAM cells were synchronously infected with MeV (MOI=10), washed 
and incubated at 37ºC in dextran-containing PBS for the indicated time, fixed, 
prepared and analysed by CSLM. Dextran is showed in green while MeV N is 
pseudocoloured in red; arrows indicate co-localisation of N and dextran-positive 
vesicles, quantified in (B). Scale bars are representative of 10um. 
  
207 
 
 
  
208 
 
 
 
 
 
 
 
 
 
Fig.4-9. MeV-induced fluid-phase uptake is SLAM-specific. (A) To assess the role 
of SLAM in fluid-uptake during MeV-infection, A549 and A549-SLAM cell were 
synchronously mock- or MeV-infected (MOI=10), incubated with Dextran-containing 
PBS for 30min, fixed and analysed by CSLM. Bar represents 30µm. (B) Six 
representative micrographs of each condition was analysed and mean fluorescence 
intensity in the green channel was quantified and plotted. Student’s t test *, p<0.05. 
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Treatment of cells with the amiloride analogue 5-(N-ethyl-N-isopropyl) amiloride 
(EIPA), a compound that selectively blocks the formation of macropinosomes [401], 
reduced  
infection with MeV-PP (Fig.4-10A). Efficiency of EIPA in blocking fluid-uptake was 
assessed prior to MeV infections (see appendix section A-4). When cells were pre-
treated with EIPA, infected with MeV and analysed by flow cytometry at 6.5h post-
infection, MeV infection was reduced in a dose dependent manner (Fig.4-10B). 
Interestingly, when infected cells were analysed by western blot 24hpi, EIPA had an 
effect following both pre- and post-treatment, suggesting that its effect could be 
related not only to the immediate steps of MeV entry but possibly also on the stability 
of MeV H (Fig.4-10C). Nevertheless, our results highlight a critical role for the 
process of macropinocytosis in MeV-particle entry.  
 
4.5 MeV induces actin rearrangements during entry.  
Fundamental to the formation of membrane blebs and the capture of extracellular 
fluid via macropinocytosis is a dynamic actin network located at the cortex of the cell, 
on the inner face of the plasma membrane [402]. Using standard phalloidin-based 
actin staining techniques I examined the rearrangement of this cortical actin 
cytoskeleton during MeV entry. MeV (MOI=15) was bound to A549-SLAM cells at 
4°C, washed and cells were incubated for 0, 20 or 60 min at 37°C prior to fixation and 
staining with phalloidin (Fig.4-11A). Cell contraction was observed, particularly at the 
cell periphery (inset Fig.4-11A) where partial loss of attachment led to the formation 
of multiple podosomes. Analysis of total cell area, based on measurement of the 
visible cell surface stained with actin, also demonstrated these cells were significantly  
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Fig.4-10. MeV infection is sensitive to EIPA. (A) MeV- or VSV-PPs were incubated 
for 3h with A549-SLAM cells pre-treated with 25µM of EIPA and incubated in 
complete medium. Luciferase activity was measured 72h later. (B) A549-SLAM cells 
were pre-treated with EIPA and infected with MeV (MOI=1) at the indicated 
concentrations, before being trypsinised and incubated for an additional 6.5h. Cells 
were then detached with 2mM EDTA solution and GFP-fluorescence was analysed 
by flow cytometry. (C) Cells were either pre- or post-treated with EIPA at indicated 
concentration, infected with MeV (MOI=1), trypsinised and incubated for 24h. After 
that period, whole cell lysates were generated and resolved on an SDS-PAGE gel 
prior to western blotting using a polyclonal antibody raised against the cytoplasmic 
tail of MeV H. Statistical analysis was performed using Student’s t-test, *p<0.05, 
**p<0.01. 
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Fig.4-11. MeV infection induces rapid but transient contraction of the 
cytoskeleton. (A) A549-SLAM cells were synchronously infected with MeV 
(MOI=15) for 1h at 4ºC or incubated with 20% FBS-DMEM under the same 
conditions (No virus). Cells were washed in cold PBS and incubated at 37ºC for 0, 
10, 20 or 60min prior to fixation with 4% PFA, staining with phalloidin-TRITC 
(pseudocoloured in white) and analysis by CSLM. Details of the edge of cells are 
highlighted in selected area. (B) The average cell area (in pixel units) of individual 
cells was calculated based on representative micrographs of each condition using 
ImageJ (see chapter 2 section 2.9.3). Statistical analysis was performed using 
Student’s t-test, *p<0.05. 
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(p<0.05; t-test) contracted relative to uninfected cells (Fig.4-11B). These 
modifications were transient and cells recovered normal morphology by 60 mpi 
(Fig.4-11C).  As before, I assessed the specific role of SLAM in the MeV-induced 
actin cytoskeleton contraction. A549 and A549-SLAM cells were infected with MeV, 
incubated for 20 min at 37ºC and the surface area analysed as before (Fig.4-12A 
and B). Contraction of the actin cytoskeleton was significantly higher in infected 
A549-SLAM when compared to A549 cells. To evaluate the localisation of MeV 
particles within these cytoskeletal modifications, I synchronously infected A549-
SLAM cells (MOI=10) and incubated at 37ºC for 0, 15, 30 or 60 mpi prior to 
preparation for CLSM (Fig.4-13). Interestingly, MeV N was shown to be associated 
with actin before internalisation (blue arrows, inset 0 min), presumably as actin is 
present inside the MeV particle, as reported previously [391]. At 15 min, MeV N was 
associated with actin enriched domains (blue arrow, 15 min) and at 30 min it was 
frequently found at the base of actin-enriched membrane structures resembling 
membrane blebs (blue arrows, inset 30 min). At 60 mpi, MeV N was no longer 
associated with actin and cells presented a cytoskeletal morphology similar to that of 
mock-infected cells (Fig.4-13, 60 min). Based on these findings I then evaluated 
whether a responsive and dynamic actin network is required for efficient viral entry, 
using a panel of well-characterised chemical inhibitors. MeV entry was shown to be 
sensitive to both cytochalasin D, an inhibitor of actin polymerization, and 
jasplakinolide, a promoter of actin polymerization (Fig.4-14A). Efficiency of these 
drugs in altering the cytoskeleton were confirmed by immunofluorescence prior to 
MeV infection (see appendix section A.5).  
 
217 
 
 
 
 
 
 
 
 
 
Fig.4-12. MeV induced cytoskeletal contraction is SLAM-specific. (A) To assess 
the role of SLAM in inducing the contraction of the cytoskeleton during MeV-infection, 
A549 and A549-SLAM cell were synchronously mock- or MeV-infected (MOI=10), 
incubated at 37ºC for 30min, fixed and analysed by CSLM. Bar represents 30µm. (B) 
Six representative micrographs of each condition were analysed and the average cell 
area was calculated and plotted. Statistical analysis was performed by applying 
Student’s t tests. *, p<0.05; **, p<0.01. 
  
218 
 
 
219 
 
 
 
 
 
 
 
 
 
 
Fig.4-13. MeV N colocalises with actin-rich domains upon entry. A549-SLAM 
cells were synchronously infected with MeV (MOI), incubated at 37ºC for 0, 15, 30 or 
60min, fixed and prepared for CSLM. Blue arrows represent co-localisation of MeV N 
(in red) and actin (white). Scale bars are representative of 10µm.  
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Fig.4-14. MeV infection is sensitive to pharmacological inhibitors that target 
actin and microtubule dynamics. (A/B) A549-SLAM cells were pre- or post-treated 
with the indicated concentrations of cytochalasin D or jasplakinolide in relation to 
infection with MeV (MOI=1). Total cells lysates were generated 24h post infection 
and resolved on a 15% SDS-PAGE gel prior to western blotting using a polyclonal 
antibody raised against the cytoplasmic tail of MeV H. Densitometry analysis of 
western blot bands was performed and it represented in the figure. Ratio between 
area beneath peak of MeV H and GAPDH bands, normalised to DMSO.  (C) In 
similar experiments A549-SLAM cells were pre-treated with 30µM of latrunculin A 
(LatA), 200µM of CK-666 Arp2/3 complex inhibitor, 5µM of wiskostatin (Wisk), 
5µg/mL of nocodazole (Noco) or 5µM of taxol and infected with MeV (MOI=1). Total 
cells lysates were generated 24h post infection and resolved on a 15% SDS-PAGE 
gel prior to western blotting using a polyclonal antibody raised against the 
cytoplasmic tail of MeV H. 
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Furthermore, MeV infection was also shown to be sensitive to inhibitors of related 
cytoskeletal components including CK-666, that inhibits the Arp2/3 complex, and 
wiskostatin, a Wiskott-Aldrich syndrome protein (WASP) inhibitor (Fig.4-14B). Both 
factors are involved in the branching of the actin cytoskeleton and contribute to the 
rigidity of plasma membrane structures [403]. In contrast, latrunculin A (LatA), an 
alternative inhibitor of actin polymerization, failed to block infection. Contrasting 
results were also observed when I analysed a role for microtubules in MeV entry. In 
these experiments treatment with nocodazole (noco) or taxol, which promotes or 
stabilizes microtubule formation, respectively, were shown to have opposed results. 
Together these results demonstrated that reorganization of the cytoskeleton was 
essential for establishing MeV infection; however, the exact dependence on specific 
components of the cytoskeleton and related regulatory pathways remains to be 
determined. 
 
4.6 MeV entry is dependent on Rac1, RhoA, and, to a lesser extent, Cdc42 and 
PAK-1.  
To identify specific pathways involved in MeV entry I therefore focused on the 
established cellular regulators of intracellular actin dynamics. Like many actin-
dependent processes occurring at the plasma membrane macropinocytosis requires 
phosphatidylinositol-3-kinase (PI3K) and is orchestrated by the activation of small 
Rho GTPases, particularly Rac1 and Cdc42 [321]. I hypothesised that other 
GTPases including RhoA, not thought to be necessary for the induction of 
macropinocytosis, may also be involved as their presence mechanistically underpins 
the generation of membrane blebs [404]. 
225 
 
To individually examine the roles of these factors I transfected cells with constructs 
expressing DN or constitutively active (CA) mutants of these proteins and 
subsequently infected them with MeV-PP or MeV. Entry of MeV-PPs in cells 
expressing DN forms of these Rho GTPases was significantly lower (p<0.01; t-test) 
when compared to cells transfected with an empty plasmid, but CA forms had no 
effect (Fig.4-15A). Similarly, MeV infection was reduced in cells expressing the same 
DN Rho GTPases (Fig.4-15B). In addition, when the Cdc42-specific inhibitor ML141 
was used to pre-treat cells, infection was only modestly affected (Fig.4-15C); 
however, when using H-1152, an inhibitor of the Rho-associated protein kinase 1 
(ROCK1), an effector of RhoA, MeV-PP entry was significantly (p<0.01; t-test) 
reduced (Fig.4-15D). In the context of MeV infection, H-1152 reduced measles virus 
infection when cells were treated pre-infection (Fig.4-15E). These results suggest 
that multiple Rho GTPases are required for MeV entry, particularly RhoA and Rac1 
and to a lesser extent Cdc42. I also examined downstream effectors involved in 
macropinocytosis including p21-activated kinase-1 (PAK-1), a protein activated by 
Rac1 and Cdc42 and involved in macropinosome formation. Cells transfected with a 
CA form of PAK-1 were slightly more permissive to MeV PP and virus infection 
(Fig.4-16A and B). Similarly, siRNA knock-down of PAK-1 or inhibition via treatment 
with IPA-3 modestly affected MeV infection (Fig.4-16C and D), suggesting only a 
partial requirement for PAK-1 in MeV entry 
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Fig.4-15. MeV infection is dependent on the activities of Rac1 and RhoA. (A) 
A549-SLAM cells were transfected with constructs encoding myc-tagged dominant 
negative (DN) mutants (Rac1 N17, RhoA N19 and Cdc42 N17) or GFP-tagged 
constitutively (CA) active forms (Rac1 L61, RhoA L63 and Cdc42 L61) of the 
indicated RhoGTPases. Cells were then transduced with MeV-PP and the luciferase 
activity measured 72h later. (B) Similarly, cells were transfected with the same 
constructs, infected with MeV (MOI=1) and incubated for 24h. Infected cells were 
quantified under UV-microscopy. (C/D) A549-SLAM cells were pre-treated with the 
Cdc42 inhibitor ML141 or ROCK inhibitor H-1152 at the indicated concentrations for 
5h before infection with MeV- or VSV-PP. Luciferase activity was measured 72h later. 
(C) A549-SLAM cells were pre- or post-treated with the indicated concentrations of 
H-1152 in relation to infection with MeV (MOI=1). Total cells lysates were generated 
24h post infection and resolved on a 15% SDS-PAGE gel prior to western blotting 
using an antibody raised against MeV H. Student’s t test, **, p<0.01, n.s. non-
significant.  
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Fig.4-16. MeV infection is not strictly dependent on PAK-1 activity. (A/B) Cells 
were transfected with plasmid constructs encoding wildtype (WT) or a CA mutant of 
PAK-1 and either transduced with MeV-PP (A) or infected with MeV (MOI=1, B) 
before quantification by luciferase assay or under UV microscopy. (C) A549-SLAM 
cells were transfected with either random siRNA (control), siRNA targeting PAK-1 or 
carrier. Seventy-two hours later, cells were infected with MeV (MOI=1), incubated for 
24h and lysed for western blot analysis. (D) A549-SLAM cells were pre- or post-
treated with the indicated concentrations of IPA-3 in relation to infection with MeV 
(MOI=1), incubated for 24h and analysed by western blot. Student’s t test, **, p<0.01, 
n.s. non-significant. 
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4.7 MeV enters lymphocytes via a macropinocytosis-like mechanism.  
SLAM/CD150-positive lymphocytes are key targets for MeV infection, particularly 
circulating and lymph-node resident B-cells [36]. A patient-derived immortalized 
lymphoblastoid B-cell line (LCLs) expressing endogenous levels of surface CD150 
was identified from a selection of lymphocyte cell-lines by CD150 flow cytometry (a 
kind gift from Dr. Claire Shannon-Lowe; data not shown) and subsequently used as a 
physiologically relevant model for MeV entry. LCLs were synchronously infected with 
purified MeV (MOI~20) and observed under SEM (Fig.4-17A). Infected LCLs 
presented significantly more membrane blebs that uninfected cells (p<0.005; t-test); 
however, interestingly, no difference was observed in the proportion of cells with 
membrane ruffles, another common feature of macropinocytosis (Fig.4-17B). In 
subsequent experiments with the fluorescently labelled dextran I again observed that 
MeV-infected cells took up more extracellular fluid into large endosomal 
compartments when compared to uninfected cells (white arrows, Fig.4-17C). Finally, 
when LCLs were pre-treated with our previously established inhibitors of MeV entry, 
MeV infection was reduced by cytochalasin and blebbistatin and to a lesser extent 
EIPA (Fig.4-17D).  
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Fig.4-17 – MeV enters lymphocytes via macropinocytosis-like mechanism. (A) 
LCLs were synchronously infected with MeV (MOI~20) or uninfected with 20% FBS-
containing DMEM, before fixation in 2.5% glutaraldehyde, preparation and 
visualisation by SEM. (B) Images were blinded and representative micrographs were 
subsequently used to quantify membrane blebs and membrane ruffles. Statistical 
analysis was performed using Student’s t-test, ****p<0.001; n.s., non-significant. (C) 
LCLs were attached to a glass coverslip, synchronously infected with MeV (MOI~20) 
and incubated with DMEM containing 0.25mg/mL of Dextran Alexa Fluor-488 
conjugate. Cells were moved to ice, washed, and fixed in 4%PFA before analysis by 
CLSM. (D) LCLs were pre-treated with 2.5µM of cytochalasin D (CytoD), 25µM of 
EIPA or 25µM of blebbistatin (Blebb) and infected with MeV (MOI=1). Total cells 
lysates were generated and resolved on a 15% SDS-PAGE gel prior to western 
blotting using a polyclonal antibody raised against the cytoplasmic tail of MeV H.  
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4.8 Discussion 
My initial experiments characterising the sensitivity of incoming MeV glycoproteins to 
trypsin, together with my pseudoparticle data ruling out clathrin and caveolin-
mediated endocytosis, led me to investigate macropinocytosis as a potential entry 
pathway for this virus. As such I investigated a number of characteristic features of 
this pathway including gross morphological changes, fluid uptake, cytoskeletal 
modification and Rho GTPase involvement. 
The formation of membrane blebs, ruffles and filopodia at the plasma membrane are 
typical features of macropinocytosis. Our experiments demonstrated a SLAM- and 
MeV- specific activation of these features, particularly membrane blebs, upon virus 
attachment to cells; however, it remains unclear if collapse of these blebs leads to 
direct virus internalisation or alternatively if the virus “surfs” on these structures 
directing particles to the correct site of internalization [405]. A recent review on virus 
entry has highlighted the role of immunoglobulin-like domains, found in molecules 
such as SLAM, in driving pathogens to the correct site of entry [406], and although 
evidence is fairly limited, this could explain the extensive formation of filopodia-like 
structures I also observed.  
Another critical characteristic of macropinocytosis is the uptake of large amounts of 
extracellular fluid into cells. Viruses that induce macropinocytosis are commonly 
found inside resulting macropinosomes, often remaining there until membrane 
penetration is triggered and the virus genome is released into the cytosol. Our 
experiments showed that MeV also induces a significant uptake of extracellular fluid 
and that incoming MeV particles associate with fluorescent-dextran positive 
macropinosomes. However, I observed that association with these labelled 
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endosomes is lost within 60 min, perhaps indicating the rapid escape of MeV 
genome into the cell, discussed in more detail below.  
Actin rearrangements in the cell’s cortical cytoskeleton are absolutely essential for 
efficient macropinocytosis [402, 407]. Our results showed that when actin dynamics 
were abrogated by a range of drugs, MeV entry was inhibited. In addition, I observed 
that MeV infection induced the profound rearrangement of the cytoskeleton and that 
particles directly associated with these arrangements. This was reflected in changes 
to the cell’s overall morphology (cells contracted and became rounded) and the loss 
of adhesion sites. Similarly dramatic morphology changes were observed with 
Kaposi's sarcoma-associated herpesvirus (KSHV), Vaccinia and ASFV [408-410] and 
this is generally seen as a major feature of virus entry via macropinocytosis [321].  
Macropinocytic rearrangements are controlled by a range of cellular factors. This 
requirement is highlighted by the sensitivity of macropinocytosis to blebbistatin and 
EIPA, two drugs that are commonly used to inhibit this pathway and were shown to 
inhibit MeV entry in our experiments. Blebbistatin blocks the action of the non-muscle 
myosin-II, a protein involved in the formation of ruffles and blebs [398, 411] while 
EIPA is a potent inhibitor of the Na+/H+ ATPases located at the plasma membrane. 
Accordingly, other viruses known to enter cells via macropinocytosis are inhibited by 
these drugs, e.g. RSV and Vaccinia virus [195, 408, 409].  
The sensitivity of MeV, and other macropinocytosed viruses, to these chemical 
inhibitors is linked to key cellular regulators that coordinate the actin cytoskeleton 
during macropinocytosis, in particular Rho GTPases. For instance it is believed that 
changes in submembranous pH are the activation signal for Cdc42 and Rac1, and 
that EIPA prevents macropinosome formation by interfering with this process [401]. 
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Interestingly, our results using a range of Rho GTPases mutants and inhibitors 
suggest a dependency on the activity of not only Rac1 and Cdc42, but also RhoA. 
RhoA is not generally perceived as being related to macropinocytosis; however, 
there is evidence for a role in the formation of membrane blebs [404].  
The added requirement for RhoA and the observation that particle entry relies heavily 
on the formation of membrane blebs is an intriguing observation. These 
discrepancies build on the idea that macropinocytosis might not be just one single 
pathway, but rather an umbrella term for several endocytosis mechanisms for fluid 
internalization with distinct, yet overlapping, phenotypes and mechanisms [399, 412]. 
A RhoA/Rac1-dependent endocytosis mechanism was first described in the 
internalisation of the interleukin-2 receptor [413]; however, despite the observation 
that MeV particles co-localised with a small number of Dyn2 positive particles it would 
appear MeV entry is dynamin-independent, since it is insensitive to the specific 
inhibitor dynasore as well as dominant negative mutants. However, there are other 
viruses that enter via macropinocytosis where dynamin is also not required, for 
instance Vaccinia virus [414] and RSV [195]. In fact in some studies of the same 
virus, there is contradictory evidence for the role dynamin plays in entry [415-417]. 
Another interesting observation was the differing sensitivity of MeV entry to EIPA in 
A549-SLAM and LCL cells. This may indicate a degree of cell-type specificity within 
macropinocytosis and highlights MeV as a useful tool for future characterisation of 
this phenotype. It is also worth highlighting that the MeV cellular receptor I have 
investigated, SLAM (specifically SLAMF1), has recently been characterised as a 
microbial sensor that regulates phagocytosis in macrophages [210]. During this 
process it is thought that the cytoplasmic tail of SLAM interacts with Beclin-1, 
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recruiting a class III PI-3 kinase (PI3KC3) that generates phosphatidylinositol-3-
phosphate (PI3P): a powerful signalling molecule involved in membrane 
rearrangement, cell motility and protein sorting [418]. This fits with the uptake of a 
range of pathogens (bacteria and viruses) that occur in a receptor-dependent manner 
[419-421]. To my knowledge the role of the cytoplasmic tail of SLAM in MeV entry 
has not yet been thoroughly investigated and it will be interesting to correlate how 
closely the atypical macropinocytosis of MeV particles correlates with SLAM-
mediated bacterial phagocytosis.  
Until recently, paramyxovirus genome entry into the cell was assumed to occur 
immediately after direct fusion of the virus particle envelope with the plasma 
membrane [380, 394]. The major argument for this theory is that triggering of the 
paramyxovirus fusion protein is pH-independent; a process that leads to extensive 
syncytia formation during in vitro passage of these viruses. In this model the particle 
remains at the cell surface without internalisation; however, in recent years several 
studies on paramyxovirus entry, i.e. RSV, NDV, Sendai virus and Nipah, have shown 
that these virions are actually endocytosed [195, 325, 394]. Our data now 
demonstrates that MeV particles are also internalised; however, it should be noted 
that the two processes are not necessarily mutually exclusive. It is possible that 
activation of the F protein is still initiated at the plasma membrane, but that this 
process is synchronous with particle endocytosis, unlike RSV where proteolytic 
activation of the F protein must take place in the macropinosome before the 
ribonucleocapsid can escape [195]. The changing environment of the maturing 
macropinosome could therefore play a role in pore expansion, rather than F 
activation allowing RNP escape into the cytoplasm. In this sense it was interesting to 
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observe that nucleocapsid co-localisation with fluorescent dextran was lost within 60 
min of MeV-particle uptake. These discussions also highlight the difficulty in 
experimentally distinguishing a whole virus particle from a single oligomeric complex 
of F and H. MeV particles are large (up to 1 µm) and their size, shape and density of 
glycoprotein packaging may be a key additional factors in the stimulation of endocytic 
uptake. 
In summary I have described a novel entry pathway for MeV that has major hallmarks 
of macropinocytosis. This adds MeV to the growing list of pathogens that are taken 
up by this pathway. Given their ubiquitous use of SLAM/CD150 as an entry receptor 
[16] these findings are also likely to apply to the other morbilliviruses, e.g. canine 
distemper and peste des petits ruminants viruses. This research therefore expands 
the potential for antiviral targeting of these viruses through the identification of novel 
pathways and host factors involved in infection.  
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5. Chapter 5 – Early stages of measles virus-induced cell-cell 
fusion are controlled by the cytoskeleton, Rho GTPases and 
moesin 
 
Chapter 5 
EARLY STAGES OF MEASLES 
VIRUS-INDUCED CELL-CELL 
FUSION  ARE CONTROLLED BY 
RHO GTPASES AND MOESIN 
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Viruses have evolved a variety of ways to disseminate within the host.  Viral spread 
centres on how virions, or infected cells, interact with uninfected, susceptible cells. 
Enveloped negative-stranded RNA viruses assemble into viral particles carrying one 
or more copies of the viral genome enclosed by a lipid envelope embedded with 
membrane proteins. These envelope proteins regulate particle entry via interaction 
with a variety of cellular plasma membrane proteins or ligands, known as cellular 
receptors. These glycoprotein-receptor interactions are key to establishing infection, 
since viruses have evolved several mechanisms to induce their uptake and 
internalisation by the host.  
In the previous chapter, I demonstrated that MeV particles can be endocytosed by 
SLAMF1+ cells using a mechanism that resembles macropinocytosis, the 
internalisation of the IL-2 receptor and the mechanotransduction pathway. Alongside 
cell-free particle infection MeV can infect neighbouring cells by inducing cell-cell 
fusion that leads to the formation of multinucleated giant cells (known as syncytia); 
cells which are commonly observed both in vitro [95] and in vivo [295, 422]. This cell-
associated transmission is an efficient and rapid mechanism to aid viral 
dissemination [423] and evade the adaptive humoral immune response [380]. Cell-
cell fusion and syncytia formation may contribute to the exacerbation of pathogenesis 
in vivo. The eventual breakdown, detachment or death of these fused cells 
contributes to tissue damage and the severe pathological and inflammatory effects of 
viral infection [146, 424]. In addition persistent MeV infection in the brain and the 
expression of defective measles proteins leads to extensive cell-cell fusion and 
formation of plaques [46, 54, 425].  
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In tissue culture, the expression of MeV glycoproteins in permissive cell lines is 
sufficient to induce cell-cell fusion and formation of large syncytia. Indeed, this is a 
common feature among paramyxoviruses, which encode fusion proteins that promote 
the fusion of the plasma membranes of two cells. The fusion of membranes is a 
common process in the cell cycle, albeit occurring at a smaller scale, such as in the 
fusion of endosomes to lysosomes, or alternatively on a larger scale, with the fusion 
of myoblast in skeletal muscles, for example. Thermodynamically, the process of 
membrane fusion is associated with a high energy barrier and cells have evolved 
several families of proteins that reduce this energy barrier and assist membrane 
fusion [390, 426]. One such family are the SNARE proteins that promote the fusion of 
intracellular vesicles, such as endosomes, to other organelles like the Golgi 
apparatus or the plasma membrane [427]. The cellular interactions and molecular 
mechanisms underpinning physiological cell-cell fusion, e.g. the fusion of myoblasts, 
the generation of osteoclasts or trophoblasts, are not well understood [428]. Very few 
human cell proteins with fusogenic properties have been identified: the most striking 
example is employed during the formation of the placental syncytiotrophoblast. The 
formation of this layer of fused trophoblasts is dependent on the activity of 
endogenous retroviral fusion proteins called syncytin-1 and -2 [429-431].  
As cell-cell fusion induced by MeV is likely to encounter a significant energy barrier at 
the point of membrane fusion, it is possible that MeV is hijacking previously 
unidentified membrane fusion cascades to overcome this energy barrier and promote 
viral spread by syncytia formation. An interesting observation that might be indicative 
of such manipulation is that viruses with defective cytoplasmic tails of H and F have 
enhanced cell-cell fusion activity [432]. The cytoplasmic tails of glycoproteins from 
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other paramyxoviruses have been implicated in the regulation of cell-cell fusion [433-
436]. While paramyxovirus cell-cell fusion appears to be controlled, at some level, by 
the actin network [437], the involvement of the cytoskeleton in the establishment and 
expansion of the fusion pore has not been studied. Although MeV encoded N, M and 
L proteins are known to interact with the cytoskeleton [131, 132, 349], such 
interactions are not known for the two proteins that induce cell-cell fusion, MeV F and 
H. Understanding the early stages of MeV cell-cell fusion may impact on the design 
of new therapeutics and enhance our capacity to control disease progression in 
infected individuals. I will use my quantitative MeV F and H dependent cell-cell fusion 
assay to assess the role of several components of the cytoskeleton during stages of 
syncytia formation.  
 
5.1 MeV-induced cell-cell fusion does not induce membrane blebbing 
Previously I demonstrated that attachment of MeV to SLAMF1+ cells leads to 
extensive rearrangement of the plasma membrane, and the formation of membrane 
blebs. I speculated that this phenotype is dependent on the interaction of H with its 
receptor SLAMF1 via the myosin-II-RhoA-ROCKI axis, which is also involved in 
mechanotransduction processes. To evaluate if MeV-induced cell-cell fusion induce 
similar rearrangements of the plasma membrane, I infected A549-SLAM cells with 
recombinant MeV (MOI~1) expressing EGFP or, alternatively, mock-infected cells. 
After wide-spread virus-induced syncytia was observed, these monolayers were co-
cultured with non-infected A549-SLAM cells (in suspension) for 30 min at 4ºC, 
washed in PBS and incubated for 30 or 60 min at 37ºC, prior to fixation and 
preparation for SEM (Fig.5-1). Monolayers of non-infected cells presented some 
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filopodia-like structures at the plasma membrane, as observed previously, but overall 
demonstrated a smooth cell surface (Fig.5-1A, non-infected, inset). In contrast, the 
surface of infected cells contained several additional structures, including small buds 
(Fig.5-1A, infected, blue arrows), possibly nascent MeV egressing from the cell. 
However, co-culture of uninfected A549-SLAM with MeV-infected cells did not induce 
observable membrane rearrangements in these cells after either 30 or 60 min of 
incubation (Fig.5-1B), contrasting with my previous findings with cell-free MeV entry 
into SLAMF1+ cells.  
 
5.2 MeV-induced cell-cell fusion is restricted by the actin network 
Since MeV-induced cell-cell fusion did not generate similar macropinocytosis-like 
plasma membrane structures in uninfected A549-SLAM cells, I investigated other 
cellular mechanisms that might potentially control cell-cell fusion. This was performed 
using the quantitative cell-fusion assay, described in chapter 3, section 3.1. In brief, 
plasmids encoding the MeV F and H proteins were transfected into HEK293T 
‘effector’ cells expressing half of a dual-split reporter (an inactive form of Renilla 
reniformis luciferase and EGFP). A separate population of ‘target’ cells was 
generated expressing the MeV receptor SLAMF1 and the complementary part of the 
RLuc and EGFP reporter protein. Forty-eight hours post-transfection, target and 
effector cells were co-cultured. When the fusion processes started, the cytosolic 
content of these cells mixed, allowing the complementary parts of RLuc and EGFP to 
assemble and become functional (Fig.5-2A). Luciferase activity was then measured 
at several times following this initial point of co-culturing to monitor cell-cell fusion.   
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Fig.5-1. MeV-induced cell-cell fusion does not induce membrane blebbing. 
(A/B) A549-SLAM were infected with MeV (MOI~1) and incubated at 37°C for 48h, 
when large syncytia were observed (A). A549-SLAM cells were then co-cultured with 
infected or non-infected monolayers at 4°C for 30min, washed and further incubated 
at 37°C for 30 or 60min. Cells were then fixed and prepared for scanning electron 
microscopy (B) (n=1 with 1 technical replicate).  
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Fig.5-2. MeV-induced cell-cell fusion is restricted by the actin network. (A) 
Schematic representation of the fusion assay. Target cells, expressing SLAMF1, and 
effectors cells, expressing MeV F and H, each carrying a complementary part of the 
dual-split reporter EGFP-Renilla luciferase, are co-cultured. (B) Effector cells carrying 
full-length MeV F and H or cytoplasmic tail mutants (MeV FΔ30 and HΔ24) were co-
cultured with SLAMF1-positive target cells. Luciferase activity was measured at the 
indicated times post co-culture (tpc) (n=2 with 4 technical replicates). As a control, 
effector cells were co-cultured with target cells lacking the expression of SLAMF1; 
luciferase activity was measured and subtracted to related SLAMF1-expressing co-
cultures at indicated timepoints. (C/D) Effector cells carrying full-length MeV F and H 
were co-cultured with target cells and incubated for 90 min. At this time, cytochalasin 
D (5µM, CytoD), jasplakinolide (1µM, Jasp), wiskostatin (25µM, Wisk), griseofulvin 
(25µM, Griseo), nocodazole (10µg/mL, Noco) or taxol (1µM) were added and 
incubated for further 30 min prior to measurement of luminescence (n=3 with 5 
technical replicates). All values were normalised to solvent (Solv, DMSO) treated 
cells which absolute RLUs were 9822±178 in C and 8662±449 in D, while negative 
control RLU was 838±102. Statistical analysis was performed using Student’s t test; 
*,p<0.05; **,p<0.01, ***p<0.001. 
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As mentioned previously, MeV glycoproteins with defective cytoplasmic tails have 
enhanced fusogenic activity [432], with some researchers suggesting a possible 
interaction of these tails with the cytoskeleton [433]. By quantifying fusion in the first 
six hours after co-culture (hpc), I was able to observe the overall kinetics of fusion 
including the initial steps of membrane pore formation and later stages of pore 
expansion (Fig.5-2B). Interestingly, I observed that when cells were transfected with 
wild-type (full-length) MeV F and H and co-cultured with target cells, cell-cell fusion 
peaked at 2hpc, followed by a slow decrease. However, when effector cells were 
transfected with plasmids expressing MeV F and H with 30 and 24 amino acid 
cytoplasmic tail truncations, respectively, cell-cell fusion increased steadily post co-
culture (Fig.5-2B).  
Since wild-type and truncated MeV F and H induced similar cell-cell fusion at 2hpc 
but developed differently afterwards, I hypothesised an equivalent level of pore 
formation (occurring prior to 2hpc), but varied expansion of the fusion pore, a feature 
dependent on the cytoplasmic tails of F and H. Building on my earlier hypothesis that 
the cytoskeleton restricts pore expansion co-cultured cells were treated with drugs 
that: promote actin filament depolymerisation (cytochalasin D [438]), polymerisation 
(jasplakinolide [439]), or target  actin branching (wiskostatin [440]) (Fig.5-2C). These 
experiments showed that abrogation of cytoskeleton dynamics increases cell-cell 
fusion induced by wild-type MeV GPs, when compared to solvent treated cells at 
2hpc. Using the same approach with drugs that target the microtubule network - 
nocodazole (which promotes the stabilisation of microtubules [441]), taxol (a 
microtubule destabiliser [442]) and griseofulvin (which disrupts centrosomes [443]) – 
I observed that all reduced cell-cell fusion (Fig.5-2D). This suggested that although 
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actin filaments may work as a restriction to pore expansion, microtubule dynamics 
may be important to initialise cell-cell contact and in formation of the membrane pore. 
These data support my previous observation that the cytoplasmic tail mutants of F 
and H show enhanced fusion activity, an effect that may be due to the expansion of 
the fusion pore and rapid mixing of cytosolic content. Due to time limitations, I was 
not able to evaluate the effect of such inhibitors in the context of cell-cell fusion 
induced by the mutants lacking the cytoplasmic tails. It is clear, however, that 
interfering with cytoskeletal dynamics impacts on cell-cell fusion, providing evidence 
that the actin network at the cell’s cortex restricts the expansion of nascent MeV-
induced fusion pores. 
5.3 Dynamin-2 contributes to MeV-induced cell-cell fusion 
The cell cortex is a highly dynamic region where components of the cytoskeleton 
concentrate to interact with membranous elements, such as membrane proteins and 
phospholipids. In particular, the cortical actin network has been implicated in a 
myriad of cellular process, such as motility, immune activation and endocytosis. As 
mentioned previously, dynamin-2 (dyn2) is a GTPase involved in the scission of 
endosomes from the plasma membrane and is regarded as an important factor in 
endocytosis. However, in recent years, dyn2 has been shown to interact with 
cortactin and actin filaments and also appears to be involved in cortical actin 
dynamics via interactions with Arp2/3 complex [444]. Following on from my 
observations that actin dynamics at the cell cortex are important during cell-cell 
fusion, I assessed the role of this protein in the initial stages of MeV-induced fusion. 
Using the cell-cell fusion assay, in combination with a pharmacological inhibitor of 
dyn2, dynasore [445], I observed that cell-cell fusion was significantly reduced at 
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2hpc following perturbation of dyn2 (Fig.5.3A). To further examine the role of dyn2, I 
co-transfected effector cells with plasmids expressing wild-type (WT) or dominant 
negative (DN) K44A dyn2. As a control, I compared cell-cell fusion in cells co-
transfected with a plasmid encoding only EGFP, since both WT and DN-dyn2 
constructs are EGFP-tagged. Expression was confirmed by visualisation under 
fluorescence microscopy where approximately 70% of the cells were GFP-positive. 
Interestingly, the co-expression of these plasmids in effector cells resulted in an 
increase in cell-cell fusion, particularly with the DN mutant (Fig.5-3B). I hypothesised 
that over-expression of dyn2 WT or DN may affect turnover of plasma membrane 
proteins, including MeV F and H, since this protein is also involved in several 
recycling processes, therefore impacting on the sequestration of MeV H into 
pathways targeted for degradation [446] . When the total amount of MeV H produced 
in the context of dyn2 co-expression was analysed, I observed elevated MeV H 
expression with dyn2 DN. This suggests that MeV H might have a high level of 
steady-state turnover mediated by dyn2 (Fig.5-3C). Since a dyn2 inhibitor decreased 
cell-cell fusion and overexpression of a DN mutant of dyn2 increased fusion (and 
MeV H expression), it is likely that dyn2 plays multiple roles in this process. As a 
result, further experiments are required to elucidate the specific role of this GTPase. 
Although this chapter focuses on is the early stages of cell-cell fusion, I also 
examined the effect of overexpression of the dyn2 DN mutant on both target and 
effector cells in the context of cell-cell fusion (Fig.5-3D). In this fusion assay, MeV-
based target or effector cells were co-transfected with dyn2 DN and co-cultured 
overnight. Interestingly, in this experiment effector cells transfected with dyn2 DN 
showed reduced cell-cell fusion, when compared to cells transfected with EGFP,  
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Fig.5-3. Dynamin-2 contributes to pore-formation. (A) Effector cells carrying full-
length MeV F and H were co-cultured with target cells and incubated for 90 min. At 
this time, co-cultures were incubated with Dynasore at indicated concentrations for a 
further 30 min prior to measurement of luminescence. RLUs were plotted in relation 
to solvent (DMSO) treated cells that had an absolute value of 9822±178. (B) Effector 
cells were co-transfected with plasmids encoding a wild-type (WT) or dominant 
negative (DN, K44A) mutant of dynamin-2 (Dyn2). Cells were then co-cultured with 
target cells, incubated for 2h at 37ºC prior to measurement of the luciferase activity. 
RLUs were plotted in relation to GFP expressing cells that had an absolute value of 
8722±578. Negative control values were subtracted to Dyn2 WT and DN co-cultures 
and plotted. (C) The effect of co-transfecting Dyn2 WT and DN mutants on the 
expression of MeV H was assessed by lysing effector cells and analysing MeV H by 
SDS-PAGE/western blot. (D) Effector cells or target cells co-transfected with a 
plasmid encoding Dyn2 mutant or pcDNA3.1 were co-cultured for 24 prior to 
assessment of luciferase activity (n=3 with 5 technical replicates). RLUs are plotted in 
relation to vector-transfected cells with absolute value of 48334±3666. Statistical 
analysis was performed using Student’s t test; **,p<0.01, hpc, hours post-co-culture. 
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while dyn2 appeared to have little effect on cell-cell fusion when transfected into 
target cells, suggesting a specific  role of this protein in effector cells and not a 
general consequence of overexpression of these mutants in HEK293T. Altogether, 
these data provide evidence for a role for dyn2 in cell-cell fusion and MeV 
glycoprotein stability.  
 
5.4 The activity of Rho GTPases modulate cell-cell fusion 
The family of Rho GTPase proteins contains multiple members that mediate 
cytoskeleton organisation, impacting on cell motility, cell cycle progression and the 
vesicular trafficking system [447]. In particular, Rho GTPases tightly regulate the 
organisation of the cell cortex by orchestrating cytoskeletal rearrangement and the 
formation of specific micro-domains at the plasma membrane [448]. This family of 
proteins has also been implicated as being important in cell-cell fusion induced by 
other paramyxoviruses [449]. To assess the role of these proteins in the initial stages 
of MeV-mediated cell-cell fusion, effector cells were co-transfected with DN mutants 
of Rho GTPases, co-cultured with SLAMF1-expressing target cells and cell-cell 
fusion was assessed using a fusion assay (Fig.5-4A). The expression of DN mutants 
of RhoA, Rac1 and Cdc42 in MeV-effector cells dramatically increased cell-cell fusion 
in the two hours following co-culture, even though the total expression of MeV H 
remained relatively unaltered (Fig.5-4B). To further assess the role of these proteins 
in cell-cell fusion, we treated co-cultured cells with pharmacological inhibitors of 
Cdc42 (ML141) and the RhoA-associated kinase I (ROCKI), a downstream effector of 
RhoA (H1152) (Fig.5-4C). Interestingly, both inhibitors induced an increase in cell-
cell fusion, particularly ML141 which targets Cdc42. As previously, I also evaluated  
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Fig.5-4. Rho GTPases are important in cell-cell fusion. (A) Effector cells were co-
transfected with plasmids encoding dominant negative (DN) mutants of RhoA (N19), 
Rac1 (N17) and Cdc42 (N17). Cells were then co-cultured with target cells, incubated 
for 2h at 37ºC prior to the measurement of luciferase activity. RLUs were plotted in 
relation to GFP transfected cells which had an absolute value of 13124±836 (n=4 
with 5 technical replicates). (B) The effect of co-transfecting these mutants on the 
expression of MeV H was assessed by lysing effector cells and analysing MeV H by 
SDS-PAGE/western blot. (C) Effector cells carrying full-length MeV F and H were co-
cultured with target cells and incubated for 90 min. At this time, co-cultures were 
incubated with the ROCKI inhibitor H1152 or the Cdc42 inhibitor ML141 at the 
indicated concentration for a further 30 min prior to measurement of luminescence. 
RLUs were normalised to solvent (Solv, DMSO) treated cells that had an absolute 
value of 12282±422. (D) Effector cells or target cells co-transfected with plasmids 
encoding mutant Rho GTPases or pcDNA3.1 (vector) were co-cultured for 24 prior to 
assessment of luciferase activity. Statistical analysis was performed using Student’s t 
test; **,p<0.01, ***,p<0.001, ****,p<0.0001 hpc, hours post-co-culture. 
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the effect of the DN Rho GTPase mutants (expressed in either target or effector cells) 
when cell-cell fusion was allowed to proceed for 24h post co-culture (Fig.5-4D). 
Although the DN mutants had little effect on fusion when expressed in target cells, 
these mutants significantly reduced cell-cell fusion when co-transfected with MeV 
glycoproteins, as observed elsewhere in similar assays with glycoproteins of Hendra 
and SV5 virus [449]. Altogether, these results suggest that inhibiting the activity of 
Rho GTPases impacts on the initial steps of cell-cell fusion.  
5.5 Moesin regulates MeV-induced cell-cell fusion 
Of particular importance to the organisation of microdomains within the plasma 
membrane is a family of proteins, known as the Ezrin/Radixin/Moesin (ERM(s)) 
family. ERMs function as cross-linkers between the plasma membrane and the actin 
cytoskeleton [450]. It has been observed previously that phosphorylated (activated) 
ERMs are components of the virological synapse between T lymphocytes and 
dendritic cells during MeV infection [266]. In a similar way, I hypothesised that ERMs 
might play role in the contextualization of the MeV fusion apparatus, i.e. in relation to 
the cytoskeleton and plasma membrane. I therefore examined the role of ezrin and 
moesin in the initial stages of cell-cell fusion. Initially, I observed that over-expression 
of MeV F and H in HeLa cells is sufficient to induce an increase in phosphorylated 
ERMs, particularly the lower molecular weight band that corresponds to the MSN 
protein (Fig.5-5A). In addition, phosphorylated ERMs also co-localised with MeV 
glycoproteins, when observed under confocal laser scanning microscopy (Fig.5-5B). 
A similar observation was made by Koethe et al. during MeV infection of immune 
cells. These data suggest that MeV glycoproteins can trigger the activation of ERMs 
and provide evidence for a role for these proteins in the MeV lifecycle. To further  
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Fig.5-5. Expression of MeV GPs promotes ERMs phosphorylation. (A) HEK293T 
cells were transfected with plasmids encoding wild-type MeV F and H or with 
pcDNA3.1 (vector). After 48h, cells were lysed and protein samples resolved in a 
SDS-PAGE gel; MeV H, ERMs or phosphorylated ERMs (P-ERMs) were 
subsequently analysed by western blot. (B) HeLa cells were transfected with HA-
tagged MeV H and wild-type MeV F and incubated for 48h at 37ºC. Cells were then 
fixed, blocked in 1% BSA and incubated with antibodies specific for HA (Red) or 
phosphorylated ERMs (Green). Cells were then prepared for CLSM and observed by 
fluorescence microscopy. Scale bar is representative of 15µm. 
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evaluate the involvement of ERMs in cell-cell fusion, constitutively active (CA) ezrin 
and moesin mutants were transfected into effector cells and their impact on MeV-
induced cell-cell fusion was assessed as described previously (Fig.5-6A). Whilst the 
ezrin CA mutant had little effect on fusion, the moesin CA mutant significantly 
increased cell-cell fusion at 2hpc (Fig.5-6A). These constructs also impacted on the 
size of syncytia formed when co-transfected into Vero-SLAM cells with plasmids 
encoding the MeV glycoproteins (Fig.5-6B). These constructs did not, however, alter 
expression levels of MeV H (Fig.5-6C), suggesting the effect of MSN CA might 
perhaps be related to spatial organisation of MeV GPs at the plasma  
membrane. In reciprocal studies, I employed specific shRNA constructs to target EZR 
and MSN and knock-down endogenous expression of these proteins (Fig.5-6E). 
When these shRNAs were used to knock down EZR and MSN in effector cells, in the 
context of the fusion assay, MeV-induced cell-cell fusion was significantly increased 
in both cases (Fig.5-6D).  Accordingly, MeV H expression in these effector cells was 
enhanced (Fig.5-6F). Since knockdown of ERMs has been implicated in the 
sequestration of plasma membrane proteins, such as the transferrin receptor [451], it 
is likely that ERMs, particularly moesin, are involved in controlling both turnover and 
organisation of MeV glycoproteins, ultimately impacting on the initial stages of cell-
cell fusion. 
 
5.6 MeV budding may be regulated by Rac1, ezrin and moesin 
Canonical MeV exit is widely regarded to be through viral particle formation and 
budding from the cell, whilst cell-cell fusion has historically been considered an 
artefact of (1) receptor abundance on permissive cell lines used in vitro and (2) a  
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Fig.5-6. Moesin affects early stages of MeV-induced cell-cell fusion. (A) Effector 
cells were co-transfected with plasmids encoding constitutively active (CA) mutants 
of ezrin (EZR) or moesin (MSN). Cells were then co-cultured with target cells, 
incubated for 2h at 37ºC prior to the measurement of luciferase activity. (B) Vero-
hSLAM cells were co-transfected with MeV F and H and EGFP, EZR CA-GFP or 
MSN CA-GFP. Cells were incubated for 48h at 37ºC, and prepared and observed by 
CLSM. The scale bar is representative of 20µm. (C) The effect of co-transfecting 
these mutants on the expression of MeV H was assessed by lysing effector cells at 
48h post-transfection and analysing MeV H by SDS-PAGE/western blot. (D) Effector 
cells carrying full-length MeV F and H were transfected with shRNA constructs that 
target EZR and MSN mRNAs for degradation, incubated for 72h and co-cultured with 
target cells. Co-cultures were incubated for 2h prior to assessing luciferase activity. 
(E) Efficiency of EZR and MSN knock-down was confirmed by SDS-PAGE/western 
blot of lysed transfected cells. The white arrow indicates the predicted EZR and 
radixin (RDX) molecular weight, while the black arrow indicates MSN. (F) The effect 
of co-transfecting these shRNAs on the expression of MeV H was assessed by lysing 
effector cells at 72h post-transfection and analysing MeV H by SDS-PAGE/western 
blot. Statistical analysis was performed using Student’s t test. *,p<0.05, **,p<0.01. 
hpc, hours post-co-culture. 
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result of the frequency of in vitro cell-cell contacts in a 2D monolayer of cells. In 
recent years, however, mounting evidence for MeV-induced syncytia in vivo [36, 295, 
422] together with the elucidation of molecular mechanisms associated with cell-to-
cell spread [423] has highlighted cell-cell fusion as a viable and important route in 
MeV transmission. Previously, I have demonstrated that certain cytoskeletal 
components impact upon cell-cell fusion induced by the viral glycoproteins, 
suggesting a complex mechanism underpinning this exit route. In particular the Rho 
GTPases and ERMs appear to be involved in the very early stages of MeV-induced 
cell-cell fusion. The immediate question that this raises is how the process of cell-cell 
fusion is distinguishable from MeV budding and how the virus balances the two 
processes. However, due to time-limitations, I was unable to thoroughly address this 
question. Nevertheless, using the budding assay developed in our laboratory and 
described in the chapter 3, section 5, I gathered some preliminary data on the 
impact of Rho GTPases and ERMs in MeV budding, mediated by the viral matrix (M) 
protein. Briefly, a plasmid expressing a fusion protein containing the MeV M protein 
and the firefly luciferase connected by a glycine-rich, flexible linker (M-Fluc) was 
transfected into HEK293T cells along with plasmids encoding DN mutants of Rho 
GTPases (Fig.5-7A), CA mutants of ezrin and moesin (Fig.5-7B) or ezrin- or moesin-
specific shRNAs (Fig.5C). After 48h, supernatants were collected and M-Fluc-
containing VLPs were pelleted by centrifugation through a 20% sucrose cushion. 
Respective pelleted lysates (SUP) and whole cell lysates (WCL) were generated from 
each transfection and the luciferase activity measured. Luciferase activity readings 
were then normalised to cells co-transfected with EGFP. The ratio between SUP 
values and WCL – that should reflect the amount of released VLPs in relation to total  
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Fig.5-7. MeV budding may be regulated by Rac1, ezrin and moesin. (A/B/C) 
HEK293T cells were co-transfected with a fusion construct described in chapter 3 
section 3.5 (M-Fluc) and plasmids encoding DN mutants of Rho GTPases (A), CA 
mutants of ezrin (EZR) and moesin (MSN) (B) or plasmids encoding shRNAs 
targeting EZR and MSN (C). Cells were then incubated for 48h at 37ºC, supernatants 
were collected, clarified by centrifugation and virus-like particles (VLPs) containing 
the fusion protein M-Fluc were pelleted through a 20% sucrose cushion in HBSS. 
Pellets were lysed and luciferase activity was measured. Statistical analysis was 
performed using Student’s t test. *,p<0.05, ***, p<0.001, n.s., non-significant.  
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M-Fluc present in the cell – was significantly higher for co-expression of RhoA and 
Cdc42 DN mutants (Fig.5-7A). Interestingly, co-transfection with the Rac1 DN led to 
a substantial decrease in released VLPs and an increase in cell-associated or 
“retained” M-Fluc. This suggests that the activity of Rac1 might be important in MeV 
budding and directly contrasts with the observed increase in cell-cell fusion seen 
previously (Fig.5-4A). Moreover, when co-transfecting the M-Fluc construct with 
plasmids expressing ERMs CA mutants, expression of MSN CA led to an increase in 
released VLPs; however, no significant effect was observed after co-expression with 
EZR CA (Fig.5-7B). This observation is similar to the effect seen with MSN CA in the 
early stages of MeV-induced cell-cell fusion (Fig.5-6A). Finally, I assessed the 
specific role of endogenous ERMs by targeting ezrin and moesin with specific 
shRNA-encoding plasmids. The amount of released VLPs was substantially higher 
when ezrin in particular was knocked down (Fig.5-7C). MSN shRNA also increased 
the amount of released particles. To some degree these results mirror what was 
observed during MeV-induced cell-cell fusion (Fig.5-5D). Collectively these data 
suggest that although the activity of ezrin and moesin may play a role in MeV 
budding, the activity of Rac1 appears to be important in the release of MeV M-
derived VLPs. Further experiments are required to confirm this dependence.  
 
5.7 Discussion 
Infection by MeV induces cell-cell fusion in various tissues, including lymph nodes, 
airway epithelia and the brain. This process relies on the interaction of MeV fusion 
machinery with cellular receptors, such as SLAMF1 and nectin-4. Since the activity of 
MeV F protein is independent of low pH, in contrast with other enveloped viruses 
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[452], it is commonly believed that fusion of the viral envelope with the plasma 
membrane at the moment of entry shares a common mechanism with the initial 
stages of cell-cell fusion. Nevertheless, the context in which these two events occur 
may differ.  
My initial observation that the deletion of the cytoplasmic tails of F and H increases 
the kinetics of MeV-induced cell-cell fusion is evidence that MeV GPs-cytoskeleton 
interactions might restrict the progressive development of the fusion pore. It is 
unlikely that these differences in cell-cell fusion are due to altered protein expression 
since it has previously been shown that removing the cytoplasmic tail of morbillivirus 
F and H does not alter cell surface expression [453]. Previously it has been shown 
that MeV isolates recovered from patients suffering from SSPE, characterised by the 
formation of plaques of syncytiated cells in the brain, present mutations in their matrix 
protein and glycoprotein cytoplasmic tails, which impact on cell-cell fusion [425, 432]. 
It has been suggested that the increased fusogenicity of these viruses may be due to 
defective viral budding and the accumulation of viral glycoproteins at the plasma 
membrane, however, it is also possible that these mutations alter specific interactions 
with the cytoskeleton, therefore impacting on cell-cell fusion. Related viruses, such 
as PIV5 and RSV, have been shown to be sensitive to perturbation of cytoskeleton 
dynamics [437, 454]. My results show that abrogating actin dynamics with 
cytochalasin D and jasplakinolide very early in the fusion process, increases cell-cell 
fusion. This is in contrast with similar studies that looked at the effect of these drugs 
on long-term treatment and at later stages in cell-cell fusion [348]. Similarly, a 
restrictive role for the actin cytoskeleton in pore expansion was observed using 
exogenous fusogens, such as the baculovirus protein gp64 [455].  
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During physiological cell-cell fusion, such as the multinucleation of osteoclasts, an 
actin-enriched zipper-like structure is formed that regulates cell-cell fusion [456, 457]. 
Interestingly, this structure, and subsequent fusion of the two cells, has been shown 
to be sensitive to dynasore, a drug that targets dynamin GTPase [458]. My 
experiments show that short treatment with dynasore, during the initial stages of 
MeV-induced cell-cell fusion, reduced fusion suggesting a role for dyn2 in this 
process. In contrast, co-transfection of a DN dyn2 mutant into effector cells, 
increased cell fusion as well as the overall expression of MeV glycoproteins. Since 
this mutant has been show to impact on the sequestration and recycling of 
membrane receptors [459, 460], I hypothesised this increase in fusion might be due 
to the accumulation of viral glycoproteins, as a resulted of impaired turnover. Future 
experiments may examine the turnover or degradation of MeV F and H during a 
normal infection and its subsequent role in budding and fusion. 
A role for Rho GTPases has been implicated in the cell-cell fusion induced by several 
viruses [449, 461, 462]. These studies support the theory that Rho GTPase activity 
promotes cell-cell fusion in the later stages of infection. Interestingly, the data 
presented here shows that the activity of Rho GTPases, particularly Cdc42, is 
deleterious to pore formation and expansion in the first moments of cell-cell fusion. It 
is plausible that interfering with Rho GTPase activity might result in the cortical actin 
network becoming less organised, alleviating the inherent restrictions to cell-cell 
fusion that this structure offers. Accordingly, a study has previously shown that 
inhibiting ROCKI in cancer cell lines increases MeV-induced syncytia [463]. One 
applicable theory is that Rho GTPases may impact on the activation and localisation 
of ERMs [464]. My results showed that shRNA knockdown of ezrin and moesin 
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dramatically increases cell-cell fusion. The knockdown of ezrin, in particular, has 
been shown to enhance cell-cell fusion induced by other viruses, such as HIV [465]. 
Since ezrin knock-down reduces the tension of the cell membrane [466], I 
hypothesise that targeting the ERMs might cause the cell membrane to become 
untethered from the cytoskeleton, perhaps promoting rapid pore expansion. 
Interestingly, moesin was initially thought to be a cellular receptor for MeV [259, 261]; 
however, over-expression of this molecule in non-permissive cells did not sustain 
MeV infection [262, 263]. Beside its ability to cross-link actin filaments to the plasma 
membrane, moesin has also been shown to interact with microtubules at the cell 
cortex and stabilise them to maintain cell shape [467]. In my results, disrupting 
microtubule dynamics reduced cell-cell fusion, however after overexpressing moesin, 
I observed an increase in cell-cell fusion. Although at first instance these data might 
appear contradictory, moesin is also known to antagonise the RhoA pathway [468]. 
Therefore, it is possible that the increase in cell-cell fusion induced by the 
overexpression of moesin might be due to diminished RhoA/ROCKI activity. Finally, I 
observed co-localisation of phosphorylated ERMs with MeV glycoproteins, a finding 
previously reported by another research group [266]. ERMs play a role during the 
budding process of some viruses and can sometimes be incorporated into virions 
[469-471]. They also function as organisers of the cell cortex [450]. Electron 
microscopy studies of MeV particles showed heavily decorated virions with H and F 
in organised arrays of proteins [292, 387, 389]. It is possible that ERMs might be 
organising and concentrating viral components, as suggested previously [266], 
promoting the formation of viral particles. Consequently, such organisation of MeV F 
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and H complexes may also impact, ultimately, on the activity of F and H and cell-cell 
fusion. 
In conclusion, I have analysed the very early stages of MeV-induced cell-cell fusion 
and its dependence on the host cytoskeleton, in particular actin filaments, 
microtubules, dyn2, RhoGTPases and moesin. My results confirm that cell-cell fusion 
is likely to be a very complex process coordinated by several proteins with varying 
levels of interaction with the cellular cytoskeleton and plasma membrane. Future 
targeted research on how the MeV F and H glycoproteins specifically interact with the 
cellular cytoskeleton might help to elucidate this phenomenon.  
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Viruses have evolved a myriad of ways to establish infection and generate progeny in 
the host cell. For instance, viruses are known to hijack several molecular 
mechanisms normally related to homeostatic processes of the cell cycle. Enveloped 
viruses hijack exocytosis pathways to accumulate viral components at the cell 
surface and to assemble new viral particles and egress. MeV relies on the 
expression of three viral proteins, F, H and M, to exit the cell via cell-cell fusion 
and/or viral budding. In the previous chapter of this thesis, I have demonstrated that 
several components of the cellular cytoskeleton are required for viral exit. However, 
the true complexity of host cell manipulation by MeV is far from being completely 
understood, since it is likely such process requires the interaction of multiple viral 
components and numerous host proteins. 
Several envelope viruses are known to hijack the ESCRT pathway to facilitate 
particle egress [472-474]; a group of proteins involved in exocytosis of vesicles. 
However, MeV budding has been shown previously to be independent of this 
pathway [346]. What is known is that MeV M protein interacts with both the viral RNP 
complex and Rab11-containing endosomes to facilitate transport to the plasma 
membrane [344]. In addition, MeV glycoproteins assemble in the ER and traffic 
through the Golgi apparatus, wherein certain asparagine residues are N-glycosylated 
[475]. These glycosylated residues are known to impact on surface expression of 
viral glycoproteins and to stabilise the structure of MeV H [183, 196, 476], implicating 
a key role for post-translation modifications in the correct assembly and transport of 
envelope proteins to budding sites. Despite several efforts to elucidate this process, 
the finite budding mechanisms of morbilliviruses remain largely uncharacterised.  
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Next generation proteomics have helped to elucidate global changes in the cellular 
proteome during viral infection [477-479]. Allied to cellular fractionation, quantitative 
proteomics has been shown to be an effective systems-based approach to study how 
cellular components are manipulated by viruses. Advances in the field have allowed 
the simultaneous analysis of multiple samples using differently labelled proteins. One 
recent technology, known as stable isotope labelling of amino acids in cell culture 
(SILAC), takes advantage of isotopically labelled amino acids to distinguish peptide 
populations and therefore abundance of proteins within certain regions of the cell, i.e. 
under differing conditions [480]. This technology can also be used in vivo through 
labelling of multicellular organisms [481]. Briefly, the principle of SILAC relies on the 
differential incorporation of stable-isotope labelled amino acids through repeated 
culturing of cell lines in media containing these amino acids. Specifically, 
combinations of 13C, 15N and deuterium (D) of arginine and lysine residues are used 
as substrates to produce proteins with altered molecular weights. After protein 
extraction, labelled proteins are digested with trypsin, which cleaves at arginine and 
lysine residues, ensuring that each digested peptide will have at least one of these 
two labelled amino acids. These modifications are translated as small shifts in the 
detected mass-to-charge ratios during mass spectrometry analysis, allowing the 
relative quantification of protein abundance, specifically in lysates containing an 
equimolar ratio of protein lysate from two or more samples. The result is high-
resolution characterisation of the proteome in certain organelles or whole cells. For 
virology researchers, this allows us to pinpoint the cellular pathways that may be 
hijacked by viruses. In this chapter, I summarise how I used SILAC to characterise 
the membrane proteome of MeV-infected LCLs with a focus on the identification of 
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cellular proteins involved in MeV budding. Initially I studied the growth kinetics of 
MeV in LCLs, in the context of a low MOI infection, to clarify the temporal nature of 
MeV infection and to identify when viral and cellular components concentrate to 
promote virus egress. Suitably SILAC-labelled LCLs were then infected and the 
membrane proteome extracted and analysed by quantitative mass spectrometry. 
Subsequently I used this SILAC data to identify post-translation modifications in 
several viral proteins and, focusing on the MeV H protein, I then evaluated their role 
in infection.  
 
6.1 MeV growth in LCLs and Vero-hSLAM cells 
During in vivo infection, lymphocytes are major targets for MeV, a tropism that greatly 
contributes to measles pathogenesis. Circulating human lymphocytes are naturally 
permissive to MeV due to expression of the cellular MeV receptor SLAMf1. When 
evaluating modifications in the cellular proteome induced by the virus, it was 
imperative that a physiologically relevant cell line be used, in order to capture 
changes of relevance to in vivo infections. I therefore employed human-derived 
LCLs, a cell line derived from circulating SLAMf1-positive human B lymphocytes. I 
initially investigated the kinetics of MeV replication in these cells and compared these 
to the well-established MeV-permissive cell line Vero-hSLAMs (see methods chapter 
2, section 2.2.4). Cells were synchronously infected with recombinant EGFP-
expressing MeV (MOI~0.01), washed and then incubated at 37°C. At the indicated 
time-points post infection, cells and supernatants were freeze-thawed and virus titres 
assessed by calculating individual TCID50s (Fig.6-1A). Graphical analysis of these 
growth  
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Fig.6-1. MeV growth in Vero-SLAM cells and LCLs. (A/B/C) LCLs or Vero-hSLAM 
cells were infected with MeV-EGFP (MOI~0.01), washed and incubated at 37ºC. 
Progression of infection in LCLs was followed by fluorescence microscopy (C). Foci 
of infection (red arrows) and multinucleated cells (white arrows) were observed. At 
each time point, cells and supernatants were freeze-thawed and virus titres were 
calculated (A) and MeV H expression in LCLs was confirmed by SDS-PAGE/western 
blot (B). 
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curves of infection, in Vero-hSLAM cells and LCLs, demonstrated a similar hyperbolic 
shape, with both infections producing similar viral titres at the later stages of 
infection. Infection in LCLs showed a prolonged eclipse phase of 48h (when 
compared to the 24h eclipse phase in Vero-hSLAM infection); however this was 
associated with higher viral titres – approximately 10-fold higher than in Vero-hSLAM 
cells at the same time-point. Although MeV titres in Vero-hSLAM cells plateaued at 
48h, infection in LCLs only reached comparable levels at 96 and 120h post-infection. 
These delayed replication kinetics were also reflected in the amount of viral protein 
produced, with detectable levels of MeV H protein only observed after 96 and 120h 
post-infection by SDS-PAGE/western blot (Fig.6-1B). MeV infection led to enhanced 
aggregation of LCLs, as reported previously [482], possibly due to modulation of the 
leukocyte function-associated antigen-1 (LFA-1). During the time-course of this 
infection, and as soon as 48h post-infection, these large aggregates of LCLs were 
shown to contain multiple infected cells (red arrows, Fig.6-1C). MeV infection also 
induced the formation of multinucleated cells within these aggregates; often 
presenting with distended plasma membranes (white arrows, Fig.6-1C). Together, 
these data demonstrate that MeV can efficiently replicate in human-derived LCLs, 
leading to the formation of large fused cells and the production of high viral titres.  
 
6.2 MeV replication is retarded in media containing 10 kDa-dialysed FBS 
For efficient labelling of cellular proteins with stable isotope-labelled amino acids, 
external sources of protein, e.g. those found in the FBS used in tissue culture, must 
be eliminated or reduced [483]. These exogenous proteins carry naturally occurring 
amino acids and can be used as substrates to produce proteins. Quantitative SILAC 
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relies on homogenous populations of differentially labelled cells; hence contamination 
with other isotopes can mislead interpretation of any correlative proteomic study. To 
avoid these issues, LCLs were grown in media containing 10 kDa molecular weight-
dialysed FBS and passaged for several weeks. MeV replication kinetics were then re-
examined in these adapted cells and compared to LCLs cultured in standard FBS, by 
synchronously infecting LCLs (MOI~0.01), as before, and examining progeny virus 
production (Fig.6-2A). LCLs grown in dialysed FBS-containing media generally 
produced lower titres of MeV virus, with a significant difference between conditions 
seen at 96h post-infection. This discrepancy was also reflected in viral protein 
expression, since MeV H could be detected by western blot as early as 48h, in cells 
cultured in normal FBS, but only by 96h in LCLs cultured in dialysed FBS (Fig.6-2B). 
In summary, these data show that although MeV replication was retarded in LCLs 
grown in dialysed FBS, the infections still generated comparable virus titres by 120h 
post-infection.   
 
6.3 Using SILAC to characterise the plasma membrane proteome of MeV-
infected cells  
Negative-stranded RNA viruses usually cause acute infections and rely on the rapid 
modulation of the host cell to replicate and assemble viral progeny. During the latter 
stages of the MeV life cycle viral components concentrate in the cytoplasm and are 
subsequently transported to the plasma membrane, where viral particles form and 
egress from the cell. Associated with this rapid takeover of the cell are the cytopathic 
effects commonly seen in tissue culture. These later stages of infection are 
associated with extensive cell death, as discussed in chapter 1, section 1.10. To 
capture the intact membrane protein profile of MeV- infected LCLs at the moment of 
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Fig.6-2. MeV growth is attenuated in media containing dialysed FBS. (A/B) LCLs 
cultured in media containing standard FBS or 10 kDa dialysed FBS were infected 
with MeV-EGFP (MOI~0.01), washed and incubated at 37ºC. At the indicated time-
points, cells were freeze-thawed, virus titres were calculated (A) and MeV H 
expression was observed using SDS-PAGE/western blotting (B). Statistical Student’s 
t test was performed between each time-point of differently grown cells, *,p<0.05 
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viral budding, and to avoid the consequences of extensive virus-induced apoptosis, I 
selected two time-points during MeV LCL-infections to analyse the cellular and viral 
proteome: 64 and 96h post-infection. Specifically, both time-points are located in the 
exponential phase of MeV growth, preceding production of peak virus titres in in vitro 
infections. 
To analyse the membrane proteome of infected cells, I applied the workflow 
represented in Fig.6-3A. Using three RPMI-40-based cell culture medias, 
supplemented with unlabelled arginine and lysine (R0K0, light), 13C-labelled arginine 
and 2D-labelled lysine (R6K4, medium) or 13C- and 15N-labelled arginine and 13C- and 
15N labelled lysine (R10K8, heavy) I labelled LCLs. Since cells can efficiently use 
labelled arginine as a substrate for proline production – thereby inferring with 
analysis of SILAC data - all cell culture medias were supplemented with non-
essential amino acids, including proline [484].  Of note, to ensure total incorporation 
of the labelled amino acids, LCLs were cultured in SILAC media for at least 8 
passages with efficient labelling being subsequently confirmed by mass spectrometry 
(data not shown). Cells cultured in light and heavy media were infected with MeV, 
while a mock-infection was performed in LCLs grown in the R6K4 medium (Fig6-3A). 
Importantly, late time-point infected cells were labelled with R0K0 medium, i.e. 
medium with naturally occurring amino acids, so post-translational modifications 
could be detected effectively. After 64h of incubation, the MeV-infected cells cultured 
in heavy medium were pelleted by centrifugation. Equivalent pelleting of the light- 
and medium-labelled cells was performed at 96h post-infection. At these time-points, 
total RNA and protein samples were collected. Membrane proteins were isolated as 
described in chapter 2, section 2.10.2, and resolved in a 10% SDS-PAGE gel which  
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Fig. 6-3. Diagram of experiment setup to determine the plasma membrane 
proteome of MeV-infected cells. (A) LCLs were cultured in three medias containing 
naturally occurring amino acids (L, light, R0K0), R6K4 (M, medium) or R10K8 (H, 
heavy) labelled arginines and lysines. LCLs grown in L and H media were infected 
with MeV-EGFP (MOI~0.01) while cells grown in M medium were mock-infected. At 
the indicated time-points, cells were collected and the membrane protein fraction was 
extracted. Protein samples from L, M, and H labelled cultures were analysed by SDS-
PAGE/Silver stain (B) and mixed at an equimolar ratio before mass spectrometry 
analysis.  
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was subsequently silver stained (Fig.6-3B). The protein concentration of these three 
lysates was determined using two independent protein quantification assays (BCA 
and Bradford methods, see chapter 2, section 2.8.1), before being mixed at an 
equimolar ratio to achieve a final mass of 45μg of protein. This sample was then 
analysed using mass spectrometry; performed by the Proteomics Facility at the 
University of Bristol. Briefly, the protein sample was resolved on an SDS-PAGE gel 
and the complete lane sliced into 10 fragments. Proteins were digested with trypsin 
and analysed on an Orbitrap Fusion Tribrid Mass Spectrometer equipped with 
electron transfer dissociation. Observed mass-to-charge ratios were compiled with 
Proteome Discoverer v1.4 Software (Thermo Scientific) and compared against an in 
silico database of human proteins as well as the 8 MeV proteins of the Ichinose 
strain. Further explanation of the methods employed can be found in chapter 2, 
section 2.10.3. 
 
6.4 Analysis of the membrane proteome in MeV-infected LCLs   
Proteomics approaches in virology often yield an extensive and complex dataset, 
where true viral targets or interaction partners are mixed with the dense background 
of the cellular proteome. In order to reduce the complexity of my dataset, I 
computationally filtered the data using a well-established protocol for SILAC, as 
described by Emmott and Goodfellow [367]. After comparison of mass spectrometry 
hits against an in silico protein database, the Proteome Discoverer software returns a 
list of proteins with specific SILAC ratios, i.e. quantifying the relative abundance of 
light/medium, light/heavy and medium/heavy proteins in the analysed sample. To 
determine significance within these relative peptide abundances, a threshold was 
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calculated based on the Gaussian distribution of the three SILAC ratios (Fig.6-4). 
Peptides with ratios above or below that threshold were considered up- or 
downregulated in the sample, respectively, with a 95% confidence interval. The 
distribution of detected proteins was then compared between samples, specifically 
64h vs Mock and 96h vs Mock (Fig.6-5A). Global distribution followed a typical 𝑦 = 𝑥 
correlation, as seen in similar proteomic studies [367]. Although most of the detected 
peptides clustered around the mean of the two ratios (following an, as expected, 
Gaussian distribution), two distinct populations of peptides were observed: (1) a 
population that is underrepresented after analysis of both the 64h vs Mock and 96h 
vs Mock data sets (Fig.6-5A, orange circle) and (2) a population of proteins 
upregulated in the same analysis (Fig.6-5A, blue ellipse). Peptide counts, which 
often correlate well with the abundance and overall confidence of identified proteins, 
also followed a similar distribution (Fig.6-5B) with equivalent up- and downregulated 
populations being identified (Fig.6-5B, blue and orange shapes). Interestingly, 
peptides with particularly high numbers of counts clustered in the centre of the 
distribution (i.e. are equally abundant in both samples) and also in a specifically 
upregulated population (Fig.6-5B, black arrow). When defined, this cluster of highly 
abundant and well resolved proteins, upregulated in both samples, comprised the 
viral proteins (most prominently MeV H and F) as well as a small number of cellular 
proteins. These data are evidence for a significant alteration in the cellular membrane 
proteome induced after MeV infection. Selecting only significantly under- or 
overrepresented peptides, I subsequently determined the general composition of 
cellular components in these subsets, using pathway analysis software such  
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Fig.6-4. Analysis of the SILAC dataset: thresholds. Detected peptides were mined 
against an in silico library of human and MeV proteins.  The abundance of a specific 
protein, which is related to the ratio of detected peptides in three differently labelled 
media, was calculated at 96h (A) or 64h (B) compared to mock, or 64h compared to 
96h (C), and the frequency of each ratio was plotted. (D) Using linear normalisation 
of frequency distribution to Gaussian distribution, standard deviation and mean was 
calculated to each ratio.  
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Fig. 6-5. – Analysis of the SILAC dataset: distribution of peptides (A) Ratios 
were normalised in relation to individual means and plotted. Ratio distribution was 
correlated to a y=x linear regression (black line). (B) Total counts were sorted into 
class (light grey is peptides with low count numbers, while black is peptides with a 
high count number), and plotted onto a graph comparing 96h and 64h ratios. Under- 
and overrepresented peptides are highlighted in orange and blue shapes, 
respectively. Black arrow indicates viral peptides population. 
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as STRING [485] and PANTHER [486] (Fig.6-6A). In both 64h vs Mock and 96h vs 
Mock comparisons, most proteins belonged to ‘organelles’ or ‘cell parts’, while 
isolated plasma membrane proteins represented approximately 10% of the 
population. Pathway analysis software such as STRING [485] and PANTHER [486] 
showed that upregulated proteins in the 96h vs Mock comparison contain 
components of extracellular vesicles and exomes with an associated false discovery 
rate (FDR) of 6.45×10-40 and 3.01×10-39, respectively (Fig.6-6B). Many of the 
downregulated proteins in both 64h vs Mock and 96h vs Mock comparisons were 
part of ribosomal or nuclear components. Additionally, when studying the enrichment 
of specific biological processes, cellular, metabolic and locomotion processes were 
largely downregulated in both samples (Fig.6-7B). In particular, RNA processing was 
greatly underrepresented in these samples, when compared to mock infected cells 
(Fig.6-7A). On the contrary, the proteins upregulated in the membrane proteome of 
infected cells were shown to be involved in metabolic and cellular processes (Fig.6-
7A and B). Together, these results suggest that within the membrane proteome MeV 
infection induces the modulation of the host’s translational machinery and 
upregulates exocytosis pathways and metabolic processes.  
 
6.5 MeV proteins contain numerous post-translational modifications   
Post-translation modification (PTMs) – a broad term to define modification to amino 
acids within a peptide or protein – can alter the function, localisation or abundance of 
a particular protein, both intra- and extracellularly [487]. The cell takes advantage of 
such PTMs to bypass information encoded in its genome and expand the overall 
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Fig.6-6. Analysis of the SILAC dataset: cellular components. (A/B) Upregulated 
or downregulated proteins at 96 and 64 hpi were analysed using the PANTHER 
Pathway Database. Enriched and depleted cellular components were plotted into pie 
charts (A) while specific components were arranged by lowest false discovery rate 
(FDR) (B).   
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Fig.6-7. Analysis of the SILAC dataset: cellular pathways. (A/B) Upregulated or 
downregulated proteins at 96 and 64 hpi were analysed using PANTHER Pathway 
Database. Enriched and depleted cellular pathways were plotted into pie charts (A) 
while specific pathways were arranged by lowest false discovery rate (FDR) (B).  
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phenotype of one particular protein. Several enveloped viruses take advantage of 
these PTMs to expand the functional repertoire of their encoded proteins. For 
instance MeV glycoproteins contain several sites for N-glycosylation of specific amino 
acids, which is important for the stability of the fusion complex and immune evasion 
by neutralising antibodies [181, 197, 311]. Additionally, MeV N and P proteins are 
phosphorylated at several key residues; PTMs that are important for genomic 
replication [488]. My analysis of the membrane proteome of MeV-infected LCLs also 
allowed me to map the virome (viral proteome) with great coverage and high 
confidence. In order to identify previously uncharacterised post-translation 
modifications in the MeV virome I reanalysed my mass spectrometry data set using 
another in silico mining approach, performed using the Proteome Discoverer 
software. In this search, mass/charge ratios of MeV peptides were compared to a 
library of in silico digested peptides of MeV proteins containing the following post-
translation modifications: N-glycosylation of asparagines; ubiquitination of lysines; 
phosphorylation of tyrosines, serines and threonines; methylation of lysines; 
SUMOylation of lysines and α-acetylation of amino acids. Using this approach I 
identified a total 32 PTMs in several of the viral proteins, an overview of which can be 
found in Fig.6-8. Six of the identified PTMs have already been described elsewhere, 
namely the phosphorylation of residues S479, S510 and T279 of MeV N protein [489, 
490] as well as the acetylation of its N-terminus [491]. In addition we identified 
phosphorylation of S86 and S151 in the MeV P protein [492]. In this experiment, 
however, no N-glycosylated asparagines were detected, as reported previously for 
the MeV F and H proteins [196, 384, 476]. Feasibly, this could be due to the 
protein/peptide fragmentation technique used in this experiment: collision-induced 
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Fig.6-8. Overview of MeV PTMs. A schematic representation of identified post-
translation modifications in MeV proteins. The individual position of each coloured pin 
approximately refers to the number of the amino acid residue. Legend for each 
modification: orange, phosphorylated tyrosine, serines or threonine residues; dark 
blue, ubiquitinated lysines; grey, methylated lysines; purple, α-acetylation of amino 
acids; cyan, N-glycosylation of asparagines; and pink, SUMOylation of lysine 
residues. * indicates post-translation modifications that were previously reported.  
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dissociation (CID), which occurs through successive collisions between peptides. 
During this process, sugar moieties, such as the ones linked to asparagines during 
N-linked PTM glycosylation might be lost due to their high molecular weight and 
sterical hindrance. Accordingly, the PTMs identified in our experiment are considered 
more stable than N-glycosylated residues [493]. Interestingly, although we could not 
detect the expected glycosylation of MeV F and H proteins we did detect several 
phosphorylations and methylations, distributed mainly in the ectodomain of both 
proteins. Since the topic of this thesis lies mainly on the interaction of MeV H with its 
cellular receptor SLAMF1, I subsequently investigated the role of these putative 
phosphorylation sites in the activity of H.  
Mapping the detected PTMs onto the crystal structure of H revealed these modified 
residues were distributed throughout the protein structure with no apparent pattern 
(Fig.6-9A). Exceptionally, a pocket of phosphorylated residues localised to the H 
dimer interface, three of which could be resolved in the structure (T221, T273, and 
Y275, Fig.6-9B), and another two (S240 and S241) which, feasibly, could be nearby 
matched to an unresolved part of the crystal (due to high instability). Building on the 
hypotheses that these PTMs are essential to the functionality of the MeV H protein 
we examined their conservation amongst other MeV H proteins and more broadly 
among other morbillivirus H proteins. Sequence analysis of several H proteins 
showed that certain residues are highly conserved (Fig.6-9C), in particular the 
threonine residues at positions 221 and 273 were absolutely conserved, while the 
tyrosine at position 275 was highly conserved, being variant in only one strain of 
PPRV which contains a histidine at this position (Fig.6-9C, red boxes). Of note,  
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Fig.6-9. Overview of MeV PTMs. (A) Phosphorylated (yellow) and methylated (red) 
residues identified in MeV H were mapped onto the crystal structure of MeV H bound 
to its receptor SLAMF1. Orange dotted boxes mark PTMs that map unresolved parts 
of the crystal. (B) Inset: a zoomed image of the dimer interface identifying the 
position of the relevant PTMs. (C) Alignment of MeV H protein sequences of several 
morbilliviruses. Yellow shading represents highly conserved amino acids.  
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histidine residues can function as substrates of histidine kinases that catalyse their 
phosphorylation [494]. Therefore, these data suggest a conserved patch of 
phosphorylated amino acids that localise to the H-H dimer interface of H monomers.  
 
6.6 MeV H residues T221, T273 and Y275 are important for dimerization and 
cell-cell fusion   
Since the residues T221, T273 and Y275 located at the dimer interface and were 
highly conserved across the morbillivirus genus, I hypothesised that they might be 
important for the formation of H-H dimers. To investigate this hypothesis, I initially 
examined the phosphorylation state of H using an in vitro dephosphorylation assay 
as described in chapter 2 section 2.8.5 (Fig.6-10). In this experiment, cells 
expressing HA-tagged MeV H were lysed in a mild detergent solution, homogenised 
using a syringe and the protein fraction extracted. This lysate was then incubated 
with 100 units of λ Protein Phosphatase (λPP). As a control, λPP activity was blocked 
using 25mM of sodium orthovanadate. Dephosphorylation of proteins should induce 
mobility shifts in SDS-PAGE/western blot, since the removal of phosphate groups 
(𝑃𝑂4
3−) alters the net charge of the protein and molecular weight. Accordingly, I 
observed a small shift in the migration of the MeV H when pre-incubated with λPP 
and analysed using a low density SDS-PAGE gel (Fig.6-10). This shift was not 
observed in the presence of sodium orthovanadate. As a positive control, to establish 
the dephosphorylation efficiency of the λPP, I used cofilin-specific antibodies that 
detect either total or phosphorylated forms of this protein. In this instance incubation 
with λPP reduced the amount of phosphorylated cofilin that  
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Fig.6-10. MeV H contains phosphorylated residues. HEK293T cells were 
transfected with a plasmid encoding MeV H with an N-terminal HA epitope tag. After 
48h, cells were lysed and the protein fraction was incubated with or without λ protein 
phosphatase (λPP) in the presence or absence of its inhibitor sodium orthovanadate 
at 37ºC for 30min. Proteins were then resolved onto a 15% or 7.5% SDS-PAGE gel 
and MeV H-HA, cofilin and phospho-cofilin were visualised by western blot.  
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Fig.6-11. Conserved phosphorylated residues may contribute to dimerization of 
H. (A/B) Several MeV H phospho-defective mutants were generated (T221A, T273A, 
Y275A and Y275F), transfected into HEK293T and cell-cell fusion assays were 
performed (A). HEK293T cells were transfected with constructs expressing the 
indicated mutants and 48h later cell lysates were generated and resolved in SDS-
PAGE gels under reducing and non-reducing conditions, visualised by western blot 
(B). (C/D) Similarly, MeV H phospho-mimetic mutants were generated (T221D, 
T221E, T273D, T273E and Y275E), transfected into HEK293T and cell-cell fusion 
assays were performed (A). HEK293T cells were transfected with plasmids 
expressing the indicated mutants, and 48h later cell lysates were generated and 
resolved in SDS-PAGE gels under non-reducing conditions and visualised by 
western blot (B). Student’s t test, **,p<0.01; ***, p<0.001. 
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I could detect and I observed a small migration shift in the total protein. These data, 
together with the previous detection of PTMs by mass spectrometry, provide 
evidence of specific phosphorylation of amino acids in MeV H.  
Analysing of the impact of phosphorylated residues on the activity of a protein can be 
hindered with biochemical studies due to the difficulties in interfering with phosphate 
groups. Common approaches include the mutagenesis of the phosphorylated 
residues with phospho-defective amino acids, i.e. residues that cannot be 
phosphorylated, such as alanine and phenylalanine, or phospho-mimetic amino 
acids, i.e. residues that resemble the negative charge of phosphorylated residues, 
such as aspartic or glutamic acids. Therefore, I have introduced alanine substitutions, 
which abrogate the addition of phosphate groups at these positions, since alanine 
residues are not substrates of kinases, or aspartic acid or glutamic acid substitutions 
– which mimic the negative charge of the phosphate group. To assess the role of the 
phosphorylated residues in H, I have generated MeV H constructs with phospho-
defective substitutions and analysed the activity of H using a cell-cell fusion assay 
(Fig.6-11A). Interestingly, the substitution Y275A increased cell-cell fusion while 
T273A modestly decreased fusion, even though not significantly. As my initial 
hypothesis was that these residues might be involved in the dimerization of H, I 
looked at the abundance of dimeric and monomeric states of H using SDS-PAGE 
under reducing and non-reducing conditions (Fig.6-11B). Moreover, when mutating 
to phospho-mimetic residues, T221E increased cell-cell fusion, while substitutions in 
T273 and Y275 reduced cell-cell fusion (Fig.6-11C). In particular, replacing the 
threonine 273 to D or E residues completely abrogates cell-cell fusion. This might be 
greatly explained by the loss of the dimeric form of H, as shown by non-reducing 
321 
 
SDS-PAGE (Fig.6-11D). Although further investigation is required to determine the 
role of these phosphorylated residues, these data point to a particular sensitivity to 
the residue T273 to accommodate mutations, but also other residues in promoting 
dimer stability and cell-cell fusion. 
  
 
6.7 Discussion 
The complexity of virus-host interactions likely hinders our understanding of 
pathogenesis and virus biology, even in the case of small enveloped viruses, such as 
MeV. To address this problem, several high-throughput approaches have been 
applied in virology to better comprehend how viruses manipulate their hosts. In 
particular, and to this end, proteomics has become an important methodology in 
infectious disease research. In this chapter, I describe the use of SILAC technology 
to examine the membrane proteome of infected LCLs, with the intention being to 
investigate the egress mechanism of MeV. The dataset generated and presented 
herein demonstrates dramatic alteration of the cellular proteome following MeV 
infection of lymphocytes. Interestingly, infection in LCLs was shown to be slower than 
in Vero-hSLAMs. Since the parental Vero cell line is a primate cell line lacking 
expression of IFNα and IFNβ, it is possible that innate immunity in LCLs may be 
dampening MeV infection. Nevertheless, the growth curve I performed suggested 
that infection in both cell lines can generate equivalent titres of viral progeny. To this 
end, it was important to avoid cytopathic effects and, therefore, extensive protein 
degradation. 
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Analysis of the membrane proteome of infected cells showed that at both 64 and 96 
hours post-infection the translation machinery was significantly downregulated. 
Particularly, proteins involved in RNA processing were highly affected by infection 
with FDRs of 1.54×10-124 and 3.81×10-9, supporting previous evidence for host 
translational shut-off [137, 495]. Of note, FDRs were calculated based on multiple 
comparisons and enrichment analysis of cellular protein networks listed in PANTHER 
and STRING databases, as described previously [485, 486]. A very low FDR value 
for a particularly pathway (as the ones mentioned herein) suggests that pathway is 
significantly enriched or depleted when comparing two populations. Interestingly, 
proteins involved in metabolic pathways were significantly enriched in both samples, 
with associated FDRs ranging in order of magnitude from 10-9 at 96h and 10-2 at 64h. 
Using pathway analysis, I determined which cellular compartments (including the 
plasma membrane or organelles) were enriched in the SILAC dataset. Extracellular 
exosomes and vesicles were shown to be enriched in infected cells. Together, these 
observations suggest a possible upregulation of exocytosis pathways for metabolite 
secretion during infection. Although further investigation is required, it is plausible 
that MeV hijacks the exocytosis pathway to assemble at the plasma membrane and 
egress from the cell.  MeV proteins have previously been shown to interact with 
Rab11+ endosomes, culminating in the accumulation of viral components at the 
apical side of polarised cells [344]. The budding of other viruses, such as varicella-
zoster virus and RSV, has been shown to be dependent on exocytosis pathways and 
interactions with Rab11 [496, 497]. Rab11 is a cellular GTPase that is involved in the 
trafficking of recycling endosomes [343] and the regulation, formation and secretion 
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of exosomes [498, 499]. Further analysis of the upregulated proteins belonging to 
these pathways might help to elucidate the budding mechanism for MeV. 
Of particular interest was the identification of a myriad of post-translation 
modifications in the MeV proteome. Several phosphorylated residues in N and P 
have previously been identified and shown to have an impact on the activity of these 
proteins and, ultimately, viral replication and RNA synthesis [489, 490, 492]. 
Furthermore, PTMs in F and H, specifically glycosylated residues in the ectodomain, 
are known to modulate fusion activity and contribute to immune evasion. It is 
therefore clear that viruses, including MeV, have evolved to take advantage of the 
modification of proteins to expand their repertoire of functions during infection, such 
as the glycosylation of envelope proteins and the phosphorylation of residues 
involved in replication. Some suggest PTMs may play an important alternative role in 
viral evolution, in which additional ORFs can be replaced by protein modifications, 
bypassing the information contained in the genetic material [500]. Within my SILAC 
dataset, several PTMs were present in almost all viral proteins, most of which have 
not been reported yet. Another interesting observation is the diversity of amino acid 
modifications that I uncovered. The L and N proteins were associated with peptide-
specific PTMs, respectively ubiquitin and the small ubiquitin-like modifier (SUMO). 
Ubiquitin is a small protein that, when covalently bound to a target protein, can trigger 
a signalling cascade impacting on its stability [501]. Other functions have also been 
attributed to ubiquitin conjugation, such as nuclear-cytosolic translocation and 
modification of the enzymatic activity of the target protein. Since the ubiquitin 
footprint after peptide fragmentation and mass spectrometry analysis – characterised 
by two remaining glycine residues of the ubiquitin peptide bound to a lysine – was 
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identified at both termini of the L protein, it is also possible that the ubiquitination that 
I identified might also be a sign that L is targeted for degradation. However, in other 
viruses, such as influenza A virus, ubiquitination of lysine residues within the 
polymerase polypeptide can lead to increased activity of the RNA polymerase without 
affecting protein expression levels [502]. Ubiquitination was shown to impact several 
steps of the virus lifecycle, contributing to the modulation of innate immunity, virus 
entry and egress from the cell [503]. In the study of Pentecost et al. several 
paramyxoviral matrix proteins are described to be ubiquitinated, with disruption of this 
ubiquitination impacting on nuclear translocation of this protein, including MeV M 
[504]. In contrast, my SILAC data identified no ubiquitin footprint on this protein. In 
the cited study MeV M protein was the least affected protein and the role of ubiquitin 
conjugation was inconclusive. It is also possible that transient expression of MeV M, 
rather than endogenous expression during a normal MeV infection, may alter the 
physiological background of M in these cells, explaining the observed ubiquitination. 
In support of this conclusion, my proteomics dataset was extracted from infected cells 
that more closely resemble natural infection in the host.  
Interestingly, a small peptide related to ubiquitin, SUMO, was found associated with 
the N protein. The addition of SUMO molecules to proteins, often described as 
SUMOylation, can have a much broader impact on the protein than ubiquitin, such as 
the modulation of transcription and protein stability, nucleus-cytosol translocation, 
apoptosis, etc. [505]. Although this process might not be as well-characterised as 
ubiquitination cascades, some viruses have been shown to interfere with host 
SUMOylation upon infection [506-508]. Influenza A virus matrix 1 and nucleocapsid 
proteins have been shown to be SUMOylated, impacting on viral assembly, 
325 
 
trafficking and replication [509, 510]. Addition of SUMO molecules to paramyxoviral 
proteins has previously been reported [511]; in this study the P protein of PIV5 was 
shown to be SUMOylated, playing a role in virus replication. Although SUMO 
footprints were not identified in MeV P protein, my data supports the idea that this 
pathway might be involved in MeV infection. Network analysis of enriched pathways 
in SILAC samples showed that components of the protein polyubiquitination 
(FDR=0.98×10-2) and ER-associated ubiquitin-dependent protein catabolic process 
(FDR=3.98×10-2) were upregulated in infected cells. Nevertheless, since this 
experiment was designed to capture membrane proteins and SUMOylation and 
ubiquitination pathways are mainly cytosolic/nuclear, it is possible that the dataset 
does not reflect a putative subversion of these pathways.  
Phosphorylation of virally encoded amino acid residues were among the most 
common post-translation modifications detected in the MeV proteome. Five of the 
eight viral proteins presented such modifications with additional phosphate groups 
attached to threonine, serine or tyrosine residues. Unsurprisingly, the N and P 
proteins were shown to be phosphorylated at different sites. It was previously 
demonstrated that phosphorylated MeV N is preferentially assembled into RNPs 
[512], a process which is also aided by P protein [513]. MeV P is thought to be a 
substrate for the cellular casein kinase II and has multiple phosphorylation sites 
[514]. Although the role of these phosphorylated residues is not fully understood, 
researchers believe that they are important in gene regulation [515] and the 
modulation of innate immune responses [488]. Similarly, phosphorylated residues in 
N have also been implicated in regulating gene expression and, by extension, 
modulating virus replication [490]. During my SILAC screen, additional 
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phosphorylated residues were identified in P and N, suggesting the existence of 
other active phosphorylation sites that might impact on the virus lifecycle. To my 
knowledge, no phosphorylated residues have been reported in the RNA-dependent 
RNA-polymerases of non-segmented negative-sense single-stranded RNA viruses. 
However, some positive strand RNA virus RNA polymerases were shown to be 
phosphorylated [516, 517], as well as certain subunits of the influenza A virus 
polymerase [518]. It is possible that the phosphorylated residues in L affect 
polymerase activity, as seen for other viruses, but further experiments are required to 
evaluate their role in the MeV lifecycle. 
To my knowledge no previous report has shown phosphorylation of F and H either; 
however, my data also points to several phosphorylated residues within these 
proteins. In particular for H, although there are five crystal structures available; none 
of them show clear signs of phosphorylation [180, 181, 183, 296, 302]. In all these 
crystallisation studies, H is expressed as a truncated form, i.e. only the globular head 
is expressed, a process that is required for efficient secretion of a soluble form of H 
that can be subsequently purified and crystallised. It is possible that this soluble form 
of H might not function as a substrate for endogenous kinases, and may not be 
phosphorylated under these conditions. Additionally, these studies used insect cells 
[183, 296], Chinese hamster ovary cells [302] or HEK293 cells [180, 181] to produce 
the MeV H protein for crystallisation. None of these cells are naturally permissive for 
MeV; in addition none of these studies were performed in the context of viral 
infection. In contrast, my proteomics and PTM data was obtained from human 
derived-lymphocytes – a known target of virus infection in vivo and readily permissive 
to MeV – and infected with a wild-type strain of MeV. It is entirely possible that the 
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expression and isolation conditions in which these crystals were obtained interrupted 
the normal maturation pathways for MeV H. One argument to support this hypothesis  
is the limited detection of glycosylated sugar moieties attached to residues in these 
crystals: even though a total of five N-glycosylated residues have been identified 
biochemically, only two [181, 302] or three [296] were resolved within the protein 
structures, highlighting the limitation of crystallographic approaches in defining the 
complete structure of viral glycoproteins.  
In preliminary studies I further investigated the phosphorylation of certain residues in 
H; in particular, focusing on three conserved amino acids located at the dimer 
interface of H (T221, T273 and Y275). Using site-directed mutagenesis, these 
residues were shown to be highly sensitive to certain amino acid changes, affecting 
both dimer formation and cell-cell fusion. The formation of H-dimers is not completely 
understood, with several studies suggesting that the globular head domain of H is, in 
solution, a monomer [183] or a dimer [181]. Two disulphide bridges located at the 
interface of the globular domain and the stalk domain are also implicated in dimer 
formation since these bridges are established between cysteines of different 
monomers [519]. As these cysteine residues are important for dimerization, induced 
reduction of these residues by β-mercaptoethanol and subsequently SDS-
PAGE/western blot of these proteins shows the monomeric molecular weight of H 
around 75 kDa; however, if no reduction step is performed, the disulphide bounds 
remain intact and the detected MeV H band is located at 160 kDa (dimeric molecular 
weight).  Alanine substitutions in all three residues decreased the total level of 
protein, while a phenylalanine mutation in Y275 maintained similar expression levels 
to wild-type H protein. Since phenylalanine residues are not kinase substrates, it is 
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possible that the phosphorylation of Y275 does not have an effect on cell-cell fusion 
and dimerization of H and might play other roles in MeV lifecycle that these assays 
cannot elucidate. In contrast, both phospho-defective and phospho-mimetic amino 
acid substitutions in the T273 severely affected dimer formation and cell-cell fusion, 
suggesting that this position is very sensitive to amino acid variation. Also, a caveat 
of using mutagenesis to evaluate the role of phosphorylated residues is the difficulty 
in accurately mimicking the phosphate groups bound to the original amino acid. It is 
possible that the E and D substitution at position T273 both cause steric hindrance, 
impacting on the formation of the dimer. Finally, an alanine substitution in T221 
abrogated dimer formation while D or E substitutions maintained the dimer and 
increased cell-cell fusion. It is possible that this phosphorylated residue is affecting 
the overall stability of the protein, similar to what has been shown for N-glycosylated 
residues [181], thereby impacting on the ability of H to promote cell-cell fusion.  
In summary, I have shown that MeV infection in LCLs induces a significant change in 
the membrane proteome with upregulation of cellular pathways involved in 
exocytosis. Additionally, PTMs in MeV H were shown to be important in the 
dimerization and function of this protein. Further experiments are required to 
determine the role of these phosphorylated residues in the MeV lifecycle. 
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7.1 Background and General Aims 
MeV is one of the most contagious viral pathogens known to science. Like the other 
recognised members of the Morbillivirus genus, MeV interacts with SLAMF1 on 
immune cells of the lung to rapidly establish infection (see [41] for a review). These 
infected cells then drain to local lymph nodes, where several cell types become 
infected, including B- and T- lymphocytes, leading to the occasional formation of 
multinucleated cells. The virus then enters the bloodstream, mainly in association 
with circulating cells, and infection spreads to other parts of the body. The final stage 
of MeV infection occurs when infected circulating immune cells interact with the 
basolateral surface of polarised cells in the lung epithelium. Infection and spread 
within the airway epithelium can then occur by cell-cell fusion. At this point, nascent 
viral particles are preferentially released into the lumen of the lung and expelled to 
the environment.  
For the virus to successfully complete this lifecycle in the host, it interacts with at 
least two cellular receptors, SLAMF1 and nectin-4. Both molecules grant cell’s 
permissivity to MeV through direct interactions with viral particles but also by allowing 
cell-cell fusion. Until now it has commonly been assumed that the fusion 
mechanism underpinning both processes are the same. To be more specific, this 
fusion mechanism involves the initial interaction of H with either SLAMF1 and nectin-
4, depending on the target cell type. This interaction induces conformational changes 
in H that trigger F. The F protein undergoes dramatic refolding leading to the 
insertion of the fusion peptide into the target cell’s plasma membrane and fusion of 
both membranes. Although the structural rearrangements of these proteins during 
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this process is a topic of intense investigation, the cellular factors governing this 
process remain poorly defined.  
Early evidence for specific differences between the cell-cell fusion process and the 
fusion occurring upon viral particle entry came from the François-Luic Cosset’s lab: 
they showed that lentivirus particles pseudotyped with MeV glycoproteins were able 
to transduce quiescent human lymphocytes in a process that was sensitive to 
macropinocytosis inhibitors [328, 374, 385]. These reports provide evidence that 
more complex events are occurring at the moment of particle entry, processes that 
rely not only on the fusion of the viral envelope with the plasma membrane but also 
the involvement of other cellular factors, such as proteins involved in 
macropinocytosis. In addition, Stephen Russell’s lab previously showed that soluble 
MeV H is internalised by cells via macropinocytosis or clathrin-mediated endocytosis 
[329]. The same lab showed that attachment of MeV to cells leads to the clustering of 
CD46 upon viral entry. Clustering of CD46 was observed upon infection with 
Neisseria gonorrhoeae and led to cytoskeletal rearrangements important for the entry 
of the pathogen [248, 253, 520]. These reports are evidence that MeV H interactions 
with its receptors might be more complex than previously thought, inducing cellular 
responses that might be important for the establishment of infection. Although these 
reports are specific for the CD46-MeV H interaction, recent findings from Cox 
Terhorst’s lab have shown that SLAMF1 interacts with Gram-negative bacteria and 
controls the internalisation of the pathogen through the recruitment of autophagic 
machinery [210]. Interestingly, autophagy responses to MeV infection have been 
reported previously, where an early wave of autophagy was observed soon after 
MeV entry [172].  In addition, during MeV infection of DCs, attachment of the virus to 
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the cell surface leads to the clustering of SLAMF1 [332]. Based on these data and 
observations, I have revisited the entry mechanism of MeV entry into SLAMF1+ cells.  
 
7.2 Redefining MeV entry via SLAMF1 
In chapter 4, I have shown that MeV and lentivirus pseudotyped with MeV 
glycoproteins are internalised by SLAMF1+ cells via a pathway that resembles 
macropinocytosis. Evidence for this conclusion can be divided into two main 
observations: i) MeV entry required the activity of certain cellular components, 
such as myosin-2, ROCK-I and a dynamic actin cytoskeleton, and ii) attachment and 
entry led to specific cellular responses, including membrane blebbing, 
cytoskeleton contraction and fluid uptake. Before making any further conclusions on 
the entry pathway used by MeV particles, it is worth highlighting that these two 
observations are sufficient to disprove that MeV entry is an entirely unregulated 
process; moreover, it is likely to be far more complex than simple fusion of the viral 
envelope at the cell surface and subsequent release of the RNP complex into the 
cytosol. Firstly, one should consider the observed cellular responses to MeV entry as 
mentioned in ii). One of the most striking observations described herein are the 
morphological rearrangements of the plasma membrane that led to the formation of 
membrane blebs. This was a rapid but transient phenomenon that occurred in the 
first 20 minutes of infection. As discussed previously, other viruses, such as vaccinia 
virus, were shown to induce similar membrane blebs upon entry [409, 521]. These 
structures are important in cellular homeostasis as membrane blebs play a role in 
locomotion and invasion [404] but also in phago- and macropinocytosis [195, 409]. 
Similarly, MeV attachment and entry led to other phenotypes related to the 
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macropinocytosis pathway, such as fluid-uptake and reorganisation of the actin 
cytoskeleton. Although the cellular proteins involved in the regulation of 
macropinocytosis are not fully described, it is plausible that this is modulated by 
molecular signalling from the plasma membrane, similarly to several receptor-
mediated endocytosis pathways [420]. Macropinocytosis appears to be governed, at 
some level, by very mobile elements present at the plasma membrane, such as 
cholesterol-rich microdomains and phosphatidylinositol-3-phosphate[321]. I also 
performed experiments showing that certain macropinocytosis-related responses 
induced by MeV, namely the internalisation of fluid and the contraction of the 
cytoskeleton, are SLAMF1-specific. This observation shows that (1) MeV interaction 
with SLAMF1 is sufficient to induce these phenotypic responses and (2) the observed 
cell responses are not due to any contaminant present in the viral preparations, since 
the viral inoculum had little effect on cells lacking expression of SLAMF1. One 
plausible conclusion that can be drawn from the observations described in (1) is that 
the membrane blebbing, fluid-uptake and contraction of the cytoskeleton, brought 
about as a consequence of MeV-SLAMF1 interactions are related to signalling 
mediated by SLAMF1. As mentioned before, CD46-mediated signalling regulates the 
entry of the pathogen Neisseria gonorrhoeae, in a process that is dependent on the 
phosphorylation of the cytoplasmic tail of CD46 [520].  In our lab, we are currently 
investigating the role of the cytoplasmic tail of SLAMF1 in MeV entry. As mentioned 
in chapter 1, the cytoplasmic tail of SLAMF1 contains three SH2-binding motifs; 
motifs that are known to interact with several cellular proteins, each one starting with 
a tyrosine residue that it is phosphorylated by kinases located near the inner leaflet of 
the plasma membrane. We are developing SLAMF1 mutants in which these tyrosine 
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residues are substituted by phenylalanine residues as well as mutants with serial 
truncations of the cytoplasmic tail. The substitution mutants should have minimal 
impact on the overall folding of the protein, since the side chains of tyrosine and 
phenylalanine differ only in one hydroxyl group, however, importantly phosphorylation 
of this altered residue by cellular kinases can no longer occur. Although preliminary 
data suggests a specific role for a particular region of the cytoplasmic tail in MeV 
entry, further experiments are required to confirm downstream signalling mediated by 
SLAMF1 is directly involved in this process.  
Secondly, one should reflect on the consequences of the observations listed in i) 
related to the requirement activity of certain cellular components. In chapter 4, I have 
shown that MeV entry is sensitive to inhibition of: myosin-II (a protein necessary for 
actin contraction and membrane blebbing), as well as certain Rho GTPases and 
actin dynamism (as demonstrated by the effects of cytochalasin D and 
jasplakinolide). Several of these components have been shown to be required for the 
formation of the macropinosome[321] and furthermore entry of other viruses that 
invade cells via macropinocytosis [195, 416, 521], supporting my hypothesis that 
MeV is entering cells using a pathway similar to this one. To my knowledge, this is 
the first time that cellular proteins were shown to be involved in MeV entry (either 
directly or indirectly) aside from the cellular receptors and co-entry factors previously 
identified. Indeed, actin, myosin-II and Rho GTPases are all cytosolic proteins; 
therefore, if they do indeed play a role in MeV entry, it is likely that there impact and 
role is in steps subsequent to MeV attachment.  
Before continuing I provide a more detailed examination of the current dogma of 
entry for MeV; i.e. (1) the virus adsorbs to the cell surface; (2) attachment of MeV H 
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with SLAMF1 leads to conformational changes in H, triggering F; (3) activated F is 
sufficient to induced the fusion of the viral envelope to the plasma membrane and (4) 
the interior contents of the measles virion are released into the cytoplasm to initiate 
replication. This is assumed to be identical to the initial step of cell-cell fusion when a 
MeV-infected cell contacts with an uninfected SLAMF1+ cell. When looking at these 
two phenomena, i.e. entry of virions and cell-cell fusion, at approximately the same 
time point – i.e. the very early steps of infection – (see chapters 4 and 5), two very 
distinctive and opposite features were observed: (1) MeV entry was very sensitive to 
inhibitors of actin dynamism while the same drugs at the same concentration 
increased cell-cell fusion and (2) infection was shown to require the activity of Rho 
GTPases while blocking their activity led to an increase in cell-cell fusion. These 
contrasting findings, gathered and described in chapters 4 and 5, are evidence that 
indeed, even if MeV is entering cells at the plasma membrane, the fusion mechanism 
is not governed by the same cellular components nor in the same manner. 
Nevertheless, I am aware that the findings herein described are per se not sufficient 
to discern between the two fusion processes, but are indeed evidence of a more 
complex mechanism that involves other cellular proteins.  
In conclusion, I believe that the current understanding of MeV entry should be re-
assessed since my data and that of others suggest a more complex mechanism, 
than previously thought. Here I propose a new model for MeV entry, schematically 
represented in Fig.7-1, based on the current understanding of the fusion mechanism 
and the data collected during my doctorate. Upon binding of MeV to its receptor 
SLAMF1, extensive plasma membrane rearrangements lead to the formation of 
membrane blebs within 10min of viral attachment. It is likely that MeV binding to the  
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Fig.7-1. Model of endocytic MeV entry into SLAMF1-positive cells. (A) MeV binds 
to human SLAMF1 (CD150) via a specific protein-protein interaction between the 
viral haemagglutinin and SLAMF1. (B) Within 10 minutes the receptor interaction 
induces the formation of membrane blebs, governed in part by the RhoA-ROCK-
myosin-II axis. Inhibition of this axis (with chemical inhibitors or dominant negative 
mutants) reduces MeV entry. (C) The formation of membranous blebs is followed by 
an acute retraction of the cell, orchestrated by the cortical cytoskeleton. Perturbation 
of this process with chemical inhibitors of actin modulation also reduces MeV entry. 
(D) The internalisation of MeV particles is concurrent with fluid uptake via a 
macropinocytosis-like pathway, a process that is sensitive to chemical inhibition with 
EIPA. Within 45 minutes infected cells begin to re-establish their characteristic 
morphology through specific phosphorylation of ERM proteins  
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cell leads to clustering of SLAMF1, as observed previously [332], and SLAMF1-
mediated signalling might activate the myosin-II-ROCKI-RhoA axis, as MeV entry 
was sensitive to mutants and drugs that target elements of this axis. It is also very 
likely that triggering of MeV F protein occurs at this point leading to hemifusion of the 
viral envelope with the plasma membrane or fusion pore formation, since binding to 
SLAMF1 is sufficient to activate the fusion complex in a pH-independent manner. 
Importantly, however, the expansion of the pore, and release of the viral genome into 
the cytosol, might be delayed until later stages. In the scenario where the 
RNP/genome is released directly into the cellular cortex, the RNP would immediately 
be presented with a dense cortical actin network that it must overcome before 
transport to the perinuclear region where replication starts. Hence it is plausible that 
MeV has evolved to exploit trafficking systems to reach this replication site. 
Accordingly, even 20min after infection, MeV colocalises with actin-enriched domains 
and vesicles containing extracellular fluid. This observation is in line with the entry 
pathways of other related viruses, such as RSV [195], in which the virus colocalises 
with macropinosomes upon entry. Disrupting actin dynamics and macropinosome 
formation blocked MeV entry, suggesting that the virus requires a macropinocytosis-
like pathway to successfully establish infection. Finally, at 45 min post attachment, 
the viral RNP complex is released from the macropinosome and replication can start. 
This new model of MeV entry can certainly impact on the control of the disease, as 
we have identified several drugs that can block infection. Additionally, with the 
ongoing use of MeV as a therapeutic tool to treat certain types of cancer, this 
information can aid researchers in the design of better therapies, tuning MeV entry 
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into cancer cells by, for instance, the use of drugs that promote macropinocytic 
uptake of the virus. 
 
7.3 The thermodynamics of disease: a hypothesis on MeV exit 
MeV can exit cells via the formation of new virions, a process known as viral budding, 
or by inducing fusion of neighbouring cells, generating multinucleated cells known as 
syncytia. Several viruses are known to cause syncytia in vitro, including RSV, HIV-I, 
human metapneumovirus, Hendra and Nipah viruses, etc. Evidence for in vivo 
syncytia formation is also available, with MeV generating multinucleated fused cells 
in lymph nodes, airway epithelium and in the brain [422]. The relevance of such 
structures in viral spread has been largely neglected by the scientific community with 
several observations justifying this opinion in field. Historically, the most notorious 
example of cell-cell fusion induced by MeV is the formation of viral plaques in the 
brain during infection of the nervous system. Similarly to other pathogenic infections 
of the CNS, MeV infection of the brain is commonly seen as a “dead-end” infection, 
i.e. an infection that does not result in the transmission of virus to other hosts due to 
the anatomically isolated nature of the brain. MeV genomes isolated from patients 
suffering from SSPE accumulated several mutations in the F and M genes; some of 
these mutations were shown to impact on the ability of M to interact with the 
cytoplasmic tail of F, hampering the formation of viral particles and increasing the 
fusogenicity of F [134, 432, 522]. In other tissues, cell-cell fusion is unlikely to be the 
result of defective M or F genes, since infectious viral particles can be recovered from 
infected lymph nodes and lung epithelium where syncytia are normally observed. In 
recent years, studies on the mechanism of viral induced cell-cell fusion have shed a 
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new light on its relevance in viral spread. In particular, several reports from Roberto 
Cattaneo’s lab have shown that MeV infection rapidly spreads through polarised lung 
epithelial cells where cell-cell fusion, induced by the virus, allows cytosolic content 
mixing and transmission of infection[423]. It is plausible that this mode of infection 
conveys certain advantages to the virus: by remaining intracellular, MeV escapes 
antibody neutralisation of virions while more resources for viral production and the 
release of particles are diverted from neighbouring cells. In our lab, we have been 
investigating the concept of “viral factories”, i.e. infected multinucleated cells that 
concentrate molecules necessary for viral release leading to the focused production 
of viral particles. Early reports on the structure of MeV-induced syncytia in vitro show 
that human erythrocytes – that naturally bind MeV H – adsorb to the centre of the 
syncytium, where presumably MeV H is concentrated [523]. The same study showed 
that the area of attachment of erythrocytes expands with the maturation of the 
syncytium forming a ring. It is possible that MeV has evolved to compartmentalise the 
syncytium in order to maximise the production of viral particles, and perhaps the 
extensive subversion of the cytoskeleton by MeV, as summarised by Avota and 
colleagues [524], is evidence of such compartmentalisation. In chapter 5, I have 
explored the role of several cytoskeletal components in the early stages of MeV-
induced cell-cell fusion. Particularly, cell-cell fusion was shown to be restricted by an 
intact actin cytoskeleton, as observed by other viruses [433, 437, 525]. I am aware, 
though, that the results presented in chapter 5 were not performed in the context of 
infection: MeV protein levels were modulated by the strength of the plasmid 
promoters and most likely certain elements of infection are being ignored or 
overlooked. However, for the sake of the argument, one should assume that MeV 
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has evolved to exploit any advantages of cell-cell fusion. One immediate question 
that emerges after accepting this concept is the balance between fusion and budding 
and the timing in which both processes occur. Gene expression precedes genome 
replication during the viral lifecycle, suggesting that MeV-induced cell-cell fusion 
happens first, as this is only reliant on viral protein expression. Additionally, in the in 
vitro model of infection of human-derived B lymphocyte cell line LCLs described in 
chapter 6, cell-cell fusion was observed very early in infection but infectious viral 
particles were only detected later. It was shown previously that interaction of MeV M 
with the cytoplasmic tails of F and H reduces cell-cell fusion by recruiting these 
glycoproteins to assembly sites [349, 524]. It is therefore evident that M may function 
as the molecular “switch” between cell-cell fusion and budding. Nevertheless, the M 
ORF precedes the F and H genes in MeV genomes, as described in chapter 1, which 
suggests that M is at least more transcriptionally abundant than F and H because of 
the morbillivirus transcriptional gradient. The untranslated region between M and F, 
present in their mRNAs, also appears to accentuate the difference in the expression 
of the two proteins, however the role of this region might be more complex than 
previously stated [124]. If the M protein is indeed more abundant than F and H, how 
can cell-cell fusion occur so profusely during infection? My prediction is that a 
putative switch from cell-cell fusion to viral budding is not solely governed by the 
overall ration of M/F+H but also on the inherent activity and localisation of M. 
Wakimoto et al. showed that actin competes with the cytoplasmic tail of H in the 
binding of M [349], while M has been shown to interact strongly with filamentous 
actin, and promote the formation of actin-rich viral-like buds[524]. My hypothesis is 
that interactions of M with the cytoskeleton impact on cell-cell fusion regardless of the 
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competitive interaction with cytoplasmic tails of F and H. Currently in our lab we are 
addressing the role of this protein in cell-cell fusion using our fusion assay. 
Preliminary data has shown that co-expression of MeV M increased cell-cell fusion 
induced by either full-length or cytoplasmic-tail-deletions of F and H. Further studies 
are required to determine the role of cytoskeleton components in cell-cell fusion, 
particularly in the context of infection.  
To finalise, I would like to comment on the difficulties of relating observations in vitro 
to in vivo infection. For centuries, MeV has evolved together with the human 
population, tuning its molecular mechanisms of replication to optimise infection in the 
host. As shown in several studies [526, 527], in vivo infections present viruses with 
consecutive bottlenecks, as a result of the ever-changing environments that viruses 
face in the host. Taking MeV as an example, infection arguably starts in the lumen of 
the lung where the virus interacts with DCs and macrophages, and later infects highly 
organised tissues, such as those found in lymph nodes and the spleen. With the 
onset of the first symptoms, such as fever, the virus faces additional changes in the 
environment, followed by the emergence of IgM antibodies and specialised T cell 
populations. The complexity of this scenario is hard to reproduce in vitro. However, in 
my opinion, it is almost certain that such changes in environment may impact on the 
virus itself and the infection it causes. In 1987, Ogura and colleagues documented 
that the synthesis of the MeV M protein is blocked by exposure to high temperatures, 
i.e. 39ºC, although its transcript is as stable as the transcripts of other MeV proteins 
[118]. In the study, they argue that the high temperature blocks the interaction of M-
encoding mRNA with polysomes. One can only speculate that the virus may have 
evolved to take advantage of the onset of fever, which can happen as early as nine 
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days after initial contact, to block the production of M protein. If so, the reduced 
expression of M may have certain implications for viral spread. In the future 
technological advances and a better understanding of the biology of viruses will 
certainly impact on how we perceive pathogen interactions with highly complex and 
dynamic organisms, such as humans.  
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APPENDIX 
 
The following data supports some of the findings mentioned previously in this document.  
A.1 – Primers used for SDM 
All primers used in SDM are listed in Table A-1.  
 
Description Sequence 
MeV H T221A 5’-TCTATAGTCGCTATGACATCC 
MeV H T221D 5’-TCTATAGTCGACATGACATCC 
MeV H T221E 5’-TCTATAGTCGAGATGACATCC 
MeV H T273A 5’-TTCCATATGGCAAACTATTTT 
MeV H T273D 5’-TTCCATATGGACAACTATTTT 
MeV H T273E 5’-TTCCATATGGAAAACTATTTT 
MeV H Y275A 5’-ATGACAAACGCTTTTGAGCAA 
MeV H Y275F 5’-ATGACAAACTTCTTTGAGCAA 
MeV H Y275E 5’-ATGACAAACGAATTTGAGCAA 
 
A.2 – Protein sequences of MeV Ichinose-B95a strain proteins 
All protein sequences of Ichinose-B95a strain proteins used for bioinformatics purposes in 
this these are presented below.  
>sp|Q9WMB5|NCAP_MEASC Nucleoprotein OS=Measles virus (strain Ichinose-B95a) 
GN=N PE=3 SV=1 
 
MATLLRSLALFKRNKDKPPITSGSGGAIRGIKHIIIVPIPGDSSITTRSRLLDRLVRLIG 
NPDVSGPKLTGALIGILSLFVESPGQLIQRITDDPDVSIRLLEVVQSDQSQSGLTFASRG 
TNMEDEADQYFSHDDPSSSDQSRSGWFENKEISDIEVQDPEGFNMILGTILAQIWVLLAKAV
TAPDTAADSELRRWIKYTQQRRVVGEFRLERKWLDVVRNRIAEDLSLRRFMVALILDIKRTP
GNKPRIAEMICDIDTYIVEAGLASFILTIKFGIETMYPALGLHEFAGELSTLESLMNLYQQMGET
APYMVILENSIQNKFSAGSYPLLWSYAMGVGVELENSMGGLNFGRSYFDPAYFRLGQEMV
RRSAGKVSSTLASELGITAEDARLVSEIAMHTTEDRISRAVGPRQAQVSFLHGDQSENELPG
LGGKEDRRVKQGRGEARESYRETGSSRASDARAAHPPTSMPLDIDTASESGQDPQDSRR
SADALLRLQAMAGILEEQGSDTDTPRVYNDRDLLD 
 
>sp|Q9WMB4|PHOSP_MEASC Phosphoprotein OS=Measles virus (strain Ichinose-B95a) 
GN=P/V PE=3 SV=1 
 
MAEEQARHVKNGLECIRALKAEPIGSLAVEEAMAAWSEISDNPGQDRATCKEEEAGSSGLS
KPCLSAIGSTEGGAPRIRGQGSGESDDDAETLGIPSRNLQASSTGLQCYHVYDHSGEAVKG
370 
 
IQDADSIMVQSGLDGDSTLSGGDDESENSDVDIGEPDTEGYAITDRGSAPISMGFRASDVET
AEGGEIHELLKLQSRGNNFPKLGKTLNVPPPPNPSRASTSETPIKKGTDARLASFGTEIASLL
TGGATQCARKSPSEPSGPGAPAGNVPECVSNAALIQEWTPESGTTISPRSQNNEEGGDYY
DDELFSDVQDIKTALAKIHEDNQKIISKLESLLLLKGEVESIKKQINRQNISISTLEGHLSSIMIAI
PGLGKDPNDPTADVELNPDLKPIIGRDSGRALAEVLKKPVASRQLQGMTNGRTSSRGQLLK
EFQLKPIGKKVSSAVGFVPDTGPASRSVIRSIIKSSRLEEDRKRYLMTLLDDIKGANDLAKFH
QMLMKIIMK 
 
>sp|Q9W850|MATRX_MEASC Matrix protein OS=Measles virus (strain Ichinose-B95a) 
GN=M PE=3 SV=1 
 
MTEIYDFDKSAWDIKGSIAPIQPTTYSDGRLVPQVRVIDPGLGDRKDECFMYMFLLGVVEDS
DPLGPPIGRAFGSLPLGVGRSTAKPEELLKEATELDIVVRRTAGLNEKLVFYNNTPLTLLTPW
RKVLTTGSVFNANQVCNAVNLIPLDTPQRFRVVYMSITRLSDNGYYTVPRRMLEFRSVNAVA
FNLLVTLRIDKAIGPGKIIDNAEQLPEATFMVHIGNFRRKKSEVYSADYCKMKIEKMGLVFALG
GIGGTSLHIRSTGKMSKTLHAQLGFKKTLCYPLMDINEDLNRLLWRSRCKIVRIQAVLQPSVP
QEFRIYDDVIINDDQGLFKVL 
 
>sp|Q786F3|FUS_MEASC Fusion glycoprotein F0 OS=Measles virus (strain Ichinose-
B95a) GN=F PE=3 SV=1 
 
MGLKVNVSAIFMAVLLTLQTPTGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNIT
LLNNCTRVEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVASSRRHKRFAGVVLAGAALGV
ATAAQITAGIALHQSMLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPS
MNQLSCDLIGQKLGLKLLRYYTEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSG
GDLLGILESRGIKARITHVDTESYFIVLSIAYPTLSEIKGVIVHRLE 
GVSYNIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGTVCSQNALYPMSPLLQECLRG
STKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHCPVVEVN
GVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMKG
LSSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRPGLKPDLTGTSKSYVRSL 
 
>sp|Q786F2|HEMA_MEASC Hemagglutinin glycoprotein OS=Measles virus (strain 
Ichinose-B95a) GN=H PE=1 SV=1 
 
MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRL 
HRAAIYTAEIHKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKFISD 
KIKFLNPDREYDFRDLTWCINPPERIKLDYDQYCADVAAEELMNALVNSTLLEARATNQFLA
VSKGNCSGPTTIRGQFSNMSLSLLDLYLSRGYNVSSIVTMTSQGMYGGTYLVGKPNLSSKG
SELSQLSMHRVFEVGVIRNPGLGAPVFHMTNYFEQPVSNDFSNCMVALGELKFAALCHRED
SITIPYQGSGKGVSFQLVKLGVWKSPTDMRSWVPLSTDDPVIDRLYLSSHRGVIADNQAKW
AVPTTRTDDKLRMETCFQQACKGKNQALCENPEWAPLKDNRIPSYGVLSVNLSLTVELKIKI
ASGFGPLITHGSGMDLYKTNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPNLFTVPIKEA
GEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYF
YPFRLPIKGVPIELQVECFTWDKKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDG
TNRR 
 
>sp|Q9WMB3|L_MEASC RNA-directed RNA polymerase L OS=Measles virus (strain 
Ichinose-B95a) GN=L PE=3 SV=1 
 
MDSLSVNQILYPEVHLDSPIVTNKIVAILEYARVPHAYSLEDPTLCQNIKHRLKNGFSNQ 
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MIINNVEVGNVIKSKLRSYPAHSHIPYPNCNQDLFNIEDKESTRKIRELLKKGNSLYSKV 
SDKVFQCLRDTNSRLGLGSELREDIKEKIINLGVYMHSSQWFEPFLFWFTVKTEMRSVIKSQ
THTCHRRRHTPVFFTGSSVELLISRDLVAIISKESQHVYYLTFELVLMYCDVIEGRLMTETAM
TIDARYAELLGRVRYMWKLIDGFFPALGNPTYQIVAMLEPLSLAYLQLRDITVELRGAFLNHC
FTEIHDVLDQNGFSDEGTYHELIEALDYIFITDDIHLTGEIFSFFRSFGHPRLEAVTAAENVRKY
MNQPKVIVYETLMKGHAIFCGIIINGYRDRHGGSWPPLTLPLHAADTIRNAQASGEGLTHEQ
CVDNWKSFAGVRFGCFMPLSLDSDLTMYLKDKALAALQREWDSVYPKEFLRYDPPKGTGS
RRLVDVFLNDSSFDPYDMIMYVVSGAYLHDPEFNLSYSLKEKEIKETGRLFAKMTYKMRAC
QVIAENLISNGIGKYFKDNGMAKDEHDLTKALHTLAVSGVPKDLKESHRGGPVLKTYSRSPV
HTSTRNVKAEKGFVGFPHVIRQNQDTDHPENIETYETVSAFITTDLKKYCLNWRYETISLFAQ
RLNEIYGLPSFFQWLHKRLETSVLYVSDPHCPPDLDAHVPLCKVPNDQIFIKYPMGGIEGYC
QKLWTISTIPYLYLAAYESGVRIASLVQGDNQTIAVTKRVPSTWPYNLKKREAARVTRDYFVI
LRQRLHDIGHHLKANETIVSSHFFVYSKGIYYDGLLVSQSLKSIARCVFWSETIVDETRAACS
NIATTMAKSIERGYDRYLAYSLNVLKVIQQILISLGFTINSTMTRDVVIPLLTNNDLLIRMALLPA
PIGGMNYLNMSRLFVRNIGDPVTSSIADLKRMILASLMPEETLHQVMTQQPGDSSFLDWAS
DPYSANLVCVQSITRLLKNITARFVLIHSPNPMLKGLFHDDSKEEDERLAAFLMDRHIIVPRAA
HEILDHSVTGARESIAGMLDTTKGLIRASMRKGGLTSRVITRLSNYDYEQFRAGMVLLTGRK
RNVLIDKESCSVQLARALRSHMWARLARGRPIYGLEVPDVLESMRGHLIRRHETCVICECGS
VNYGWFFVPSGCQLDDIDKETSSLRVPYIGSTTDERTDMKLAFVRAPSRSLRSAVRIATVYS
WAYGDDDSSWNEAWLLARQRANVSLEELRVITPISTSTNLAHRLRDRSTQVKYSGTSLVRV
ARYTTISNDNLSFVISDKKVDTNFIYQQGMLLGLGVLETLFRLEKDTGSSNTVLHLHVETDCC
VIPMIDHPRIPSSRKLELRAELCTNPLIYDNAPLIDRDATRLYTQSHRRHLVEFVTWSTPQLYH
ILAKSTALSMIDLVTKFEKDHMNEISALIGDDDINSFITEFLLIEPRLFTIYLGQCAAINWAFDVH
YHRPSGKYQMGELLSSFLSRMSKGVFKVLVNALSHPKIYKKFWHCGIIEPIHGPSLDAQNLH
TTVCNMVYTCYMTYLDLLLNEELEEFTFLLCESDEDVVPDRFDNIQAKHLCVLADLYCQPGT
CPPIRGLRPVEKCAVLTDHIKAEARLSPAGSSWNINPIIVDHYSCSLTYLRRGSIKQIRLRVDP
GFIFDALAEVNVSQPKVGSNNISNMSIKDFRPPHDDVAKLLKDINTSKHNLPISGGSLANYEIH
AFRRIGLNSSACYKAVEISTLIRRCLEPGEDGLFLGEGSGSMLITYKEILKLNKCFYNSGVSAN
SRSGQRELAPYPSEVGLVEHRMGVGNIVKVLFNGRPEVTWVGSIDCFNFIVSNIPTSSVGFI
HSDIETLPNKDTIEKLEELAAILSMALLLGKIGSILVIKLMPFSGDFVQGFISYVGSHYREVNLV
YPRYSNFISTESYLVMTDLKANRLMNPEKIKQQIIESSVRTSPGLIGHILSIKQLSCIQAIVGGA
VSRGDINPILKKLTPIEQVLISCGLAINGPKLCKELIHHDVASGQDGLLNSILILYRELARFKDN
QRSQQGMFHAYPVLVSSRQRELVSRITRKFWGHILLYSGNRKLINRFIQNLKSGYLVLDLHQ
NIFVKNLSKSEKQIIMTGGLKREWVFKVTVKETKEWYKLVGYSALIKD 
 
A.3 – Model of MeV M protein structure 
A model of the 3D structure of M was generated as described in chapter 2 section 2.11.2 
using SWISS-MODEL software and based on the protein structure of Newcastle disease 
virus matrix protein (RSCB PDB entry #4G1L). A 3D structure of MeV M is presented in 
Fig.A-1. Two dimers of MeV M adopt a typical cubic shape as seen in other paramyxoviral 
and pneumoviral matrix proteins. The N-terminus of M was located at the dimer interface 
while the C-terminal end locates to the outside face of the dimer (Fig.A-1A). 
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Fig.A-1. Predicted 3D structure of MeV M protein. (A) A dimer of MeV M (red and blue) 
forms a compact cubic shape with the top part likely to associate with the inner leaflet of the 
plasma membrane as it is a highly hydrophobic region of the complex. The N-terminal end of 
M is located inside the dimer, i.e. buried at the interface between the two monomers. The C-
terminus of M locates to the side of dimer. (B) Top view of the MeV M dimer. 
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A.4 – Blebbistatin and EIPA effectively block fluid-phase uptake in A549-SLAM 
In chapter 4, I have used blebbistatin and EIPA to block MeV entry. As a control, I 
tested if these drugs will also block macropinocytosis as reported previously [401]. I 
pre-treated A549-SLAM with EIPA or blebbistatin at the indicated concentrations, 
washed and incubated with soluble fluorescent Dextran for 30min. Macropinocytosis 
was induced by the addition of PMA. Cells were bleached, fixed and prepared and 
observed by CSLM (Fig.A-2). The formation of macropinosomes was blocked by the 
two drugs at the indicated concentrations.  
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A.5 – Cytochalasin D and Jasplakinolide alter the pattern of the phalloidin-stained 
actin cytoskeleton 
Similarly, I have used cytochalasin D and jasplakinolide to interfere with actin polymerisation. 
A549-SLAM cells were treated with drugs at indicated concentrations, fixed and stained with 
phalloidin (Fig.A-3). Cytochalasin D decreased the formation of actin filaments while 
jasplakinolide reduced staining with phalloidin due to the competitive binding of actin, as 
reported [439].   
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